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Prostate Cancer (CaP) is a condition whose etiology is multifactorial, it goes through genetic, 
infectious, as well as environmental, among others. Currently, PCa represents the most frequent 
cancer among men and the second in mortality, however, there are still multiple gaps in the 
knowledge of this condition. One of them is related to a molecular biomarker that allows early and 
accurate diagnosis of PCa. We have the Prostate Specific Antigen (PSA), however, its diagnostic 
performance alone is very low, and it must always be associated with digital rectal examination to 




Over the years, the focus of prostate cancer has been on the treatment. A patient with the condition 
is identified and they are offered invasive and non-invasive procedures that can generate adverse 
deleterious effects for the quality of life. Some efforts have been made for prevention without 
obtaining clear results according to the available evidence, and related to food and medication. 
Other efforts have focused on early diagnosis, with emphasis on the measurement of prostate-
specific antigen (PSA) and digital rectal examination, however, there are already systematic 
reviews and meta-analyzes that show how population screening is not suggested of opportunity, 
given the large population that would have to sift to prevent a 10-year death (1). On the other hand 
but complementary, PSA and digital rectal examination, although they are fundamental elements, 
have an operative performance (Sensitivity, specificity, predictive values and probability reasons) 
that is not high and therefore, has room for false positives and negatives that would limit the 
diagnostic suspicion of prostate cancer. 
 
There are some biomolecules that have been studied both in Prostatic Hyperplasia and in Prostate 
Cancer, however its validity in the general population is still limited. There is only one identified 
genomic variation (AR-V7) that shows the probability of resistance to hormonal management with 
enzalutamide and abiraterone in patients with castration-resistant prostate cancer and therefore 
would require the use of chemotherapy(2–4). However, there is no biomolecule or genomic variant 
that can be distributed at the time as an early detection test or risk for the development of prostate 
cancer, which supports the realization of this work. 
 
Justification 
Prostate cancer (PC) is the second most common type of cancer in the world's male population (5). 
It is estimated that one in seven men will be diagnosed at the end of their life with CP, and one in 
38 men will die as a result of this in the long term. Prostate Cancer is diagnosed more frequently 
as a consequence of the introduction in 1980 of the Prostate Specific Antigen (PSA) test as a 
diagnostic tool (3). 
During the last decade, there has been a notable decrease in mortality from prostate cancer in 
developed countries, but it has not been evidenced in developing countries. GLOBCAN in 2008 
reported that in northern European countries (Denmark, Norway and Sweden) the diagnosis has 
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increased by 8.2% per year, with a mortality rate falling since 2000 of 3.1% per year (6). Similar 
data were evidenced in the United States and Canada, in which the incidence in the diagnosis of 
PC remains stable, but with a decrease in mortality of 4.3% and 3.1% respectively. On the other 
hand, in developing countries, mortality has increased (although there are trends towards an 
increase in diagnosis, mortality has increased in countries such as Colombia, 3.4% per year, Costa 
Rica, 3.4% year, Chile 2.8% per year and Cuba 5.5% per year) (6,7). With respect to the global 
context, Colombia has one of the lowest incidences in Latin America (6). Additionally, the 
mortality rate from prostate cancer has decreased in the last four years (7) and the largest number 
of cases reported originate in the cities of Bogotá, Valle and Antioquia (The most populated 
regions with the largest number of Urologists) (7).  
 
On the other hand, when considering an appetite for the treatment of localized prostate cancer, 
which is the focus of the present work, there are currently studies that show that there are no 
differences in 10-year mortality when comparing monitoring, radical surgery of prostate and 
radiotherapy (8). Even when classifying the patient according to the risk of disease progression 
(D'amico) (9), it is evidenced that when comparing radical prostatectomy with clinical observation, 
there are no differences at 10 years of follow-up for the specific cancer mortality outcome (10) in 
localized low risk PC. 
 
This is important to note because we still have gaps in knowledge. For several decades, urologists 
have performed radical surgeries that generate adverse events such as erectile dysfunction, urinary 
incontinence and urethral stricture. Given that we have elements of uncertainty such as those 
already demonstrated, we could consider the search for markers that identify which patients do not 
require a surgical procedure or those that have the risk, could be evaluated the possibility of genetic 
manipulation for prevention of prostate cancer. 
 
Recent and interesting investigations have been carried out that, although they are not yet 
conclusive, do encourage us to continue searching for risk markers and genomic alterations that 
allow us to classify and treat our patients even before developing the disease. Inhibitory markers 
such as mitochondrial autophagy have been identified, related to the poor prognosis in prostate 
cancer. Epigenetics have identified alterations in DNA methylation and microRNA expression that 
occur in the transition from the normal cell, precancerous, primary and metastatic tumors. The 
circulating DNA fragments are another important strategy to generate the genetic profile and 
sequencing of the genes of patients with prostate cancer(11). In such a way that we still have gaps 















• To describe the frequency of Inherited DNA-repair genes and their variants associated to 
Prostate Cancer in a Cancer-Free Southwest Colombian population 
 
• To identify the association between the TMPRSS2:ERG fusion gene, their variants and the 
onset of localized prostate cancer. 
 
• To describe the frequency of allelic variants of TMPRSS2 gene in this population 
 
• To analyze the metabolomic profile in patients with malignant disturbances of the prostate 
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Prostate cancer given its frequency in the populations is a pathology of importance in public health 
not only national, but of high global impact  (12). Given the difficulties of the Health System, the 
limited availability of specialists and the high prevalence of this condition, the knowledge of this 
condition should be the domain of any general practitioner, and should not remain in specialized 
medicine areas such as urology and oncology. However, the treatment in an integral way, must be 
given by centers of excellence in cancer (13). 
Objective 
To obtain an updated view through a detailed and up-to-date review of the epidemiology, risk 
factors, classification, diagnosis and treatment of prostate cancer. 
 
Methods 
A search was performed in Embase and Medline (through OVID) from January 2000 to March 
2017. The keywords used were: "prostate" OR "prostate, neoplasm" AND "diagnosis" OR 
"treatment”. Additionally, an exhaustive manual evaluation of the bibliography provided in the 




Prostate cancer (PCA) is the most frequent neoplasm in men in the world, and represents the 
second cause of cancer death in this population in the United States (14). It has an incidence of 
131.5 / 100,000 inhabitants (14) with a race distribution of 123 / 100,000 inhabitants in the white 
and 208 / 100,000 inhabitants in the African American population (15). It is estimated that 1 in 7 
men will be diagnosed throughout their life with PCA, and 1 in 38 men will die as a consequence 
of it (16). 
The GLOBCAN study reported that in the Northern European countries (Denmark, Norway and 
Sweden) the diagnosis of PCA has increased 8.2% per year, accompanied by a declining mortality 
of 3,1% per year since 2000 (6). In the United States and Canada, similar data have been found, 
with a stable incidence but with a decrease in mortality of 4.3% and 3.1% respectively; however, 
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in developing countries, mortality has increased (6,7). Regarding the national epidemiology, 
Colombia has one of the lowest incidences of PCA in Latin America and a proportion of 28% 
between incidence and mortality for it, very close to the world average of 28.6% and lower than 
countries like Ecuador (40.41%), Cuba (46.65%) and Peru (37.74%) (6). Mortality has decreased 
in the last four years (7) and the regions with the highest number of CAP patients reported are 




Black patients have a higher prevalence of PCA (17), furthermore, they present at younger ages 
with greater tumor volume, a greater prostatic antigen level and worse prognosis  (18,19). Some 
authors associate these results with social inequities and difficulties in accessing health services, 
to which this population is exposed (20), however there is much more evidence that supports this 
factor as a risk factor for PCA. On the other hand, lower rates have been found in Asians, which 
has been additionally related to diet, lifestyles and environmental factors (21). 
Family History 
Approximately 10-15% of men with PCA have at least one relative with history of this condition 
(17,22). It has been estimated that having a relative of first degree of consanguinity with PCA 
increases the RR 2 to 4 times and is 5 times higher if there are two relatives with that diagnosis. 
Inflammation 
Chronic inflammation is considered a risk factor because it leads to cellular hyperproliferation, 
which generates an alteration in antioxidant levels, in DNA repair and apoptosis. It has also been 
found that the history of a sexually transmitted infection has an OR 1.5 (23) and history or current 
prostatitis an OR of 1.57 (24). Despite being one of the strongest hypotheses, it is still unclear the 
mechanism that would lead to producing the PCA or if it is a sufficient cause for its development. 
Oxidative Stress 
Some studies have suggested that reactive oxygen species (such as superoxide or peroxide) create 
an environment of mutagenesis conducive to the initiation of PCA (25,26). This element could be 
related to the hypothesis of chronic inflammation. 
Androgens 
There is evidence that an increase in testosterone levels increases the incidence of PCA, although 
a dose-response relationship or a concentration of which the risk is increased has not been found; 
additionally, a higher risk of PCA has not been found in patients with hypogonadism treated with 
testosterone replacement therapy (27). 
Estrogens 
It has been shown that estrogens that can predispose and even cause PCA. It is necessary to 
emphasize that 17β-estradiol has already been classified as a carcinogen, especially in breast and 
endometrial cancer. It is believed that the effect of estrogen in PCA is caused by direct mutations, 
through regulation by epigenetic effects or by endocrine disruption (28). 
Diet 
Several studies have suggested that a diet low in fat, calcium, with an increase in the consumption 
of vitamin E and lycopene, as well as regular exercise, could behave as protective factors for the 
development of PCA, on the other hand, the high intake of saturated fats of animal origin and red 
meat have been described as risk factors; however, the findings are not consistent between the 
different studies. For example, in the SELECT study, the protective factor for the use of vitamin 
E and selenium was not demonstrated (29). 
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Increase in levels of insulin-like growth factor (IGF-1) 
Insulin-like growth factor is a mitogenic and antiapoptotic factor. High levels imply more PCA 
risk (30). However, other studies do not find it as a risk factor. 
Genetic 
Alterations have been found in suppressor genes such as p53, PTEN, these are related to increased 
incidence, progression and aggressiveness of the PCA. Among other altered genes have been 
found: the RAS oncogene, EIF3S3, BCL2 (anti-apoptosis), EGFR, FGFR2c, ERBB2, BRCA 2, 
MET among many others under study. Some mutations in Chromosome 1 (family PCA risk) and 
8 (sporadic cancer), among others. Genetic polymorphisms have been demonstrated in some 
enzymes such as: 
• 5 alpha reductase (higher in black race) 
• Vitamin D receptor (VDR) which has been recognized as a protective factor, however it is 
decreased in black patients, thus increasing the risk of PCA. 
• Androgen receptor (AR): Increases the risk of family PCA. 
• Telomerase: It is a risk factor for sporadic cancer. 
Much attention has been focused on the BRCA2 gene (Breast Cancer susceptibility protein type 
2), which has an autosomal dominant inheritance pattern with incomplete dominance. Codifies for 
a protein of the same name, whose function is to act as a center by recruiting regulatory proteins, 
in order to repair double-strand breaks by homologous recombination, in addition it facilitates the 
repair of simple chains promoting the formation of the RAD51-ssDNA complex (Simple chain of 
DNA) (31). 
Historically, the BRCA2 gene has been linked to breast cancer, however recent findings indicate 
that it may play an important role in PCA. It has not been possible to identify with certainty the 
mechanism by which the mutations in this gene predispose to the development of the PCA, 
nevertheless by its function it is deduced that alterations of this predispose to a minor repair of the 
damages of the genome, which could result in alterations of the cell cycle and consequently a 
greater cellular proliferation. 
It has been found that patients with mutations of the BRCA2 gene generally present a higher 
incidence of PCA (32), more advanced stages (T3-T4), more aggressive phenotypes and lower 
survival despite receiving a local treatment with similar curative intent (33). 
Obesity 
Some authors suggest that obesity plays a role in the development of PCA. It is believed that the 
resistance to insulin produced by obesity leads to an elevation of this hormone, which due to its 
anabolic capacity could generate cancer development or its progression (34). It is believed that the 
obese are less likely to have high Prostate-Specific Antigen (PSA) and therefore less likely to 
perform biopsy and thus, less likely to diagnose PCA; This, together with the associations with the 
circulating levels of metabolic and sexual hormones, leads to the suggestion of obesity as a risk 
factor for aggressive PCA (35). 
Alcohol 
The relationship of alcohol intake with PCA is controversial. Rota et al in a meta-analysis (50 case-
control studies and 22 cohorts) with a total of 52,899 cancer cases, found no evidence between 
alcohol intake and PCA, there were even no statistical differences in the high-risk group intake (> 
= 4 alcoholic drinks per day) (36). 
Smoke 
The carcinogenic capacity of tobacco is known as well as the mechanism by which genetic damage 
is generated. In PCA, an increase in incidence has not been described, however it has been found 
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that it can generate higher rates of death due to PCA, although it is modest, it could have an impact 
at public health level because it is a modifiable risk factor (37). 
Natural History 
In autopsies, a 30-40% prevalence of PCA has been found in men older than 50 years, on the other 
hand, <5% in those under 30 years and approximately 60-70% in older people 79 years (38). It has 
been calculated that 1.5% of these are detectable by clinic every year. The PCA is progressive and 
its biological aggressiveness is directly related to the degree of cellular differentiation (Gleason 
Scale), the TNM, the PSA value, among other factors. 
Histopathologic Classification 
For classification of histopathology, the Gleason classification system is used, which exposes the 
degree of cell differentiation found in the prostatic stroma. It consists of two values, the first is the 
degree found more frequently and the second the next, thus a final value is obtained (For example: 
4 + 5 = 9), the score goes from 2 to 10. In the case where the two values are in the same proportions, 
the most undifferentiated is placed first. 
The new classification of Gleason performed by the American College of Pathology relates the 
score with the prognosis of each group (see Table 1) (39). 
Table 1. Gleason classification of the American College of Pathology. Adapted from Epstein et 
al.(39). 
Classification Score Characteristics 
1 <= 6 Only well differentiated glands. 
2 3 + 4 = 7 
Predominantly well differentiated glands with less 
component of poorly differentiated, fused or cribiform 
glands. 
3 4 + 3 = 7 Predominantly poorly differentiated, fused or cribriform glands with less component of differentiated glands 
4 8  (4 + 4 ; 3 + 5; 5 + 3) 
The different ways are: Only poorly differentiated, fused or 
cribiform glands; predominantly well differentiated glands 
and minor component that lacks glands; Predominant lack of 
glands and less component of well-differentiated glands. 
5 9 o 10 It lacks gland formation (or with necrosis) with or without glands, poorly differentiated, fused or cribriform glands. 
 
Pathologic and clinical classification 
It is based in TNM classification 2016 (Table 2) (40). 
 
Table 2. TNM classification for Prostate Cancer. Adapted from American Joint Committee on 
Cancer (40). 
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TNM Classification for Prostate Cancer 
Primary tumor, (T) clinical 
TX  The primary tumor cannot be evaluated 
T0  There is no evidence of primary tumor 
T1  Primary tumor is not clinically apparent (not visible, not palpable) 
T1a  Incidental tumor in 5% or less of resected prostate tissue 
T1b  Incidental tumor in more than 5% of resected prostate tissue 
T1c  Tumor identified by needle biopsy (due to elevation of the PSA). 
T2  Primary tumor confined to the prostate 
T2a Tumor compromises <50% of a lobe  
T2b  Tumor that compromises> 50% of a lobe  
T2c Tumor compromises both lobes 
T3  The tumor extends beyond the prostatic capsule (Invasion to the prostatic apex or to the 
prostatic capsule is classified as T2). 
T3a  Unilateral or bilateral extracapsular extension. 
T3b  The tumor involves seminal vesicles 
T4  Fixed tumor or tumor that invades adjacent structures different from the seminal vesicles: 
bladder neck, external sphincter, rectum, levator ani and / or pelvic wall. 
* The tumor detected by biopsy in one or both prostatic lobes, which is not palpable or visible by 
imaging, is classified as T1c.  
* Positive margins should be indicated as R1 (residual microscopic disease). 
Regional lymph nodes (N) 
Nx  Regional metastasis not evaluable. 
N0  There are no regional metastases. 
N1  Metastasis in one or several regional nodes.  
Distant metastasis (M) 
Mx  Distant metastasis not evaluable. 
M0  There is no distant metastasis. 
M1  Remote metastasis 
M1a  To non-regional lymph nodes 
M1b  To bone 
M1c  To another site  





The staging of the PCA is shown in table 3. For this, it must be taken into account that if the PSA 
or the Gleason value are not available, the classification must be determined by the T and/or the 
PSA value or the Gleason score available. 
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Table 3. Prostate cancer staging. 
Status T N M PSA Gleason 
I 
T1a-c N0 M0 < 10 <=6 
T2a N0 M0 < 10 <=6 
T1-T2a N0 M0 X X 
IIa 
T1a-c N0 M0 < 20 7 
T1a-c N0 M0 >=10 - <20 <=6 
T2a N0 M0 < 20 <=7 
T2b N0 M0 < 20 <=7 
T2b N0 M0 X X 
IIb 
T2c N0 M0 Any Any 
T1-2 N0 M0 >=20 Any 
T1-2 N0 M0 Any >=8 
III T3a-b N0 M0 Any Any 
IV 
T4 N0 M0 Any Any 
Any N1 M0 Any Any 
Any Any M1 Any Any 
 
Risk classification for localized carcinoma: 
The risk classification for localized carcinoma used historically for PCA is the D'amico 
Classification (see Table 4) (41). However, during the last years different changes have been 
generated according to the heterogeneous prognosis that can be presented with different factors, 
for which modifications and a new classification suggested by the National Comprehensive Cancer 
Network (NCCN) have been made (see Table 5) (42). 
 
Table 4. D’Amico Classification for localized carcinoma. Adapted from D’Amico et al (41). 
 
Risk PSA  Gleason TNM 
Low <= 10 <= 6 <= T2a 
Intermediate 10 a 20 7 T2b 
High >20 >= 8 >= T2c 
 
Table 5. New classification for localized carcinoma suggested for National Comprehensive 
Cancer Network (42). 
 
Risk PSA Gleason TNM Others 
Very low <10 <= 6 T1c 
Less than 3 cores of the positive 
biopsy, all with <50% of the core 
compromised; PSA density <15 ng / 
ml / gr 
Low <10 <= 6 T1-T2a   
	 11	
Intermediate 10 a 20 7 T2b-T2c   




Currently, prostate-specific antigen (PSA) in conjunction with digital rectal examination are 
mainly diagnostic methods used in the clinic to detect prostate cancer, however, these have low 
diagnostic performance, both individually and together (16). 
Prostate-Specific Antigen (PSA) 
PSA, also called kallikrein III is a 34kDA glycoprotein which is almost exclusive of prostatic 
epithelial cells. It circulates bound to alpha-1-antichymotrypsin and alpha-2-macroglobulin and its 
duty is to divide semenogelin I and II into smaller polypeptides, thus preventing the formation of 
the seminal clot (43–47). It is found in prostatic fluid at concentrations of 1,000,000 ng / mL, under 
normal conditions a small amount, less than 4ng / mL is released into the bloodstream, but in a 
neoplastic process these levels rise (47). For this reason, it is considered to perform a prostate 
biopsy on men with a serum PSA level greater than 4ng / mL (47). However, it has also been found 
elevated in other pathologies such as breast cancer, renal cell carcinoma, ovarian cancer and 
adrenal neoplasia (48). Similarly, other urological diseases such as benign prostatic hyperplasia 
(BPH), prostatitis, cystitis, instrumentation and surgery of the recent urinary tract may be elevated 
(1,47). It should be noted that digital rectal examination does not increase PSA values. 
According to the American Cancer Society (ACS), the PSA sensitivity for reference values of 
4ng/ml and 3ng/ml for cancer diagnosis is 21 and 32% respectively. A specificity of 91% for cut-
off values of 4ng / ml and 85% for PSA values of 3ng/ml (49). 
In the PLCO study, regarding PCA, men between 55-74 years were evaluated, who underwent 
annual screening with PSA for 13 years, as a result it was obtained that screening with PSA does 
not lead to a decrease in the incidence of PCA (RR 1.09, 95% CI 0.87-1.36) (50). Another large 
study was the ERSPC where PSA screening was carried out for 11 years to men from certain 
European countries, assessing mortality by PCA, the results indicated a relative reduction in 
mortality rates of 21% (RR 0.79, 95% CI 0.68 to 0.91) (51). 
A Cochrane meta-analysis conducted in 2011 summarized the results of 5 population experiments 
with a total of 341,351 participants and showed that screening with PSA is effective for the 
detection of PCA (RR 1.35, 95% CI 1.06-1.72) However, this test did not decrease mortality (RR 
0.95, 95% CI 0.85-1.07) (52), so that population screening for PCA is currently not recommended. 
However, there is not enough evidence to determine the best measure for screening in public 
health, for now it is suggested opportunity screening, men between 50 and 70 years (according to 
the life expectancy of the population) who enter the urologist's office and patients with risk factors 
(black race and family members with prostate cancer). 
It is of vital importance to clarify that in deciding the start of the search for the diagnosis of PCA, 
rectal examination should be performed in conjunction with PSA. 
 
Other biomarkers in the PCA diagnosis  
The failure of the PSA has led to the need to identify new biomarkers, with greater sensitivity and 
specificity, which allow an early diagnosis of PCA to be achieved (16). PSA, due to being elevated 
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in both benign conditions (benign prostatic hyperplasia) and in conditions of malignancy (53), has 
led to expensive and unnecessary biopsies being requested from patients who did not require it 
from the beginning (53). As a consequence, other techniques and molecules have been explored 
to make a more specific diagnosis, such as PCA3, microglobulin, mucins, among others (16). Some 
of these were included in a detailed review previously published by Esquivel Parra et al (16) and 
it is suggested to review to deepen the topic. 
Other tools that try to decrease the number of unnecessary biopsies that have not yet been 
successful and are used for patients with PSA values between 4 and 10 ng/ml are: 
The Free PSA/Total PSA Ratio: Raises the specificity for the diagnosis of PCA, in those cases 
with the mentioned levels in the presence of doubt as to the indication for biopsy. 
PSA can transit in serum freely (fPSA) or accompanied by protease inhibitors (cPSA) in order to 
avoid proteolysis. When adding the fPSA and cPSA results in the total serum PSA (tPSA), a large 
part of this, around 70-90% can be linked to alpha-1-antichymotrypsin, in smaller proportion to 
alpha-2-macroglobulin, alpha-1 antitrypsin or a protein C inhibitor (46). Consequently, about 10-
30% of the total PSA (tPSA) circulates freely (fPSA) (16). 
With indexes <0.07, the probability of PCA is almost 90%. A limit value is not yet defined, 
however the use of 0.20 is recommended to decide between biopsy or follow-up, the values above 
this suggest a diagnosis and adequate treatment for benign prostatic hyperplasia, on the other hand, 
the realization is suggested of biopsy in values lower than this due to the high probability of PCA. 
The PSA density (total PSA/volume of the prostate in cubic centimeters (cc) determined by 
ultrasound) before values > 0.15 ng /ml/cc should be biopsied since they suggest adenocarcinoma. 
The PSA velocity > 0.75 ng/ml/year (used in follow-up after prostatectomy or initial PSA > 
4ng/ml) suggests the presence of cancer; at present it has been lowered even to values like 0.35 
ng/ml/year (for PSA <4 ng / ml). 
Although all the tools are available to raise the specificity of PSA, prostate biopsy is currently 
considered in all patients with PSA> 4 ng / ml, however some authors suggest that taking a single 
PSA value of <2.5 ng/ml (It can be applied for patients under 50 years of age, since studies are 
needed to confirm its value). 
Transrectal prostate ultrasound guided biopsy: 
It is the gold standard for the diagnosis of PCA. The samples are taken in the prostatic periphery, 
which is the site with the highest frequency of carcinoma; usually for the first biopsy, at least 6 
cylinders should be taken for each lobe, in case of having a negative biopsy with persistence of 
elevated PSA, a saturation biopsy will be performed (> 10 - 12 samples/lobe). There are studies 
that show that prostate biopsy requires adequate analgesia/anesthesia and the use of antibiotic 
prophylaxis. 
Transrectal ultrasound of the prostate is only indicated, if it is accompanied by a biopsy, it should 
not be done in another condition. The indications for prostate biopsy are PSA >4ng/ml and the 
presence of alterations in the prostatic surface (nodule or stone prostate) predominantly, although 
there are variants that are not the subject of this review. 
Nuclear medicine 
Bone scintigraphy should be performed initially, in patients with PSA> 10 ng/ml or in those 
classified as intermediate and high risk patients. The probability that patients with PSA levels <10 
have a positive scintigraphy is below 1%. On the other hand, a PSA> 49 has a LR + (positive 
likelihood ratio) >6, which means that there is a 6 times higher probability of finding a positive 
scintigraphy in patients with PCA than in patients without PCA (54).  
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Computed tomography (CT)  
Abdominal CT (like magnetic resonance imaging) indirectly evaluates nodal invasion by 
measuring the diameter of the lymph nodes. However, its sensitivity is low and microscopic 
invasion can not be detected. Using a threshold of 10 mm, the sensitivity is <40%. The median 
sensitivity, specificity, negative predictive value and estimated positive predictive value are 7%, 
100%, 85% and 100%, respectively. 
Although fine needle aspiration biopsy (BACAF in Spanish) can be a good complement in cases 
with positive images, the difficulty of reaching the ganglia due to its position, makes it not very 
sensitive for staging and has a false negative rate of 40%. %. For CT (like MRI), the detection of 
microscopic lymph node invasion is <1% in patients with a Gleason score <8, PSA <20ng / ml, or 
localized disease. Its use should be reserved for high risk patients. 
Although bone CT has low specificity, its use over other techniques to evaluate bone metastases 
is preferred. It is recommended to be performed in symptomatic patients regardless of PSA levels, 
Gleason score or clinical stage. (55). 
 
Magnetic resonance (MRI) of prostate/pelvic  
The T2-weighted image is the most useful for local staging in MRI. At 1.5 T (Tesla), MRI has low 
sensitivity to detect extraprostatic extension of carcinoma (22-82%) or invasion of seminal vesicles 
(0-71%), but greater specificity (61-100% and 62-100). %, respectively). The overall accuracy of 
MRI to distinguish T1 / T2 stages from T3 is 50-85%. These results are due to the fact that MRI 
cannot detect the microscopic extra-prostatic extension, in such a way that its sensitivity increases 
with the radius of extension within the periprostatic fat (55).  
The use of the endorectal probe improves the accuracy of the stage at 1.5T, and a better precision 
has been demonstrated in the combined use of endorectal and external probes compared to the use 
only of external one. The high field strength allows a high resolution T2-WI and the results at 3T 
seem better than at 1.5T, although the experience of the reader is still of utmost importance, the 
precision of the RM to 3T varies between 67% and 93% depending on of the reader's experience. 
Even the prediction of the pathological stage by MRI can be improved when combined with 
clinical data. Given its low sensitivity for focal extra-prostatic (microscopic) extension, 
multiparametric prostate MRI is not recommended for local staging in low-risk patients. However, 
it may be useful in planning treatment in selected low-risk patients (56). 
 
PET/CT 
Positron emission tomography of 11C- or 18F-choline (PET) / CT has a good specificity for lymph 
node metastases, but the sensitivity is 10-73%. In a meta-analysis of 609 patients, the sensitivity 
and specificity of PET/CT for pelvic node metastases were 62% (95% CI, 51-66%) and 92% (95% 
CI: 89 -94%) (57). Because of its low sensitivity, PET/CT is not recommended for initial staging 
in lymph node metastases. Currently, studies are underway with psmaPET-CT (prostate-specific 
membrane antigen-PET CT). 
The PET / CT of 18F-choline shows a superior sensitivity to conventional bone CT when 
evaluating bone metastasis. It is not clear whether 11C-choline PET / CT is more sensitive than 
conventional bone scan, but has greater specificity, with fewer indeterminate lesions. However, 
the cost-effectiveness of these interventions has not yet been evaluated. Therefore, bone CT is 





The treatment of choice depends on the stage of the tumor at the time of diagnosis. Six treatment 
modalities could be used: 
• Surgical 
• External conformational radiation therapy 
• Brachytherapy 
• Hormonotherapy 
• Active surveillance. 
• Observation 
 
Localized prostate cancer < cT2c, Nx, M0 
The approach to localized prostate carcinoma depends on the level of risk previously called by 
D'Amico and the NCCN guidelines, as follows: 
• Very low risk: Any treatment modality can be performed. Good results have been observed 
with observation and active surveillance to avoid overtreatment. However, in patients with 
life expectancy greater than 10 years, surgical treatment could be considered. 
• Low risk: As in the previous group, any treatment modality can be performed. Life 
expectancy also plays an important role, since surgical treatment is probably not justified 
in patients with <10 years of age. In those who have a life expectancy> 10 years, who are 
considered candidates for surgical treatment, radical prostatectomy is the treatment of 
choice, without the need to perform lymphadenectomy that has been shown to be more 
effective when compared to radiotherapy (58). 
• Intermediate risk: Retropubic radical prostatectomy with bilateral pelvic 
lymphadenectomy is the management of choice in these patients. Usually in patients with 
life expectancy greater than 10 years. As any surgical procedure can have complications 
such as bleeding, infection, however, the most important for the patient are urinary 
incontinence and erectile dysfunction, clarifying that the frequency of these has decreased 
along with the improvement of the surgical technique and the preservation of the 
neurovascular bundles together with the external sphincter. Another modality of treatment 
is external radiotherapy which can be performed in these patients, it can be 3D 
conformational, with modulated intensity (74-80 Gy), or low rate brachytherapy 
(preferable for low risk patients). All have related complications, similar to surgery such 
as incontinence, erectile dysfunction, proctitis and/or cystitis. 
• High Risk: In this group of patients the treatment is performed in the same way as in the 
intermediate risk patient 
 
Locally advanced prostate cancer cT3-4, Nx, M0 
One of the therapeutic options is radical retropubic prostatectomy with bilateral pelvic 
lymphadenectomy in selected young patients, with clinical stage T3, gleason < 8 and PSA less 
than 20 ng/ml, this given that up to 25% may be overstaged. 
Another option that could be performed is external radiotherapy combined with hormonal therapy 
(neoadjuvant, concurrent and adjuvant LHRH analogues (for 1-3 years)). 
 
Advanced prostate cancer; Any T, N1, M1 
Hormone therapy (surgical or medical) is the treatment of choice in patients with advanced prostate 
cancer. The drugs currently used for medical orchiectomy are the LHRH analogues (leuprolide 
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acetate, goserelin acetate, and triptorelin acetate) and the gonadotropin-releasing hormone (GnRH) 
receptor antagonists (Degarelix), whose use it must be by specialized personnel. These can be 
added to emerging medications such as Abiraterone (inhibitor of testosterone synthesis), 
Enzalutamide (Androgen receptor inhibitor) and Radio-223, when the patient is called castration-
resistant (CRPC) (9). 
 
The criteria to be defined as resistant to castration are (9): Testosterone level below 50ng/dl or 
1.7nmol/l plus 
• Biochemical progression: Three consecutive elevations of the PSA, at least one week apart 
and resulting in two increments of 50% above the nadir and a PSA> 2, or; 
• Radiological progression: Appearance of new lesions: two or more lesions in a bone scan 
or a soft tissue lesion using the RECIST criteria (Response Evaluation Criteria in Solid 
Tumors). 
 
Antiandrogens are used as adjuvants in the treatment, there are two types: steroids and non-
steroids. Among the non-steroids are flutamide, bicalutamide, among others, however its 
indications, dosage and monitoring should be performed by the specialist (9).  
In those patients with metastatic and castration-resistant PCA, different classifications can be 
made: 1. According to the functional status and 2. According to the presence of symptoms or 
visceral metastasis. For those with impaired functional status, even the treatment is under 
investigation given the poor prognosis of the patients. For those with good functional status, we 
have different treatments among which are the new generation antiandrogens and chemotherapy. 
Asymptomatic or mildly symptomatic patients may receive: Abiraterone, Enzalutamide and Radio 
223, on the other hand, those who are symptomatic and/or have visceral metastases, are candidates 
for chemotherapy (Docetaxel or Cabazitaxel (As a second line)), whose management is given by 
the specialist in oncology and/or in interdisciplinary meetings (9).  
 
Discussion 
The present review on PCA presents an updated view on different aspects of prostate cancer. 
It is a very frequent pathology, with an incidence that varies between being stable or increasing 
and a prevalence that is clearly increasing, probably due to the improvement for diagnosis and 
treatment. With regard to risk factors, we have classically recognized as race, age and genetic 
factors clearly recognized as such, those that have not yet been able to find the role that plays as 
food and some that were formerly believed were factors protective and now aim to play a 
carcinogenic role as estrogens. 
It is important to perform an adequate classification and clinical, anatomical and pathological 
staging, since the process depends on the approximation and use of imaging and radiology 
techniques, as well as timely, individualized and indicated treatment based on evidence-based 
medicine. 
The genetic characterization and the microbiology of the PCA is what most efforts and researches 
aim for and point to, since tests with greater sensitivity and specificity are required that lead to an 
earlier, more accurate diagnosis and, if possible, to reach therapies more specific and less morbid 
 
Conclusion 
We have made a journey through the conditions of risk, screening, diagnosis, new biomarkers and 
treatment of prostate cancer. Several elements have changed in recent years, mainly about the 
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understanding of the physiology of cancer, the associated factors, the search for new biomarkers 
in each of the stages of cancer and various elements related to the treatment, however, much 
research there is ongoing on the prevention, diagnosis and treatment of this condition so important, 













































Chapter 2: Molecular alterations associated with prostate cancer 
 
Type of article: Narrative Review 
 
Authors: Herney Andrés García-Perdomo MD, MSc, EdD, PhD, FACS (1,2); James Alejandro 
Zapata-Copete MD (2,3); Adalberto Sanchez BSc PhD (1,4) 
 
Affiliations 
1. Associate professor, Universidad del Valle- Cali, Colombia 
2. UROGIV research group. Universidad del Valle, Cali, Colombia 
3. Epidemiology Department, Universidad Libre- Cali, Colombia 




Recently, the quantity and quality of tools available for the genetic study of cancer and the whole 
genome have increased, with even greater detail available for the exome alone. Many molecular 
signaling pathways provide negative or positive regulatory signals that control cell proliferation in 
a way that attempts to preserve cell number and homeostasis, but this process is completely altered 
in cancer cells (59,60).  
Normal cells must acquire at least eight attributes to transition from a normal cell to a cancer cell. 
These attributes include the following: 1. Genetic instability and mutation, 2. Autonomous growth, 
3. Insensitivity to internal and external anti-proliferative signals, 4. Resistance to apoptosis and 
other forms of induced cell death, 5. Unlimited cell division potential, 6. Ability to form new blood 
vessels (Angiogenesis), 7. Local invasive behavior that enables the distinction of benign and 
malignant neoplasms, and 8. Evasion of the immune system. 
Additionally, cancer cells require energy for autonomous growth and unlimited replication. 
Tumor-associated inflammatory mediators also cause preneoplastic cells to progress to invasive 
cancer cells; finally, cancer cells gain the ability to metastasize, that is, to migrate and colonize 
organs or tissues (59,61,62). The purpose of this article was to review the main biomolecular 
mechanisms associated with prostate cancer. 
Therefore, the somatic genetic alterations that are involved in the pathogenesis of prostate 
carcinoma progression are shown in Figure 1 (63,64). The objective of this review was to describe 
some of the different biological mechanisms associated with prostate cancer 
 
Methods 
We performed a systematic literature search in Medline via Ovid, Scopus (Includes Embase) and 
Lilacs from the inception to nowadays with the following keywords: Prostate neoplasms; Prostate 
cancer; Molecular Medicine; Genomics; pathways; cell cycle. We included reviews, systematic 
reviews, basic science studies and analytical studies, which tried to explain the molecular 
disturbances associated with prostate cancer. According to the heterogeneity expected, we 
synthesized information based on the molecular mechanism. Information about most promising 




Tumor suppressor genes and oncogenes 
Suppressor genes negatively regulate cell growth, and therefore, they play an important role in the 
normal cell cycle, DNA repair and cell signaling. The loss of the function of both alleles of a 
suppressor gene leads to carcinogenesis; thus, different pathways can result in cancer, such as 1. 
Homozygous gene deletion, 2. Loss of one allele and mutational inactivation of the second, 3. 
Mutations in both alleles, or 4. Loss of one allele and epigenetic inactivation of the second allele 
(e.g., DNA Methylation)(59). The two best characterized suppressor genes thus far are the 
retinoblastoma gene (RB1) and the TP53 gene, which are described later. 
 
Oncogenes are positively associated with cell proliferation and are the mutated form of normal 
genes (proto-oncogenes). Two such oncogenes are MYC and MET. MYC is responsible for the 
regulation of cell proliferation. This amplified gene is frequently present in prostate cancer (PCa), 
and its expression in prostatic cells has been associated with immortalization(65). In contrast, MET 
has been reported in renal cell carcinoma (RCC), primarily in the hereditary type(66). 
 
The mechanisms by which a proto-oncogene can become an activated oncogene are as follows: 1. 
Proto-oncogene mutation, 2. Gene amplification and 3. Chromosomal rearrangement. An example 
of the latter mechanism is the translocation that leads to the fusion of the TMPRSS2 gene with the 
ERG oncogene in a large proportion of PCa cases(67). Figure 2 schematically represents the cell 
cycle and describes how a cell in G0 is allowed to proliferate based on a signal, is duplicated in S 
phase, the phase in which DNA is synthesized, and subsequently segregates its genomic 
complement, which results in two daughter cells in a process called M phase (Mitosis). These two 
processes are separated by two critical gaps termed Gap 1 and Gap 2. The entire cycle lasts 
approximately 24 hours, and each phase depends on the previous one. In addition, some 
mechanisms function to verify the integrity of the DNA. If any alterations are found, the cell 
attempts to repair the damage, but if repair is not possible, the cell enters an active process termed 
apoptosis, which will be described later. The loss of the ability to respond to DNA damage leads 
to genetic instability, increases the mutation rate and mutates genes associated with cancer, thereby 
contributing to carcinogenesis and progression of the disease(68,69). 
 
Retinoblastoma protein (RB1) 
RB1 is important for controlling the R-point, which is a decisive point in late G1 phase during 
which the cell is committed to undergo division. Thus, if this control is lost, the cell continues to 
proliferate. All of the above events are due to inactivation of the RB1 pathway, which is mutated 
in at least 30% of bladder and prostate tumors, although RB1 mutations have not been strongly 
associated with these cancer types. It has also rarely been associated with renal carcinoma(70,71). 
 
Cyclin-dependent kinase inhibitors 
The temporal sequence of events during the cell cycle is dependent on cyclins and cyclin-
dependent kinases (CDKs). CDKs phosphorylate protein substrates that are involved in the 
execution of specific activities in each phase. In contrast, cyclin-dependent kinase inhibitors 
(CDKIs) bind directly to CDKs and suspend their activity and their ability to phosphorylate other 
proteins(72). CDKIs belong to one of two classes: the Cip / Kip Family, which includes the 
CDKN1A (p21), CDKN1B (p27) and CDKN1C (p57) proteins, and the INK4 (inhibits CDK4) 
family, which includes the INK4B (p15), INK4A (p16), INK4C (p18) and INK4D (p19) proteins. 
The p16 protein binds to CDKs 4 and 6 and inhibits their interaction with cyclin D1; normally, 
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active CDK4 and 6 mediate the passage of the cell through G1 phase via the phosphorylation of 
RB1(59,73). The latter has also been associated with bladder cancer (by deletion of INK4A) and 
with renal cancer, and p16 inactivation has been shown to occur by hypermethylation of the DNA 
(epigenetic mechanism)(74). In prostate cancer, hypermethylation of INK4A is typically seen in 
60% of cases, although INK4B is rarely inactivated (75). 
Decreased CDKN1B has been correlated with decreased overall survival and disease-free survival 
after radical prostatectomy. In addition to positive CDKN1B in prostate biopsies, it has been 
associated with increased biochemical recurrence, and in mice, absence is associated with prostatic 
hyperplasia (76,77).  
 
Tumor suppressor TP53 
TP53 is a suppressor protein that plays an important role in response to cellular damage. It signals 
a halt to the cycle or leads to damage repair pathways (Figure 3), but if repair is not possible, the 
cell will undergo apoptosis. This suppressor is often mutated in genitourinary cancers. 
Additionally, Figure 4 shows the possible causes of alterations in TP53 and its responses in the 
cell cycle. 
 
TP53-induced apoptosis is mediated by Bcl-2 through an intrinsic pathway, and alterations in the 
regulation of this pathway have direct relevance in the etiology of cancer. This pathway is 
associated with the activation of transcriptional genes and the inhibition of other genes that block 
the cascade. On the one hand, TP-53 is dependent on the activation of the Apaf-1/caspase-9 
pathway, but on the other hand, Bax (Bcl-2 family) is not essential for TP-53-dependent apoptosis. 
In addition, different tumor suppressive pathways are associated with TP-53, and some examples 
are the response to DNA damage, cell senescence and apoptosis, and thus, it is logical to consider 
that TP-53 is frequently mutated in cancer (59,78). 
 
Methylation of DNA 
The covalent modification of the C5 position of the cytosine by a methyl group is mediated by 
DNA methyltransferase and results in the formation of 5-methylcytosine, which is an epigenetic 
modification that occurs in vertebrates and is part of normal and essential embryological 
development. As vertebrates have evolved, CpG dinucleotides have become depleted within the 
genome, but in some areas, this depletion is not seen; these areas are termed CpG islands and 
represent approximately 1% of the genome. The epigenetic properties of methylation can affect 
the genetic activity without alterations in the DNA sequence and represent an alternative means to 
inactivate the gene apart from a mutation or deletion. The three major pathways that DNA 
methylation uses to result in genetic alterations include the following: 1. Inherent mutational 
effects of 5-methylcytosine, 2. Epigenetic effects of the promoter on transcription and 3. 
Activation and potential induction of a gene due to instability of the chromosome by DNA 
hypomethylation(59).  
 
DNA methylation and prostate cancer 
Glutathione S transferases are a family of enzymes that are responsible for the detoxification of a 
large group of xenobiotics that catalyze the nucleophilic attack of reduced glutathione in 
potentially harmful electrophilic compounds. The aberrant methylation of the CpG island at the 
glutathione S transferase pi (GSTP1) locus is the most frequent somatic alteration reported in PCa 
(79). This methylation has been detected in up to 90% of PCa and in 70% of Prostatic 
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Intraepithelial Neoplasia (PIN), however it might be present in normal or hyperplastic tissue (79). 
Due to oxidative stress, this aberrant methylation leads to the overexpression of GSTP1 in prostatic 
epithelial columnar cells. These findings are also associated with worse clinical outcomes(80). 
 
The gene of the ras association domain of the familial protein 1 isoform A (RASSF1A) is located 
on chromosome 3p21. This is a suppressor gene that is methylated in 60-70% of prostate 
carcinomas, and it has been observed that this alteration is more frequent in high-grade tumors 
than in less aggressive tumors(81,82). The methylation patterns are not consistent since they can 
consist of either hypo or hypermethylation, and in addition, the methylation is conserved in all 
metastases, suggesting an alteration that follows clonal selection(83,84). 
 
DNA damage and repair 
Cancer is fundamentally a genetic disease. Alterations in different genes will lead to the activation 
of different pathways associated with cancer, leading to changes in tumor suppressor genes and 
oncogenes through epigenetic, mutational and copy number distortions. 
To counteract these elements, the cell employs different defense mechanisms including the use of 
free radicals such as alpha tocopherol, vitamin C, carotenoids, bilirubin and urate and protective 
enzymes such as superoxide dismutase, glutathione peroxidase and glutathione transferase. In 
addition to the previously described methylation of GSTP1, associations have been found between 
the polymorphisms of this gene and the risk of biochemical recurrence in patients with PCa (85). 
The cell additionally employs a series of mechanisms termed the DNA damage response (DDR), 
which involves a number of genes. DDR relies on the replication machinery, as well as on specific 




Deletions of chromosomal segments are frequently found, although gains and amplifications are 
seen more frequently in cases of advanced disease(69). These changes have been demonstrated 
through cytogenetic techniques such as genomic hybridization, fluorescence in situ hybridization 
or detection of microsatellites. Cytogenetic methods detect numerical changes, while molecular 
analytic methods identify recombinations that do not lead to changes in copy number(69). 
  
The most frequently altered autosomes are 8, 13, 7, 10, 16, 6 and 17, likely in this order. In addition, 
gains or amplification of parts of the X chromosome and losses of the Y are also observed. A 
decreased copy number and loss of heterozygosity of chromosome 8p are also consistent in 
previous studies (observed in approximately 50% of cases). Specific alterations are observed in 
each of the chromosomes, but special attention must be paid to the functional impact each 
alteration may have on the tumor phenotype and the indication or expression of the tumor 
suppressor genes or oncogenes in the affected regions (69). 
 
Recurrent genetic rearrangements in PCa 
Recurrent gene fusions have been identified, primarily between the androgen-regulated gene 
TMPRSS2 and ERG, which is a member of the ETS (E26 Transforming sequence) family. This 
fusion occurs in 90% of all fusions that involve ETS genes in prostate cancer(86). The other fusions 
occur as a result of more complex types of translocations(67,87). In 60% of cases, the fusion occurs 
due to a deletion of the sequence that separates the two genes (3 Mb). 
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These rearrangements can be readily identified through reverse transcription polymerase chain 
reaction (RT-PCR) or by multicolor fluorescence in situ hybridization (FISH). 
At present, several clinical studies have evaluated these markers in urine and blood, while other 
studies have evaluated the expression of the ERG protein using a simpler method 
(immunostaining)(88–90). The TMPRSS2-ERG fusion status is considered a possible diagnostic 
marker, although its prognostic significance is still unclear, which is a fundamental part of patient 
follow-up(91,92). 
The TMPRSS2 gene can be merged with other members of the ETS family including ETV1, ETV4 
and ETV5(93,94). 
Studies have been performed with different technologies including next generation RNA 
sequencing; in these studies, it was found that some fusions are single events or events that occur 
in only one patient, which might imply that we actually know very little about PCa (95). 
 
PTEN and PI3K/mTOR 
The PI3K/mTOR (mammalian target of rapamycin) pathway plays an important role in cell 
growth, proliferation and oncogenesis in PCa (96–98). PTEN is a negative regulator of this 
pathway. In retrospective studies, it has been shown how the loss of PTEN and consequently, the 
activation of the mTOR pathway lead to a poor prognosis in PCa (63). PTEN deletions have been 
found in up to 20% of patients with PCa and have been associated with earlier biochemical relapse, 
metastasis, resistance to castration, presence of ERG gene fusions and the accumulation of nuclear 
TP53(63). 
 
Association with telomeres 
A potential association between telomere length and prostate cancer has been found. Initially, this 
association was found only in studies with small sample sizes, but subsequently, some studies with 
larger sample sizes were performed in which associations were observed between a short telomere 
length and decreased overall survival and increased biochemical recurrence. These findings have 
been consistent even when adjusted for age, Gleason score and lymph node involvement. It has 
been proposed that cancer that develops from these areas can lead to greater genotype and 
phenotype heterogeneity, as well as to an increase in aggressiveness(99). Some studies have even 
suggested that the risk of death is increased up to 14 times in patients with short telomeres 
compared with patients with long telomeres(100). 
 
Apoptosis 
Apoptosis is an orderly, energy-requiring process in which the cellular content is degraded and 
condensed into an apoptotic body that is finally digested by neighboring cells or 
macrophages(101). The positive or negative signals of the apoptotic process finally converge in a 
family of proteases termed cysteine proteases with aspartic acid specificity. Caspases total at least 
13, and some of them are initiators (caspase-8, caspase-9, caspase-10), whereas others are 
executioners (caspase-3, caspase-6 and caspase-7). Caspases are derived from procaspases, which 
are larger inactive forms that require proteolytic cleavage in order to become active. They are 
frequently activated by other caspases (initiator) to generate an activating cascade of executioner 
caspases. The latter type attacks different anti-apoptotic intracellular proteins such as Bcl-2 and 
Bcl-XL. They not only destroy their anti-apoptotic functions but also release carboxyl-terminal 
fragments to remove the cell(102). They also degrade DNA repair and replication proteins such as 
DNA-PKcs and replication factor C, leading to nuclear dysregulation. 
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Nuclear proteins such as laminin, NuMa and SAF-A are fragmented and undergo nuclear 
dissolution and nuclear condensation (milestones in the cell that lead to apoptosis). Proteolysis of 
cytoskeletal proteins such as keratin and actin also occurs, which leads to the destruction of the 
integrity of the internal structure. A final step is the breakdown of cell-to-cell interaction proteins 
such as beta-catenin and focal adhesion kinase, which precipitates the phenotypic and irreversible 
changes associated with apoptosis(102). 
 
Global defects in apoptosis 
In both PCa and PIN, a high level of apoptosis is seen, although compared with other malignancies, 
PCa has low apoptotic activity along with increased replication. As PCa progresses, it is unclear 
whether androgen-resistant cells have an increased or decreased apoptosis rate because both have 
been found in patients with castration-resistant prostate cancer(103). In contrast, an advanced 
infiltrative tumor whose DNA is mutated and that is fast-growing may have a high rate of apoptosis 
despite the protective mechanisms that the cell has acquired. 
 
Apoptosis can be initiated by two pathways: the intrinsic and the extrinsic pathways (Figure 5). 
The intrinsic pathway monitors conditions within the cell and responds to various forms of stress. 
Pro-apoptotic signals can originate from damaged and unrepaired DNA or from the lack of signals 
from the cell surface (cell-cell or cell-matrix contacts, including hormones or diminished growth 
factors). 
 
Mitochondria and the Bcl-2 family are major components of the intrinsic pathway. The Bcl-2 
family contains 12 pro-apoptotic proteins including Bax, Bak, Bok, Bik, Bas, Bid and Bim. It also 
contains six pro-survival proteins including Bcl-2, Bcl-XL, Bcl-W and Mcl1(104).  
Each protein in the family responds to different stimuli; however, their primary function is to 
increase the permeability of the mitochondrial membrane(105). Subsequently, cytochrome c is 
released from the intermembrane space into the cytoplasm, where it binds to Apaf-1 proteins and 
forms the apoptosome complex. Caspase-9 is activated, which then activates the entire cascade 
described above. 
In addition, other activations occur such as ones that involve Bid, which is regulated by initiating 
caspases in the cytosol. Caspase-8 allows the dimerization of Bid with Bax or Bcl-2. This active 
form of Bax inhibits Bcl-2, which leads to apoptosis. This process can be blocked by anti-apoptotic 
proteins and by the IAP proteins that inhibit specific caspases(59). 
 
The extrinsic pathway mediates apoptosis after receiving external signals from surface receptors 
called "death receptors", such as TNFR1 (tumor necrosis factor receptor 1) and Fas receptor. The 
death receptor domain is located in its intracellular region and allows binding to adapter proteins 
that also contain a death domain (RIP, TRADD, FADD). Additionally, these proteins have an 
effector domain that binds to the caspase recruitment domain (CARD) of the initiating 
caspase(106). Subsequently, the initiator caspase is cleaved and is able to activate the cascade. 
 
The most well-known death receptor is CD95 or Fas, but this receptor does not appear to have a 
direct effect on the etiology of cancer. In contrast, IGF-1 can activate the PI3K / AKT anti-
apoptotic pathway and stimulate the expression of Bcl-like proteins along with Bax suppression. 
In addition, the expression of IGF binding proteins may also be altered in PCa (69,107,108).  
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Androgens and prostate cancer 
Most treatments for PCa are based on androgenic suppression, but they are rarely curative. To cure 
the disease, different mechanisms should be considered and are described as follows (Figure 6): 1. 
Some carcinomas do not express androgen receptor (AR) in some cases because the gene is 
silenced by a hypermethylated promoter; 2. Several peptide growth factors and cytokines such as 
fibroblast growth factor 7 (FGF7), epidermal growth factor (EGF) and interleukin-6 (IL-6) can 
activate the AR synergistically with or independently of a steroid ligand; 3. In some carcinomas, 
somatic mutations in the AR alter its receptor specificity and cause it to respond to estrogen, 
progesterone, dehydroepiandrosterone or synthetic anti-androgens; 4. Amplification of the AR 
gene can occur in up to 30% of cases, even in the presence of depletion, which leads to increased 
sensitivity to a minimal androgen level; 5. Different coactivating proteins have been identified as 
mediators of the effects of AR on chromatin structure, as well as transcriptional initiators and their 
interactions with other signaling pathways. All of the circumstances described above could lead to 
androgen-independent tumor growth(69). 
 
Expression profiles 
With the advent of the analysis of gene expression patterns by cDNA or oligonucleotide 
microarrays, research related to the diagnosis, prognosis and new therapeutic markers has become 
increasingly important. For example, it has been found that hepsin is not a good marker since its 
down-regulation increases tumor heterogeneity in prostate carcinomas(109). Another marker is the 
P504S protein, which is identical to Alpha-Methyl-Acyl-CoA Racemase (AMACR); the latter is a 
peroxisomal enzyme that is involved in the metabolism of branched-chain amino acids, which 
might be useful for the differentiation of hyperplasia and atrophy from cancer(110,111).    
 
Epigenetics / Environmental factors 
Lifestyle and dietary habits have been found to be triggers of the oncogenic cascade in PCa. For 
example, dietary carcinogens, estrogens and oxidants act as a trigger for chronic inflammatory 
changes within the prostatic tissue and thus act as a promoter of PCa (63,112,113). It has been 
suggested that the intake of red meat (formation of heterocyclic aromatic amines and polycyclic 
aromatic hydrocarbon, which have carcinogenic properties) or animal fat is a risk factor for PCa. 
However, when prevention studies on both of these micronutrients and other elements of the diet 
were performed, the suppression of those elements was not found to prevent prostate cancer(29). 
Additionally, sexually transmitted diseases as part of a system that triggers chronic inflammation 
in epithelial cells have been associated with the development of PCa (Figure 7)(114–116). 
Given the change from persistent oxidative stress, a survival response is generated by glutathione 
S transferase, cyclooxygenase-2 and other mediators. In general, the epigenetic silencing of 
multiple genes occurs, including the silencing of a fundamental gene, GSTP1, which is found 
throughout all stages of prostate cancer progression(63). 
 
Conclusions 
The natural history of prostate cancer involves numerous genetic and molecular alterations that 
cause the normal prostatic epithelial cell to become cancerous and resistant to castration. Different 
biological mechanisms have been associated with the development of prostate cancer, such as 
alterations in tumor suppressor genes, oncogenes (TP53, RB1, among others) and CDKIs; DNA 
methylation; chromosomal alterations and rearrangements; changes in PTEN and PI3K / mTOR; 
global defects in apoptosis; alterations in the AR; and epigenetic mechanisms. These are not the 
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only mechanisms, but they have been found to be associated with prostate cancer at a higher 
frequency than others. Similarly, the development of prostate cancer does not have a unique 
etiology, but rather, it is predominantly multifactorial and can be explained by the different 










































Figure 6. Mechanisms of altered androgen signaling in prostate carcinoma* 
*1: The androgen receptor (AR) is absent in some carcinomas. 2: Growth factors activate the AR 
or a coactivator in a ligand-independent fashion. 3: AR mutations alter ligand specificity and 
affinity. 4: AR expression is increased by gene amplification. 5: Coactivators are differentially 
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Currently, prostate-specific antigen combined with digital rectal examination are the screening 
methods mainly used in the clinic to detect prostate cancer, however, these have low diagnostic 
performance, both individually and as a whole. 
The importance of finding new biomarkers, which are more sensitive and specific for screening 
and early diagnosis of prostate cancer, has been especially reinforced by the PSA failure. The fact 
that the latter is elevated in a benign condition such as prostatic hyperplasia and also in conditions 
of malignancy (53), has led to the requesting costly and unnecessary biopsies to patients who did 
not require it from the beginning (53). As a consequence of this, other techniques and molecules 
have been explored to make a more specific diagnosis, such as PCA3, microglobulin and mucins, 
among others. 
The aim of the present work was to describe some of the new biomarkers involved in the screening 




Prostate cancer (PCA) is the second most common type of cancer in the world's male population 
(5). It is estimated that 1 in 7 men will be diagnosed throughout their life with PCA, and 1 in 38 
men will die as a result of it. Similarly, in the United States 6 out of 10 men diagnosed with prostate 
cancer are older than 65 (117). It is the type of cancer that is most often diagnosed as a result of 
the introduction in 1980 of the Prostate-Specific Antigen (PSA) test as a diagnostic tool (3). It is 
estimated that by the year 2030 there will be 1.7 million new cases of PC in the world, with an 
expected mortality of 499,000 cases (29.3%) (7). 
 
During the last decade, there has been a notable decrease in mortality from prostate cancer in 
developed countries. The GLOBOCAN study reports that the incidence of PC is variable in the 
global context: Rates are higher in countries such as Australia/New Zealand, North America (ASR) 
111.6 and 97.2 per 100,000 respectively) and in Western and Northern Europe, because screening 
with PSA and subsequent biopsy are performed routinely (118). In countries of North America 
(United States and Canada) the mortality by PCA has decreased to 4.3% and 3.1% respectively, 
and in countries such as Denmark, Norway and Sweden (Northern Europe) the mortality rates have 
declined from the year 2000 to 3.1% per year (6); however, in developing countries, mortality has 
increased (although there are trends towards increased diagnosis, mortality has increased in 
countries such as Colombia, 3.4% per year, Costa Rica, 3.4% per year, Chile 2.8% per year and 
Cuba 5.5% per year) (6,7). With regard to the global context, Colombia has one of the lowest PCA 
incidences in Latin America and a 28% share of incidence and mortality for it, very close to the 
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world average of 28.6% and lower than countries like Ecuador ( 40.41%), Peru (37.74%) and Cuba 
(46.65%) (6). Finally, in Colombia the mortality rate from prostate cancer has decreased in the last 
four years (7) and the highest number of reported cases originate in cities such as Bogotá, Valle 
and Antioquia (The most populated regions with the largest number of Urologists ) (7). 
 
Biomarkers in PCA diagnosis 
What we had? 
Prostatic-Specific Antigen 
 
The history of use of the Prostate-Specific Antigen (PSA) dates from the 1980s, when it was used 
in the follow-up of patients diagnosed with prostate cancer PCA (119), subsequently, for the year 
1994 FDA (US - Food and Drug Administration) approved the use of PSA along with digital rectal 
examination as screening methods for PCA (47). 
 
The PSA, also called kallikrein III is a glycoprotein of 34kDa produced almost exclusively by the 
epithelial cells of the prostate gland, which circulates bound to alpha 1-antichymotrypsin and alpha 
2-macroglobulin and its duty is to split semenogelin I and II in smaller polypeptides, thus avoiding 
formation of the seminal clot (43–47). Under normal conditions a small amount, less than 4ng/mL, 
is released into the bloodstream, but in a neoplastic process these levels rise (47). For this reason, 
it is considered to perform a prostate biopsy on men with a serum PSA level greater than 4ng / mL 
(47). However, PSA has also been found elevated in other pathologies such as breast cancer, renal 
cell carcinoma, ovarian cancer and adrenal neoplasia (48). Similarly, benign prostatic hyperplasia 
(BPH), prostatitis, cystitis, perineal trauma and recent urinary tract surgery may elevate it (1,47). 
PSA can be in serum freely (fPSA) or accompanied by protease inhibitors (cPSA) in order to avoid 
proteolysis. When adding the fPSA and cPSA results in the total serum PSA (tPSA), a large part 
of this, around 70-90% can be linked to alpha-1-antichymotrypsin, in smaller proportion to alpha-
2-macroglobulin, alpha-1 antitrypsin or a protein C inhibitor (46). Consequently, about 10-30% of 
total PSA (tPSA) circulates freely (fPSA), this free form of PSA is characterized by assuming three 
specific molecular forms (120). One of them is predominantly in the transition zone of the prostate 
in patients with BPH and is called BPSA (121), the second representation is called intact PSA 
(iPSA) and finally there is the proPSA (pPSA), found in its most in the peripheral zone of the 
prostate gland, which is associated with prostate cancer (122). 
 
According to the American Cancer Society (ACS), the PSA sensitivity for reference values of 4ng 
/ ml and 3ng / ml for cancer diagnosis is 21 and 32% respectively. A specificity of 91% for cut-off 
values of 4ng / ml and 85% for PSA values of 3ng / ml (49). 
 
In the USA, the study PLCO was performed to evaluate the incidence of ovarian, colorectal, 
pulmonary and prostate cancer. In the case of PCA, men between 55-74 years were evaluated, who 
underwent annual screening with PSA for 13 years, as a result it was obtained that screening with 
PSA does not lead to a decrease in the incidence of PC (RR 1.09 , 95% CI 0.87-1.36) (50). Another 
large study was the ERSPC (The European Randomized Study of Screening for Prostate Cancer), 
where PSA was screened for 11 years to men from certain European countries, evaluating the 
mortality by PC, the results indicated a relative reduction in the rates of Mortality of 21% (RR 
0.79, 95% CI 0.68 to 0.91) (51). 
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A Cochrane meta-analysis conducted in 2011 summarized the results of 5 population experiments 
with a total of 341,351 participants and showed that screening with PSA is effective for the 
detection of prostate cancer (RR 1.35, 95% CI 1.06-1.72) , however, this test did not decrease 
mortality (RR 0.95, 95% CI 0.85-1.07) (52). Another meta-analysis of the year 2010 obtained 
similar results, aimed to show evidence of the benefits of screening with the prostate-specific 
antigen, for which results were taken from 6 experiments with a total of 387,286 participants. The 
results showed that screening with PSA is related to an increased probability of diagnosing prostate 
cancer (RR 1.46, 95%, CI 1.21-1.77), but as in the previous study, no decrease in PCA mortality 
was observed. (RR 0.88, 95% CI 0.71- 1.09) (123), so that population screening for prostate cancer 
is not recommended at present. 
This suggests the importance of determining other more specific biomarkers, which lead to a 
decrease in unnecessary biopsies, as well as an early detection of prostate cancer and thus improve 
patient survival. 
 
What is more recent? 
Prostate Cancer Gen 3 (PCA3) 
The PCA3 (Long non-coding RNA prostate cancer associated 3 gene test) has been implicated in 
a significant number of investigations that reflect the rationale for the study of prostate cancer 
(124). This is involved in the survival of the cancer cell, this effect is achieved in part by 
modulating the signaling to the androgen receptor (AR) and exerts its main function in the nucleus 
and in the microsomal fraction of the cell (125). 
Taking this test requires that the process be divided into two large parts; First a prostate massage 
must be performed and then the urine sample is obtained, this will facilitate the appearance of the 
biomarker in the urine (125). 
The studies have shown promising results, but controversial at the same time for different reasons. 
They are promising because it has been found that the measurement of this biomarker can 
differentiate between cancer and chronic prostatitis/benign prostatic hyperplasia (53). In part, the 
reason why this is possible is related to the high expression of the molecule in cancer tissue 60 to 
100 times more than in inflamed tissue but without neoplasia and it should also be noted that this 
was observed in 95% of patients (124). Christos K et al., (53) mention that this biomarker is useful 
to differentiate between benign prostatic hyperplasia (BPH) from localized cancer, however, they 
suggest that the use of the molecule for screening should not be unique, but rather, should be a 
panel of new biomarkers that provide greater diagnostic precision (124). The use of Beta 2 
microglobulin (B2M) and intestinal mucin (MUC3) associated with PCA3 (53) is also mentioned. 
It was known in this study that the values taken into account to say if the increase of PCA3 is 
relevant are: 195 DU (with this reference value the diagnostic accuracy is improved up to 77%) 
(53). 
Although the advantages of the use of PCA3 for the diagnosis of prostate cancer have been 
elucidated and the idea of using it in therapeutic programs as a support has been supported (124); 
there is a counterpart that discusses the clinical validity of the findings found in the different 
studies. This controversy is based on the fact that there are few studies that provide a greater 
knowledge of the biomarker and those that currently exist are criticized that have used small 
population samples that make the final result less reliable. More studies are needed that include a 
larger proportion of patients and are followed up over a longer period of time (124). As a result of 
the above, it has been found that there is a failure to demonstrate that the associations between 
PCA3 and prostate cancer have any relevance in the patient's prognosis (125). According to this 
	 31	
study, using biomarkers in this way, the predictive value of the test is increased and it is possible 
to differentiate between benign inflammatory conditions and those that require special follow-up, 
such as neoplasia (125). 
 
β2 - microglobulin 
The b2-microglobulin (B2M) is a low molecular weight polypeptide (11,815 D), synthesized by 
nucleated cells and complexed with the Major Histocompatibility Complex I (MHC I) (126) 
(whereby it is assumed that it plays a role in the immune response). Initially identified in the urine 
of patients with renal tubular disease (127) and later in patients with breast cancer (128) and gastric 
cancer (129).  
It has been reported that B2M stimulates growth and increases the expression of genes coding for 
osteocalcin (OC) and bone sialoprotein (BSP) in cells of PCA by activating the protein kinase-A 
enzyme cascade, Cyclic AMP (cAMP) dependent. Thus, when there is an overexpression of B2M 
in prostate cancer cells, an increase in the coding of genes that will ultimately be responsible for 
generating metastases is generated, such as OC, SBP, cyclin A, cyclin D1 and vascular endothelial 
growth (VEGF). These gene pathways suggest that signaling mediated by B2M could be a 
therapeutic target for the treatment of PCA with bone metastasis (Figure 8) (130–132). Similarly, 
another molecular pathway in which B2M has been involved is in the interaction with iron 
homeostasis. When B2M interacts with the protein hemochromatosis (HFE) (which acts as its 
receptor), modulation occurs in iron homeostasis and subsequent epithelial-mesenchymal 
transdifferentiation (EMT), which ends up promoting growth, invasion and metastasis to bones 
and soft tissues (Figure 9) (133). 
 
In studies carried out by Zhang et al, it was demonstrated that the serum B2M marker could be 
used as a diagnostic marker for PCA and useful in the differentiation between malignant processes 
and BPH when finding that serum levels of B2M were significantly elevated in patients with PCA, 
unlike levels of the same marker in patients with BPH or in the control group. However, no marked 
difference was found between B2M levels between patients with BPH and those in the control 
group. 
Likewise, patients with higher PSA levels (≥ 20 mg / mL) have higher B2M levels and vice versa 
(134). Therefore, B2M levels are associated with greater clinical aggressiveness (134). 
B2M can, therefore, be an efficient biomarker for the clinical diagnosis, follow-up and prognosis 
of PC and, in turn, a potentially effective therapeutic target to reverse EMT and thus prevent 
metastatic progression (135). 
 
4Kscore (4 kallicrein assay) 
The 4Kscore test, as the name implies, combines the plasma values of four kallikreins used as 
prostate markers: total PSA (tPSA), free PSA (fPSA), intact PSA (iPSA) and kallikrein -2 (hK2) 
(136). Most plasma PSA is bound to protease inhibitors and a small amount is found freely (fPSA), 
this free PSA assumes three molecular forms: iPSA, pro-PSA and BPSA. A lower value of fPSA 
in proportion to tPSA is more related to PCA, whereas a higher value is associated with benign 
disease. Kallicrein-2 has been found to be increased in patients with high-grade prostate cancer. 
Additionally, in the 4K test, data such as the age of the person, digital rectal examination findings 
(nodules) and previous biopsy history are taken (136). 
In different studies: Gothenburg ERSPC (137), ProtecT (138), Rotterdam ERSPC (139), Braun K, 
et al. (140), Parekh Dj, et al. (141) among others it has been concluded that the use of the 4K test 
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practically halves the practice of biopsies in patients with PSA in the gray area (4-10ng / ml), since 
it allows identifying those individuals susceptible to developing cancer clinically relevant to those 
with non-malignant disease. 
In conclusion, the 4K panel allows the prediction of prostate cancer to be individualized even if 
the patient has not previously been screened or biopsied. This panel decreases around 41-71% of 
biopsies performed unnecessarily (136). However, there are limitations regarding the availability 
of the panel in the daily clinical scenario. Currently it is only available in the United States and the 
cost for patients is around $ 1185 USD (136). 
 
Mucins  
Mucins are glycosylated proteins of high molecular weight, present in most epithelial tissues, 
including the urinary tract and the reproductive system (142). 
Currently a total of 21 mucin-encoding genes are known, these have been divided into two groups: 
MUC1, MUC3 and MUC4 coding for membrane mucins, these being necessary in the cell-cell 
interaction, while the genes MUC2, MUC5AC, MUC5B and MUC6 code for mucus-secreting 
mucins (143). 
The function of mucins in general is to protect and hydrate the epithelium. However, in neoplastic 
processes its function has been affected (144). 
MUC1 has been the most studied in the development of different cancers, among those prostate 
cancer, where it has been implicated in angiogenesis, proliferation and transduction of tumor 
signals, as well as in tumor invasion and metastasis (144), and that diminishes the immune 
response and promotes tumor propagation to other tissues, as cell-cell and cell-extracellular matrix 
interactions are lost (142). 
In malignant prostatic tissue, through tissue microarrays, an overproduction of MUC1 has been 
reported, together with an aberrant distribution and alterations in the glycosylation of this mucin 
(142,144). In addition, in studies conducted by Cozzi et al., Overexpression of MUC1 was 
demonstrated in 58% of neoplastic prostate tissue samples and in 90% of metastatic lymph nodes, 
whereas in cancer free tissue it was not evidenced (143). 
 
Other Biomarkers: 
Recently there has been an interest in proteins involved with mitochondrial autophagy, as these 
may be associated with carcinogenesis (11). These proteins can be seen as new diagnostic and 
prognostic biomarkers in prostate cancer. However, they are not the only new biomarkers on which 
attention has been focused; it has been seen that by making a genetic profile of the cancer and also 
by observing the presence of stem cells in the neoplastic tissue, new markers of the disease can be 
obtained. Here are four of them: 
 
Leucine-rich pentatricopetide repeat motif-containing protein (LRPPRC) 
The LRPPRC protein stabilizes the BCL-2 oncogene and blocks autophagy, thus altering the 
regulatory mechanisms of cell death (11). In the comparison of the immunohistochemistry of 
LRPPRC expression by Mancini et al, between neoplastic tissue and BPH; it is found that this 
protein was expressed more in cancer tissue (11). This finding confirms that the LRPPRC can be 
seen as a new diagnostic biomarker and the mitochondria as a therapeutic target (11). 
 
Genetic profiling of prostate cancer: Circulating tumor DNA (ctDNA) 
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The analysis of circulating DNA fragments of the tumor supposes the possibility of being able to 
find these pieces of free DNA in bodily fluids and in the plasma of patients with solid tumors (11). 
The advantage of these sequences is that they contain the complete genetic information of the 
tumor; which would allow analyzing it to determine the prognosis and response to treatment (11). 
In addition to the benefits mentioned above, ctDNA allows non-invasive analysis, since it would 
not be necessary to obtain a biopsy as such (11). Finally, the ctDNA allows the identification of 
Novo mutations, which ultimately impacts the course of treatment. 
Stem cells 
Recent studies have shown the presence of stem cells in the prostate and its possible role in the 
progression to the disease and the response to treatment (11). What has been observed is that from 
these cells some neoplasms originate and their presence could constitute a prognostic predictor 
factor (11). Some biomarkers associated with stem cells could in the future be used as an aid in 
the approach to personalized therapy of prostate cancer (11). 
 
Alpha methylacyl CoA Racemase  
Alpha methylacyl CoA Racemase (AMACR) or also called P504S is a peroxisomal and 
mitochondrial enzyme necessary for the production of bile acids and the beta-oxidation of 
branched-chain fatty acids (145). In prostate cancer it is used as a molecular marker, since through 
DNA microarrays, a high expression of AMACR has been detected in the affected prostate tissue, 
compared with benign prostatic tissue (146,147). 
 
There are different biomarkers that are currently under investigation to determine their diagnostic 
performance in patients with prostate cancer. It should be noted that those described are not all 
biomarkers in development and it is still too early to take these tools because studies with larger 
sample size, validity and reliability are lacking, which allow us to work with certainty on our male 
population, however it is clear that the present and future should be focused on the investigation 
of this type of biomarkers in prostate cancer, as well as in other types of tumors. 
 
Legends: 
Figure 8. MHC I (Major Histocompatibility Complex1), B2M (Beta 2 microglobulin), GTP 
(Guanosine triphosphate), ATP (Adenosine triphosphate), AMPc (Adenosine monophosphate 
cyclic), PKA (Protein kinase A), DNA (Deoxyribonucleic acid), CA (Cyclin A), C-D1 (Cyclin 











Figure 9. Beta 2 microglobulin (B2M) directly regulates the levels of cellular iron (Fe) by forming 
complexes with the protein hemochromatosis (HFE), which block the Transferrin receptor 1 (RT1) 
and prevent the entry of iron into the cell and as a consequence a decrease in its intracellular 
concentration. This phenomenon promotes the expression of the Hypoxia Inductor Factor 1a (HIF-
1a), which will act on the cell nucleus to generate the synthesis of the Vascular Endothelial Growth 
Factor A (VEGF-A), which will induce the process of angiogenesis in vascular and endothelial 
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The metabolic state of an organism depends on its genome, transcriptome, proteome, epigenome, 
microbiome and exposome (environment) among other elements, including some that are still 
undiscovered. Metabolomics as a tool of study provides an abundance of information with the 
potential to accurately describe the physiological state of an organism (148). One of the objectives 
of metabolomics is to identify and characterize small molecules under physiological conditions 
and identify those that may be important biomarkers for the identification and treatment of health 
problems (149). 
In this review, we will describe a few aspects of metabolomics, the methods used for quantification 
and some clinical applications, mainly in cancer. 
 
General concepts of metabolomics 
The term metabolomics is a rapidly growing field that was defined as the quantitative study of 
metabolites (molecules smaller than 1,500 kDa) in a biological system and alterations to their 
concentrations due to environmental or genetic effects. Research has focused on areas such as 
toxicology, biomedical sciences, nutrition, genetics, innate errors of metabolism, diabetes, cancer, 
diagnostic tests, neuronal diseases and others. These applications are based on the theory that 
metabolites are the functional outputs of an organism, and measuring metabolites is a means to 
identify an alteration in the system's homeostasis that could occur before the appearance of 
symptoms of a particular disease, as a single metabolite may be the substrate for a number of 
different enzymes involved in complex metabolic pathways (150,151).  
One of the main advantages of applying metabolomics is the ability to detect hundreds of 
metabolites in parallel (152), thereby efficiently monitoring biochemical alterations. 
The metabolic profiles of biological specimens can be affected by factors such as diet, age, 
ethnicity, lifestyle, medications or microbiota, and these factors should be controlled for to obtain 
disease-specific information (153). 
 
Types of fluids used in metabolite analysis 
Analyses of metabolites can use various fluids including urine, blood plasma, serum, cerebrospinal 
fluid, saliva and tissues. The former three are the most commonly used bio-fluids in metabolomics 
studies because they contain thousands of detectable metabolites and are obtained noninvasively 
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or minimally invasively (154). The use of each fluid type presents processing and analysis 
challenges and different possible associations with diseases and the effects of drugs, among others. 
 
Urine 
The analysis of urine samples offers a number of advantages over the use of other fluids such as 
blood (serum), plasma, saliva, cerebrospinal fluid and homogenized tissues. Among these 
advantages are the following: 1. Urine can be collected in large quantities. 2. The sample collection 
process is not invasive, and samples can be taken repeatedly, sometimes without inconveniencing 
the organism from which the sample is collected. 3. Urine requires less complex pretreatment steps 
for analysis because it has low levels of proteins and high concentrations of low molecular weight 
compounds (152). Thus, urine is a sample with low complexity of analysis and few molecular 
interactions. For these reasons, urine is the most commonly used fluid in the analysis of metabolites 
for the early detection of diseases (155,156). However, given its high salt content, MS 
measurements of urine are slightly more challenging than measurements of other fluids and require 
pretreatment of the sample (148). 
 
Blood plasma and serum 
The use of these fluids for metabolite analysis allows the determination of the presence and stage 
of several diseases, but these fluids contain a wide range of macromolecules that, when analyzed, 
can overlap with the results from small molecule metabolites (156).  
Relationships can be found between serum and plasma metabolic profiles that can provide an 
overview of metabolic status at a point in time. In NMR data, this relationship includes narrow 
signals from small molecule metabolites and broad signals from proteins and lipids (152). 
 
Homogenized tissues 
The metabolic profiling of intact tissue has gained interest in recent years; its purpose is to obtain 
an approximate understanding of the molecular basis of disease and pathway analysis (157). The 
global determination of metabolite concentrations in anatomical tissues might provide information 
on unique aspects of the tissue during pathological development, which cannot be derived from 
measurements taken in other fluids, such as the relationship between metabolism and changes in 
tissues. Nonetheless, the information derived from analyzing tissue samples is inconvenient to 
obtain, requiring the use of invasive sampling and sample treatment before analysis and storage 
and involving potential interactions between compounds (156). 
 
Metabolite analysis techniques 
Two of the most important techniques currently used in metabolomics are Nuclear Magnetic 
Resonance Spectroscopy (NMR) and Mass Spectrometry (MS). NMR requires little to no 
preparation, is rapid and non-invasive, does not destroy tissue and has highly reproducible results 
(coefficient of variation 1-2%). Combining NMR with MS might increase the diagnostic yield, but 
the data obtained from NMR/MS experiments are quite complex, as they provide qualitative and 
quantitative information on several metabolites, and distinguishing statistically between disease 
and control markers can be difficult (Figure 10) (152).  
 
We would like to go deeper describing the techniques used for metabolite analysis in the following 
paragraphs: 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
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At present, single-pulse (1D) and one-dimensional nuclear Overhauser enhancement spectroscopy 
(NOESY) with water suppression is one of the most widely used methods in metabolomics. This 
technique is robust, provides a flat baseline under similar conditions and allows pulses to suppress 
elevated signals from water, leaving metabolite signals intact (158,159). Two additional important 
methods used to eliminate large signals from large molecules (e.g., tissue and serum) are the Carr-
Purcell-Mieboom-Gill (CPMG) sequence and the "edited diffusion" method that allows the 
observation of large molecules such as lipids (148).  
Other methods, such as 2D NMR, have been used in the detection of metabolites to reduce 
spectrum complexity, although these methods are expensive, time consuming and complex to 
analyze. These methods include 2D-J Spectroscopy, Correlation Spectroscopy (COSY), Total 
Correlation Spectroscopy (TOCSY), Heteronuclear Single Quantum Coherence Spectroscopy 
(HSQC) and Heteronuclear Multiple Bond Correlation (HMBC) (160,161). 
HR-MAS-NMR (High-Resolution Magic Angle Spinning NMR) is another technique used with 
tissues. This technique obtains high-resolution spectra from heterogeneous samples that are neither 
solids nor pure liquids, such as solvated resins, allowing the in situ characterization of organic 
molecules and the quantification of compounds in the solid support phase (Table 6)(162).  
 
Mass spectrometry 
Mass spectrometry (MS) is used with various separation methods, such as gas chromatography 
(GC), liquid chromatography (LC) and capillary electrophoresis (CE), to provide chemical 
information for metabolomic studies (Table 6) (163,164). 
 
Liquid chromatography coupled to mass spectrometry (LC-MS or HPLC-MS): 
LC-MS is one of the most important techniques used for metabolic analysis, with high sensitivity 
and the ability to provide a wide range of information on metabolite content (152).  This technique 
separates a sample by liquid chromatography for subsequent analysis by mass spectrometry. LC-
MS is widely used to analyze complexed substances, up to non-volatiles and can be used to 
separate macromolecules such as proteins (165). LC-MS is considered a moderate- to high-
performance method, and ultra-high pressure LC (UPLC) increases the chromatographic 
resolution of this technique 3- to 5-fold (166). Urine can be input directly into an LC system, but 
serum and other liquids require preparation for protein precipitation (152). 
 
Gas chromatography coupled to mass spectrometry (GC-MS) 
GC-MS is usually used to analyze samples of fluids such as urine and for the stable analysis of 
volatile metabolites including fatty acids, steroids and flavonoids. GC-MS has lower costs of 
analysis than HPLC-MS, but its use is limited for nonpolar thermally stable metabolites. Thus, it 
is commonly used to derivatize compounds that produce other volatile compounds. The advantages 
of GC-MS include its rapid ability to identify metabolites, supported by the commercial 
availability of extensive libraries (167,168).  
The use of different agents in the derivatization of compounds has been studied in human urine 
samples treated with N,O-bis (trimethylsilyl) trifluoroacetamide (BSTFA), N-methyl-N- 
(trimethylsilyl) trifluoroacetamide (MSTFA) and Methyl bis-trifluoroacetamide (MBTFA) and 
analyzed in GC-quadruple MS. BSTFA and MSTFA exhibit similar efficiency with respect to the 
number of peaks detected, peak intensity and reproducibility. MBTFA combined with BSTFA 
exhibits better secondary and tertiary amine derivation. Some amino acids were detected when 
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derivation with BSTFA was followed by the use of MBTFA; however, these results were not 
reproducible, and BSTFA is recommended as an optimal derivation agent for GC-MS (168).  
Combining NMR and MS 
NMR has low sensitivity for the identification of metabolites, but compared to MS, it offers the 
possibility for broad observation and quantification of the most abundant compounds in biological 
fluids and tissues without the need to prepare or fractionate samples. Additionally, NMR allows 
the identification of compounds with identical masses and the identification of dynamics that can 
reveal metabolic pathways and their compartmentalization (148). Combining NMR and MS yields 
increased identification and quantification of compounds, especially in complexed ones. 
Additionally, data from both techniques can be cross-analyzed to increase the number of 
compounds identified by using the principle of a relatively constant abundance/intensity ratio for 
the same metabolites across different samples (169,170). The combination of NMR and MS also 
allows the performance of isotope screening experiments and metabolic flow analysis (NMR 
provides position, and MS provides quantification) (171). 
 
Platforms to establish standards in NMR-based metabolomics 
Information on biological molecules associated with NMR spectra is available in databases 
including HMDB, BMRB, TOCCATA and COLMAR, but information on many metabolites is 
still needed (169,170,172,173). Repositories of results from metabolomics studies have been 
generated by the NIH Common Fund Centers (174) and by initiatives to coordinate metabolomics 
standards, e.g., COSMOS, which currently develops a robust infrastructure that allows the 
exchange of data or metadata between researchers and the development of applications 
(http://nmrml.org and http://metabolomexchange.org) (175). Many other important databases 
(pathway analysis and viewers) are now available for metabolomics analysis, these include: KEGG 
(http:// www.genome.ad.jp/kegg/), MetaCyc (http://meta cyc.org/), AraCyc 
(http://www.Arabidopsis.org/ tools/aracyc/), MapMan (http://gabi.rzpd.de/ projects/MapMan/), 
KaPPA-View (http:// kpv.kazusa.or.jp/kappa-view/), the data model for plant metabolomics 
experiments ArMet (http:// www.armet.org/), functional genomics databases MetNet 
(http://metnet.vrac.iastate.edu/) and DOME (http://medicago.vbi.vt.edu).  In addition, standards 
and best practices have been published for the metabolic phenotyping of biological fluids 
(176,177).  
 
Analysis of metabolites in clinical conditions 
The development of a pathology can be identified through different metabolic pathways, but we 
are only describing three of them: glycolysis, in which ATP production is increased, mediated by 
the increased activity of enzymes such as hexokinase and lactate dehydrogenase and the increased 
production of lactate induced by the overexpression of hypoxia-inducible factors (HIF-1). Under 
these conditions, the action of pyruvate dehydrogenase kinase 1 is induced, which in turn inhibits 
pyruvate dehydrogenase, thus reducing pyruvate input to the tricarboxylic acid (TCA) cycle and 
reducing levels of associated metabolites. The consumption of glutamine also increases via the 
action of the glutaminase enzyme. This effect presents a possible pathway for supplementing the 
induced deficit in TCA under anaerobic conditions. Some studies suggest that this pathway 
provides the main energy source used under aerobic conditions by proliferating cells such as 
lymphocytes, fibroblasts and some cancer cells. This pathway is also a precursor of oxaloacetate, 
which is involved in the synthesis of fatty acids and cholesterol. The alteration of these pathways 
in turn alters the metabolism of fatty acids, which are produced in greater quantities in cancer 
	 40	
cells due to the hyperactivity of enzymes such as ATP citrate lyase (ACL), acetyl-CoA carboxylase 
(ACC) and fatty acid synthase (FAS). The latter is expressed at low levels in normal cells and 
tissues but is highly expressed in cancerous tissues. Cancerous tissues also exhibit an increase in 
messenger lipids such as phosphatidylinositol-3,4,5-triphosphate [PI (3,4,5) P3], which is formed 
by the action of phosphatidylinositol-3-kinase (PI3K) and active protein kinase B/Akt(178). 
Alterations in these pathways can be used in the detection of metabolites and the preventive 
diagnosis, treatment, and identification of biomarkers for diseases. Therefore, the study of 
alterations to the levels of these compounds in tissue, plasma or urine has been used to study 
various pathologies. 
Urological cancer is a condition in which early detection based on biochemical methods is required 
to offer rapid treatment based on personalized medicine. Metabolomic tools based on NMR and 
MS have the potential to assist the provision of an early diagnosis and targeted therapy. Various 
biomarkers for urological cancer based on different pathways of disease in human and animal 
models are currently being studied. 
 
Bladder cancer:  
Metabolomics has been extensively used in the study of cancer, with studies on bladder cancer 
using LC/MS to compare the urine metabolites of healthy controls and those of patients with 
bladder cancer and identify differences (179).  
Recently Cheng et al (180) pooled 11 studies which described metabolites to detect bladder cancer 
in a systematic review, with different techniques and high heterogeneity: Gas chromatography-
time-of-flight mass spectrometry (Two studies); Liquid chromatography-mass spectrometry / 
Capillary electrophoresis-mass spectrometry (Three studies); High resolution-magic angle 
spinning-nuclear magnetic resonance spectroscopy (One study); Proton nuclear magnetic 
resonance (Three studies); Reversed phase liquid chromatography-mass spectrometry / 
hydrophilic interaction chromatography-mass spectrometry (One study); High-performance liquid 
chromatography-quadrupole time-of-flight mass spectrometry (One study). Regarding the altered 
glucose metabolites expression, they found no conclusion about glucose, fructose and lactic acid 
since they were found up in some studies and down in others, nevertheless pyruvic acid was found 
down in only one study (anaerobic oxidation). Similarly, citric acid and fumaric acid were found 
also down in different studies (aerobic oxidation). 
Regarding the altered amino acid metabolites expression, they found that threonine, phenylalanine, 
valine, isoleucine, lysine, methionine, leucine (Essential amino acids), glutamate, histidine, 
arginine, aspartic acid, tyrosine, glutamine and serine (non-essential amino acids) were found up. 
They found some studies regarding the lipid and nucleotide metabolites expression, however they 
were not enough to pool information and recommend for the diagnosis of bladder cancer. 
Another study found that metabolite profiles in urine can discriminate between bladder cancers 
with and without muscular invasion and between healthy patients and those with bladder cancer 
and can trace relationships between different metabolic pathways and identify where pathology-
associated alterations appear (181).  
There are few studies using different samples and analytical platforms with similar results for some 
metabolites nonetheless, it is important to standardize these two fundamental variables to establish 
a way to diagnose Bladder Cancer nowadays. 
 
Prostate cancer:  
	 41	
Plasma and tissue samples from prostate cancer (PCa) patients have been evaluated using different 
methods such as HRMAS and LC/MS, therefore alterations in amino acid levels have been found, 
such as increased levels of lactate, phospholipids and choline; low levels of citrate and polyamines; 
and regulation of spermine (182–186). One of the advantages of this marker is that non-invasive 
methods can be used for the detection of PCa, as it can be measured in urine (187). 
Regarding the complete spectrum of metabolites, so far, the most promising biomarkers for PCa 
diagnosis are: Sarcosine (AUC 0.67)(187), choline, phosphocholines (AUC 0.982) (186), 
phosphorylcholines, carnitines (AUC 0.97)(188), citrate (AUC 0.89) (189), amino acids (lysine, 
glutamine and ornithine) (190–193), arachidonoyl amine (AUC 0.86) (188) and lysophospholipids 
(Steroid hormone biosynthesis pathway and bile acids – Sensitivity and Specificity 92- 94%) 
(192). 
The following five constituents are also important when discriminating between prostate cancer 
and hyperplasia: dihyroxybutanoic acid, xylonic acid, pyrimdine, xylopyranose and 
ribofuranoside, with an AUC 0.825 (194). Additionally, citrate, glutamate and taurine have 
important discriminatory roles, with sensitivity of 100% and specificity of 96% (195). 
Regarding the metabolic pathways, many of them have been associated with PCa. The following 
are the most described in literature: 
1) Energy metabolism, including TCA cycle intermediates (195–197), lactate (196,197), citrate 
(198), phosphoenolypyruvate, and adenosine diphosphate (197);  
2) Cell growth and proliferation pathways including: common amino acids (199,200), bile acids 
(201), polyamines (202), glycerol-3-phosphate (200), long chain fatty acids (198,203,204), 
phospholipids (200), phosphocholines (205), and choline (202,206);  
3) Growth and function pathways and osmoregulation including: Steroid hormones (198,207) and  
inositol and its isomers (202) respectively;  
4) Chronic stress is another important pathway involved in developing cancer, and cortisol (208) 
is thought to be related by this way (209); 
5) Cell proliferation pathway through de novo lipid biosynthesis has participated by different 
metabolites such as: citrate, inositol, lactate (210), and cortisol (208,209), along with 
phosphoethanolamine, glycerophosphoethanolamine (211) and acetate (210). 
As readers can see, there are many metabolites that might be associated or altered in PCa, therefore, 
there is still place to study through this molecular method how to diagnose and establish a 
prognosis in patients with this condition. 
 
Renal cancer:  
Kidney Cancer is one of the most important urological cancers since it has high mortality. Research 
has been focused on the clear cell type since it is the most frequent and different studies have 
shown results from human and animal samples. Here we present some of the most promising 
metabolite biomarkers for this kind of tumor according to critical revisions from Rodrigues et al 
and Ari Hakimi et al (212,213): Regarding the amino acid metabolism, they found that Creatine, 
glutamate, glutamine and quinolinate were found upregulated mostly in renal tissue, however, 4-
Hydroxybenzoate, Gentisate and hippuric acid were found downregulated mainly in urine. 
Regarding the fatty acid metabolism, they showed that carnitine, acylcarnitines and 
acetylcarnitines were found upregulated in renal tissue, but Choline/choline-Containing 
Compounds were found downregulated in the same kind of sample. The glutathione (reduced 
form) was found upregulated in renal tissue and regarding the glycolysis, glucose was found to be 
inconclusive in different kind of samples, on the other side, lactate and pyruvate were found 
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upregulated in different samples. Citrate, fumarate, malate and succinate had inconclusive 
findings, regarding the tricarboxylic acid metabolism. Additionally, alfa-tocopherol (vitamin E 
metabolism) was found upregulated in renal tissue. Most of the inconsistencies are because of 
differences in type, collection, handling and manipulation of the samples; experimental designs 
and the kind of analytical platforms (212). 
The identification of biomarkers has been used in renal cancer patients, allowing differentiation 
between healthy controls and cancer patients and suggesting the involvement of alterations in the 
quinolinate pathways (pathways of nicotinate and nicotinamide metabolism), gentisate (benzoate 
degradation pathway) and alpha-ketoglutarate (alanine, aspartate and glutamine metabolism 




Metabolomic profiling using NMR and/or MS provides an important diagnostic tool for 
identifying metabolites under different conditions. These tools have been tried for conditions that 
greatly affect quality of life, such as cancer; in such cases, the fast, valid and reliable identification 
of biomarkers is required. Different methods involving NMR and/or MS can result in variations in 
their results; however, the appropriate control of confounding variables and the use of statistical 
and bioinformatic analyses can offer a wide range of information, useful for clinical applications. 
 
Legends: 








Table 6. NMR and MS Techniques 
 
Technique Principle Advantage Disadvantages 
NMR methods       
1D sequences 
Detects signals from 
heavy metabolites 




Spectrum complex to 
analyze. Molecular signals 






of large molecules 
and generates those 
of small molecules. 
Easy to interpret. 
High-performance 
technique that allows 
for screening and can 
be used in HRMAS-
NMR studies. 









technique with good 
results in the screening 
of large molecules in 
plasma and serum. 
Not used in urine, as there 
are no appreciable 







Easy to interpret and 
resolve overlapping 
signals. 
Time-intensive and less 
quantitative than other 
techniques. 





separated by liquid 
chromatography and 
detected with Mass 
Spectrometry. 
Simple preparation. 
The most commonly 
used technique and 
high performance. 
Suppression of ions in 
samples with multiple 
anions and cations may 
affect results. 
GC-MS 
Separation is based 
on gas 
chromatography. 
More sensitive and 
reproducible than LC-
MS. High separation 
capacity and more 
quantitative than other 
techniques. 
Requires more preparation 
than other techniques and 
cannot detect all 
compounds. May produce a 
more complex analysis than 
other techniques. 
2D GC-MS Separation occurs in two dimensions. 
Resolution allows 
better analysis of 
complex biological 
samples. 
More sample preparation 







method using two 
spray sources: one is 
nebulized and the 
other provides drops 
of charged solvent. 
No sample preparation 
required. 
Less quantitative, and the 








method that directly 
analyzes a sample. 
Sensitive, does not 
require sample 
preparation and has a 
high tolerance for salt. 
Less quantitative, and the 











sensitive and does not 
require sample 
preparation. 
Less quantitative, and the 
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INTRODUCTION 
Prostate cancer (PCa) is the most frequent malignant neoplasia diagnosed in men, considering 
developing countries and the developed ones (excluding skin cancer); besides it is one of the main 
causes of death (216–218). This condition has a high incidence and prevalence, however it is 
possible to find substantial variation according to geographic location and some ethnic groups 
(219), for example: In Asian countries like China, PCa has the lower incidence, while in 
NorthAmerica, especially for afroamerican people, incidence is too high (220–222). Additionally, 
having a first-grade relative with PCa, the risk is increased by two and with two relatives, it 
increases five times the risk (OR 2 y 5 respectivamente)(223).  
Another important factor associated is the general classification as sporadic versus familiar PCa 
(221), being the last one, the most frequently associated with early ages (~ 45 years), in members 
from the same family. This one has been reported as frequent as 15%, while in the esporadic, the 
genetic material is damaged by enviromental exposition to different factors, during the lifetime 
(Epigenetics) and its prevalence could be as high as 80 - 90% (221,224). PCa is known as one the 
most inherited cancers around the world (Almost 50%), accordingly, it increases the autosomic 
dominant cancer predisposition (225,226).  
 
Mutations in DNA-repair genes like BRCA2, BRCA1, CHEK2, HOXB13, NBN and a series of 
single nucleotide polimorfism (SNPs) (223) have been linked to PCa and have been used as 
biomarkers for PCa in order to predict clinical outcomes in a population (223,227–229). According 
to this intention, researchers need to continue studying genomic variants in different populations 
because the clinico-pathological and genomic diversity.  
 
Up to date, there are no studies about genomic diversity regarding the risk for this inherited 
condition in a southwest population. For consolidating the knowledge about this clinical condition, 
we need to translate information about mutations from similar predisposing populations to 
germline cancers to serve as centinels for identifying high-risk families to develop this condition. 
The previous could serve to diagnose earlier and to perform an intervention according to the 
individual genotype, which focuses on personalized medicine as an standard way to diagnose and 
treat nowadays.  
 
The objective was to describe the frequency of Inherited DNA-repair genes and their variants 




We designed an observational descriptive design which took place from 2014 to 2016 and included 




According to the expected frequency for hereditary Prostate Cancer (~ 15%), alfa 15% and an 




Each patient underwent blood extraction to obtain DNA. All drops were collected in filter paper 
until dried. These filters were immersed in phosphate buffer along with the DNeasy package from 
QUIAGEN ® company. Each extraction was quantified and quality verified to continue the 
sequencing processing.  
 
Sequencing protocol 
DNA aliquots from each samples underwent a preparation process with the TruSeq Exome Library 
Prep®, then the obtained libraries were normalized to be sequenced using the TruSeq Rapid 
Exome®. These packages were provided by Illumina® from San Diego, California, USA. The 
normalized fragments with its corresponding adaptors for sequencing were charged in HiSeq2500 
machine. 
We sequenced the full exome and identified the variants associated, specifically the single 
nucleotide polymorphisms (SNPs) for twelve genes which have been associated with Prostate 
Cancer (PCa) (ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, 
NBN, PMS2 y TP53)(230).  
 
This project accomplished all ethical international standards. Descriptive statistics were performed 
in R (231) and the results are shown in frequency tables for each gene and its variants associated. 
We finally searched the variants in the following public databases: Exome Aggregation 
Consortium (ExAC) (232), PharmGKB (233), Clinvar (234) and Ensemble (235), in order to look 





Frequency of genes 
 
We obtained samples from 162 people from Southwest Colombia. 9203 genes associated with PCa 
along with 7.315.466 data were sequenced in this population. The most frequent genes found were 
ATM 1221 data (13.2%), BRCA1 1178 data (12.8%), BRCA2 1484 data (16.12%) and NBN 965 
(10.42%) (Figure 11). 
 
Associated variants  
 
The missense and stop variants associated with these 12 genes were present in 22% (2043 data) 
and 0.13% (12 data) (Table 7). On the other side, ATM, BRCA1, BRCA2 and PSM2 were the 
most frequently associated with missense variants (247, 445, 490 and 289 data respectively). 
Additionally, BRCA2 and MLH1 had the highest frequency of stop variants (4 and 3 data 
respectively) (Table 8). 
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SNPs associated with Prostate Cancer 
 
The most common SNPs in these 12 genes were the following: 
BRCA2 (rs169547 (158 data; 97%), rs206075 (158 data; 97%), rs206076 (158 data; 97%)); ATM 
(rs659243 (158 data; 97%), rs228589 (134 data; 82%)); TP53 (rs1625895 (157 data; 96%), 
rs1042522 (141 data; 87%), rs1642785 (145 data; 89%)); PMS2 (rs2228006 (144 data; 88%), 
rs1805319 (142 data; 87%)); NBN (rs709816 (137 data; 84%)) and MSH6 (rs3136367 (136 data; 
83%)) (Table 9). 
 
When comparing with bioinformatics databases, we found that rs169547 (BRCA2), rs 9534262 
(BRCA2), rs659243 (ATM), rs228589 (ATM), rs1042522 (TP53) and rs2228006 (PMS2) had the 
higher Latino Allele Frequency found in ExAC. Rs1042522 (MAF 0.46), rs228589 (MAF 0.46) 
and rs9534262 (MAF 0.47) coincided with higher Minor Allele Frequency (MAF) found in 
Ensemble. Additionally, rs799917 (MAF 0.46) and rs799905 (MAF 0.45) had high MAF although 





Race, diet, family history, environmental factors and hereditary components have been reported 
as risk factors for PCa (219–222). Regarding the latter, genes such as BRCA1, BRCA 2, MSH2, 
HOXB13, ATM, CHEK2 and NBN have been proposed as important candidates contributing to 
PCa (223,226–229). The existence of single nucleotide polymorphisms (SNPs) for these genes, 
further increase the risk and even could be used as a prognostic biomarker for this condition (236). 
Additionally, observing a germline mutation in some DNA-repair gene provides information to 
patients to look for counseling, identify predisposition to cancer and perhaps to initiate 
interventions to reduce the risk (226).  
 
Regarding the frequency of these genes, Pritchard et al recently published a paper in patients with 
metastatic PCa from different series (United Kingdom and United States)(226), however it is 
important to compare some of the results: The most frequent gene was BRCA2 (5.35%) followed 
by CHEK2 (1.87%) and the third one was ATM (1.59%). BRCA 1 was present in 0.87% of the 
samples, while genes like MSH2, NBN, MSH2, MSH6 and PMS2 had lower frequency (0.14%, 
0.29%, 0.14, 0.14 and 0.29 respectively). HOXB13 was not assessed in these series. These results 
are lower than ours, and we might expect to have a higher frequency, coming from metastatic 
patients data. PCa incidence, at least in Cali, Colombia, has been stable during the last few years 
(2002 to 2007 – Annual Percent Change APC -0.5%), mortality diminished (12), and afro-
descendants population increased from 15% in 1964  to 26% in 2005 (237) however, these data do 
not explain the results since there are not previous studies that described the frequency of these 
genes and their variants. 
 
Pilié et al (238) published another important study to discuss, this one was not about frequency of 
genes, but identifying genes associated with PCa and other concomitant tumors (at least one 
additional tumor). They also found similar germline genes: BRCA2, ataxia telangiectasia mutated 
(ATM), mutL homolog 1 (MLH1), BRCA1, checkpoint kinase 2 (CHEK2) and homeobox protein 
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Hox-B13 (HOXB13), although they found 10% of pathogenic or likely pathogenic mutations in 
cancer-predisposing genes. They found 525 missense, 7 frameshit, 5 in-frame coding insertion or 
deletions and 2 nonsense variants (rs80359440, rs80359515, rs61757642, rs587781658, 
rs373226793, rs180177143, rs759113408, rs17879961 and rs138213197). On the contrary, we 
found a higher frequency of this type of variants and none of the SNPs they reported. 
 
In our study, -identified as the first study in southwestern Colombia-, the most frequently gene 
found was BRCA2, which has been considered one of the few genes that confers a high risk of 
suffering from this and other conditions (218,221,239,240).  
This gene has an important role in the repair of double-strand DNA breaks that function by 
regulating the intracellular transport and activity of RAD51, a critical protein in homologous 
recombination (241–243). The most frequent variants found for this gene, such as: rs169547, 
rs206075, rs206076 and rs9534262, are similar with other studies (244,245). These have been 
considered benign mutations (246–248) -the first three, were reported in Colombia by Arias et al 
(249)-, and rs9534262 was considered a deletion-type mutation with an unknown clinical 
relevance according to D´Argenio et al (247), although benign according to ClinVar. This one 
seems to be a QTL of significant importance since it regulates the levels of the alternative 
transcripts of BRCA2 (250). 
 
The second most frequent gene was ATM, which exerts control in cell division. When detecting a 
damage in the genetic material, it leads to either cell cycle arrest, DNA repair or apoptosis (251–
253). In addition, it can be considered as the main transducer in the double-strand rupture repair 
process, where it recruits and cooperates with other sensor proteins such as 53BP1 (p53 binding 
protein) and BRCA1.  
BRCA1 is the third most frequently gene found and associated with an increased risk of sporadic 
PCa (3.5 times), while for germline mutations in this gene only 0.44% of the cases have been 
observed of PCa (220,254,255). The Breast Cancer Linkage Consortium (BCLC) described that 
men aged 65 with mutations in BRCA1 report an increase in the risk of PCa with a relative risk 
(RR) of 1.82, being linked to a series of cellular processes such as response and repair of DNA 
damage (220,253,255,256), transcriptional regulation and chromatin modeling. This is the key in 
cellular control systems to be involved in all phases of the cycle, in such a way that it can block 
cell proliferation and promote apoptosis of cells with a high risk of malignant transformation 
(220,255). For this gene, the most frequent variant was rs799917, a nonsense mutation-type 
polymorphism (247) but benign according to Arias et al (249). This one is located in the coding 
sequence of the gene and affects the interaction of miR-638 with mRNA of BRCA1 (257). It is 
also associated with the risk of suffering from breast, stomach and esophagus cancer additionally 
(257–259). These two genes have not been reported in Colombia, according to literature review. 
 
Another important gene found in this study was NBN, which is a component of the protein 
complex hMRE11 / hRad50 / NBN that participates in the initiation of a response to DNA damage 
and is linked to the repair of double-strand rupture (260–262). This acts in the non-homologous 
junction pathway as a DNA damage sensor and in the homologous recombination pathway, 
participating in DNA repair and in the cell cycle check point in the S phase (262). rs709816 is one 
of its most frequent variant, which has been associated with bladder cancer (262); another one was 
rs3736639, which has been found at a slightly higher frequency in patients with leukemia (260). 
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On the other hand, the rs1805794 presents positive association in different types of cancer such as 
bladder (263,264), lung (265), breast, nasopharyngeal (266–268), osteosarcoma (269) and prostate 
cancers. In this last one, GG carriers have almost twice increased risk for developing PCa, 
suggesting a role for NBN in the diagnosis and progression of prostate cancer (260). rs1061302 
has been associated with an increased risk for lung, larynx and liver cancer. SNPs might affect the 
proper binding of the complex and thus alter its ability to repair or detect DNA breaks (262,265). 
Although this variant is considered a synonym polymorphism, the altered nucleotide may affect 
the stability of the mRNA, the splicing or the transduction rate (262).  
 
Additionally, rs169547 (BRCA2), rs9534262 (BRCA2), rs659243 (ATM), rs228589 (ATM), 
rs1042522 (TP53) and rs2228006 (PMS2) had the higher Latino Allele Frequency and some of 
them showed coincidence with a higher MAF. This would be the first description of these kind of 
SNPs for Colombia population which leads to studying the way to work as a network with them 
as biomarkers for PCa. 
 
Strengths and limitations 
This is the first study performed in southwest Colombian population, which is extremely important 
to characterize our population and beginning to recognize the risk for developing PCa. The quality 
of the samples, the methods we followed and the quality and analysis performed with the data are 
another important issues to highlight from our study. 
Regarding the limitations, we could declare that most of the variants found in the present study are 
considered as benign, nonetheless it is important to go deeper to analyze longitudinally these data 
and obtaining the real risk in this population. Perhaps another important limitation could be that 




To conclude, BRCA2, ATM, BRCA1 and NBN DNA-repair genes were the most frequently found 
in this Southwest Colombian Population. Additionally, there were non-pathological variants like 
rs169547, rs206075, rs206076 and rs9534262 and some other variants like rs799917, rs3736639, 













Table 7. Frequency of variants associated with PCa 
 
VARIANT Absolute Frequency 
%Relative 
Frequency 
Downstream 769 8.347 
Frameshift 5 0.054 
Intron 3906 42.397 
Missense 2043 22.175 
Nc_transcript 15 0.163 
Splice 4 0.043 
Stop 12 0.13 
Synonymous 1727 18.745 
Upstream 479 5.199 




Table 8. Frequency of variants by each gene associated with PCa 
 








Missense 247 0.202 0.027 
Stop 1 0.001 0 
BRCA1 
Missense 445 0.378 0.048 
Stop 1 0.001 0 
Frameshift 4 0.003 0 
BRCA2 
Missense 490 0.33 0.053 
Stop 4 0.003 0 
CHEK2 Missense 33 0.057 0.004 
EPCAM Missense 27 0.088 0.003 
HOXB13 Missense 2 0.025 0 
MLH1 
Missense 67 0.16 0.007 
Stop 3 0.007 0 
MSH2 
Missense 13 0.025 0.001 
Stop 1 0.002 0 
MSH6 
Missense 70 0.077 0.008 
Stop 1 0.001 0 
NBN Missense 119 0.123 0.013 
PMS2 
Missense 289 0.323 0.031 
Stop 1 0.001 0 
Frameshift 1 0.001 0 
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Introduction 
Prostate Cancer (PCa) is a heterogeneous disease with a variable natural history and slow growth 
pattern. It may display latency periods of up to 20 years in which it remains organ-confined. 
Although prostate cancer lesions can remain localized for long periods, more aggressive forms 
might occur and when metastasis occurs, lymph nodes and bones are affected predominantly with 
detrimental results(270). PCa is the second most commonly diagnosed worldwide cancer among 
men (mainly >65 years). It is a public health concern in developed countries, in which elderly men 
correspond to the greatest proportion of general population(9). 
Patients at high risk and susceptibility to develop PCa, require screening over time. Age, race and 
family history are the most important risk factors(271). A 50% higher risk in monozygotic twins 
than in dizygotic twins and the higher incidence in African Americans (and lower rate in 
Americans of Asian ancestry) supports genetic factors as an important determinant of the variation 
risk at the population level (272). There has been concerns about the diagnosis and early treatment 
of this disease due to the absence of specific markers(273). Until now, the gold standard for the 
diagnosis of PCa is an invasive procedure consisting in the histopathological evaluation of the 
prostate, a procedure with significant morbidity(92).   
Currently, the use of prostate-specific antigen (PSA) as a screening and monitoring marker for 
prostate cancer is widespread and is currently the only widely used serum biomarker for PCa(274), 
although there is still debate about the screening for PCa among men in the general population. 
This biomarker is prostate-specific but it has a low specificity and could also increase unnecessary 
biopsies, without lowering mortality(1).  
TMPRSS2:ERG has been assessed as a specific biomarker for PCa, since 2005 (275). This 
transmembrane protease serine 2 (TMPRSS2) is a promising biomarker located at 21q22.2 and 
expressed in normal and malignant prostatic epithelium. Additionally, ERG is a member of the E-
twenty six family members (ETS), which are key regulators of differentiation, apoptosis, 
embryonic development, cell proliferation and inflammation. Currently, there are different studies 
trying to look for the association between this gene, the fusion and the advanced prostate cancer, 
but less research for this gene as a diagnostic tool(276). 
The primary aim of this study was to identify the association between the TMPRSS2:ERG fusion 
gene, their variants and the onset of localized prostate cancer.  
 
Methods   
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We performed this review according to the recommendations of the Cochrane Collaboration (1) 




We included RCTs, Cohort, case-control and cross sectional studies that involved patients >18 
years-old assessing the association between TMPRSS2 fusion gene, its SNPs and PCa. Studies 
from Molecular biology, translational and clinical research and those that compare men with and 
those without prostate cancer, were also included. We excluded Observational Descriptive studies, 
studies with no human subjects and advanced prostate cancer. There was not setting or language 
restrictions. 
 
TMPRSS2 and associated SNPs 
We previously performed a search in Emsemble.org with the Prostate adenocarcinoma as 
Keyword, and then we Identified associated GENES and chose TMPRSS2 variants in humans. We 
applied the chosen gene in Genecards.org and identified the associated phenotype, additionally 
identified superpathways for PCa in KEGG and performed a final search in UCSC Genome 
Browser on Human Dec. 2013 (GRCh38/hg38) assembly. After all, we found the following SNPs 
that could be a missense variant when transcript into a protein: rs572530227, rs537370123, 
rs570454392, rs545726689, rs185312677, rs540987630, rs546335233, rs561063944, 
rs147233451, rs544474510, rs565237319, rs181414852, rs577684898, rs547544037, 
rs530689404, rs12329760, rs75603675. 
 
Primary outcome: Prostate Cancer defined by histology of the tumor coming from TRUS guided 
biopsy, TURP or radical prostatectomy 
 
Information sources  
Literature search was conducted in accordance to recommended by Cochrane. We used medical 
subject headings (MeSh), Emtree language, Decs and text words related.  
We searched MEDLINE (OVID), EMBASE, LILACS and the Cochrane Central Register of 
Controlled Trials (CENTRAL) from inception to February 2018 (Appendix 1). To ensure literature 
saturation, we scanned references from relevant articles identified through the search, conferences, 
thesis databases, Open Grey, Google scholar and clinicaltrials.gov, among others. We tried to 
contact authors by e-mail in case of missing information.   
Additionally, we looked information in the following specific databases: dbSNP, GeneSNP, 




Two researchers reviewed each reference by title and abstract. Then scanned full-texts of relevant 
studies, apply pre-specified inclusion and exclusion criteria and extracted the data. Disagreements 
were resolved by consensus and where disagreement could not be solved, a third reviewer 
dissolved conflict.  
Two trained reviewers using a standardized form independently extracted the following 
information from each article: study design, geographic location, authors names, title, objectives, 
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inclusion and exclusion criteria, number of patients included, losses to follow up, timing, 
definitions of outcomes, outcomes and association measures and funding source.  
 
Risk of bias  
The assessment of the risk of bias for each study was use QUADAS2 tool as recommended by 
Cochrane  
 
Data analysis / Synthesis of results 
The statistical analysis was performed by using Stata 14® and Review Manager 5.3 (RevMan® 
5.3). For categorical outcomes we reported information about Odds Ratio (OR), with 95% 
confidence intervals according to the type of variables and we pooled the information with a 
random effect meta-analysis according to the heterogeneity expected.  The results reported in 
forest plots of the estimated effects of the included studies with a 95% confidence interval (95% 
CI). Heterogeneity was evaluated by using the I2 test. For the interpretation, it was determined that 




An evaluation was conduct to identify reporting or publication bias using the funnel plot. 
 
Sensitivity analysis 




We performed subgroup analysis by: Geographical setting, Sample and Technique. 
 
Results 
Study selection.  
We found 241 records with the search strategies. After duplicates were removed, there were 223 
records. Finally, 18 studies were included in qualitative analysis and 15 studies in Meta-analysis 
(Albadine 2009; Chan 2013; Dimitriadis 2013; Huang 2011; Laxman 2008; Leyten 2012; Lin 
2013; Maekawa 2014; Mosquera 2009; Nguyen 2011; Park 2014; Penney 2016; Robert 2013; 
Salami 2013; Sanda 2015;Cornu 2013; Tomlins 2011; Tavukcu 2013) (92,273–275,277–
290)(Figure 12).  
Included studies.  
A total of 1057 patients were included, with a median of 25,5 patients per study. All fifteen studies 
evaluated new biomarkers in different samples for early diagnostic of PCa (Table 10). 
Albadine 2009; Dimitriadis 2013; Huang 2011; Laxman 2008; Lin 2013; Mosquera 2009; Park 
2014; Penney 2016; Salami 2013; Sanda 2015 performed their analysis based on data from United 
States (USA) (273–275,279,281,285–287,289,290). On the other side, Chan 2013 and Nguyen 
2011 brought data from Canada (278,288). Netherlands was the based for the analysis of Leyten 
2012 and Robert 2013(92,280) and Maekawa 2014 was the only one coming from Japan (277). 
 
Regarding the samples: Albadine 2009; Huang 2011; Mosquera 2009; Penney 2016; Robert 2013 
and Park 2014 performed their analysis based on tissue samples (275,280,281,285–287). On the 
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other side, Chan 2013; Dimitriadis 2013; Laxman 2008; Leyten 2012; Lin 2013; Nguyen 2011; 
Salami 2013; Sanda 2015 were based on urine (92,273,274,278,279,288–290). Only Maekawa 
2014 used blood samples for their analysis (277). 
Regarding the molecular templates: Huang 2011; Penney 2016; and Park 2014 performed their 
analysis based on protein expression (275,281,286). On the other side, Chan 2013; Laxman 2008; 
Leyten 2012; Lin 2013; Nguyen 2011; Salami 2013 and Sanda 2015 were based on techniques 
related to RNA (92,274,278,279,288–290) and Albadine 2009; Dimitriadis 2013; Maekawa 2014; 
Mosquera 2009; Robert 2013 based their analysis on techniques related to DNA 
(273,277,280,285,287) 
 
Regarding Genetic polymorphisms: Cornu 2013 evaluated two single nucleotide polymorphisms 
(SNPs) at 8q24 locus (rs1447295 and rs6983267) in all patients. These two SNPs correlated to the 
biopsy outcome in clinical practice (282). Additionally, Penney 2016 evaluated six SNPs, 
comparing ERG+ to ERG- cancers. They found four significantly associated with ERG+ compared 
to controls (rs7679673, rs902774, rs11672691, rs1859962). Three were significantly associated 
with ERG- compared to controls (rs2660753, rs7629490, rs1016343), and the associations 
trending in opposite directions for ERG+ and ERG- for three of them (rs12653946, rs1512268, 
rs11704416) (281).  
Furthermore, Maekawa et al showed that the rs12329760 polymorphism was significantly 
associated with the risk of sporadic prostate cancer in Japanese men (277).  
Risk of bias within and across the studies 
All included studies had no applicability concerns and low risk of bias for flow and timing 
(92,273–275,277–281,285–290). Regarding Patient selection, index test and reference standard 
risk of bias, we found that Chan 2013 and Leyten 2012 had low risk, however, Albadine 2009, 
Huang 2011, Maekawa 2014 and Nguyen 2011 had unclear risk of bias since they used case-
controlled studies to perform their analysis and did not describe the blinding assessment for index 
and reference tests (Figure 13). 
Dimitriadis 2013, Laxman 2008, Lin 2013, Mosquera 2009, Park 2014, Penney 2016; Robert 2013, 
Salami 2013 and Sanda 2015 had unclear risk of bias for index and reference test since they did 
not describe the blinding assessment appropriately (Figure 13).  
 
TMPRSS2:ERG and Prostate Cancer 
15 studies assessed the association between TMPRSS2:ERG and Prostate Cancer (Albadine 2009; 
Chan 2013; Dimitriadis 2013; Huang 2011; Laxman 2008; Leyten 2012; Lin 2013; Maekawa 
2014; Mosquera 2009; Nguyen 2011; Park 2014; Penney 2016; Robert 2013; Salami 2013; Sanda 
2015) (92,273–275,277–281,285–290). We found an OR 2.24 95%CI (1.29 to 3.91) I2=91%, 
showing a significant association but a high heterogeneity (Figure 14). 
 
Publication bias 








Based on sample 
When analyzing based on the sample we found: OR 2.98 95%CI (0.71 to 12.46) I2=87% (Six 
studies), OR 2.79 95%CI (1.12 to 6.98) I2=94% (Eight studies) and OR 1.33 95%CI (1.02 to 1.72) 
(one study) for tissue, urine and blood respectively (Figure 15). 
 
Based on the Molecular template 
 
When analyzing based on the Molecular template, we found: OR 1.93 95%CI (0.20 to 18.14) 
I2=90% (Three studies) , OR 2.43 95%CI (0.93 to 6.36) I2=95% (Seven studies) and OR 3.55 
95%CI (1.08 to 11.65) I2= 83% (Five studies) for Protein, RNA and DNA respectively (Figure 
16). 
 
Based on geographical setting 
 
When analyzing based on the geographical setting, we found: OR 1.73 95%CI (0.77 to 3.82) 
I2=93% (10 studies), OR 5.83 95%CI (2.86 to 11.86) I2=16% (Two studies), OR 1.33 95%CI (1.02 
to 1.72) (One study) and OR 9.92 95%CI (1.09 to 90.16) I2= 58% (Two studies) for USA, 
Netherlands, Japan and Canada respectively (Figure 17). 
 
Discussion 
Summary of the main findings 
We found that TMPRSS2: ERG fusion was significantly associated with diagnosing PCa, mainly 
in urine samples and DNA-based molecular templates, however there was an important 
heterogeneity that could not be explained with the planned subgroups.   
Contrast with literature 
Penney et al, showed that tumors that develop TMPRSS2-ERG fusion have different genetic 
etiology, suggesting also that SNPs are differently associated with the risk of developing prostate 
tumors either with or without fusion (281). Park et al, described that 53% of patients with ERG-
positive HGPIN revealed progression to PCa, which needs to be addressed in other studies and 
systematic reviews. (275). Additionally, Huang et al, determined that the fusion between the 
androgen regulated TMPRSS2 gene and the members of the ETS transcription factor family (ERG, 
ETV1, ETV4) has been identified as a genomic aberration in prostate cancer (286).  
Tavukcu et al, compared different samples (peripheral blood, pubic hair and urine). They identified 
higher number of copies of the fusion gene in post-DRE urine and tissue samples compared with 
blood and pubic hair samples. They concluded that peripheral blood and pubic hair PCR analysis 
of TMPRSS2:ERG gene fusion seemed to be suboptimal and emphasizing that the samples 
obtained from urine after prostatic massage seemed to be as effective as direct tissue sampling 
(284). 
High prevalence of TMPRSS2-ERG positive prostate cancer has been found clinically relevant. 
Studies have shown that TMPRSS2-ERG fusion prostate cancer is associated with higher tumor 
stage and cancer-specific survival or metastasis (285). Nonetheless, we evaluated the association 
with TMPRSS2-ERG gene fusion in early detection of PCa. The PSA level of subjects with the 
TMPRSS2-ERG fusion was also significantly higher than those one who do not have it.  
The main mechanisms by which the TMPRSS2-ERG fusion genes are produced are interstitial 
deletion and balanced translocation (276,291). Because of their specificity, detection of these 
fusion genes could be a valuable ancillary diagnostic tool in the early detection of PCa. In fact, 
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these rearranged genes can be detected either by fluorescence in situ hybridization (FISH), reverse 
transcription polymerase chain reaction (RT-PCR) techniques (292), or branched DNA (bDNA) 
analysis that is a very sensitive approach (291). 
FISH has been considered an standard for the detection of fusion rearrangements; the break-apart 
strategy is the main approach used for this propose (293). Yoshimoto et al. developed a three-
colour assay, which is able to distinguish between the two main mechanisms of gene 
rearrangement for TMPRSS2-ERG, the interstitial deletion, or the reciprocal translocation(294).  
Different questions arise regarding FISH and the discussion of the results, for instance, the 
presence of multiple signals showing multiple copies of the fusion gene are difficult to interpret 
(295), the number of nuclei and the score of rearranged nuclei to be assessed as positive (295,296).  
 
On the other side, RT-PCR provides some advantages such as the lower cost and its capacity of 
discriminating different variants of the TMPRSS2-ERG fusion gene. In this regard, some authors 
have shown an association between some of these fusion subtypes with good (297) and poor 
prognoses (298). However, because of its high sensitivity and cross-contamination, RT-PCR may 
show false positive results. Hence, RT-PCR is an interesting and useful technique in the diagnostic 
setting and should be considered as potential complement to FISH (291).  
 
Labor-intensive and cost prohibitive methods such as long-range PCR followed by Sanger 
sequencing or whole genome sequencing have thus far yielded only a handful of TMPRSS2-ERG 
genomic breakpoints (299).   
Assays for detecting TMPRSS2-ERG fusion have been limited to those based on RT-PCR or FISH. 
RT-PCR requires the presence of a stable, full-length transcript that can be difficult to retain in 
routine clinical processing, whereas FISH requires subspecialty molecular pathology expertise that 
is not uniformly available (300).  
Detection of TMPRSS2-ERG fusions is most commonly carried out using either fluorescence in 
situ hybridization (FISH) or reverse transcription polymerase chain reaction (RT-PCR), but these 
methods are costly and require considerable infrastructure and expertise (90).  
Strengths and limitations 
This is the first systematic review related to the association of this important gene and the prostate 
cancer in early stages, following the international recommendations for systematic reviews and 
meta-analysis. There was a very sensitive search strategy, enhanced with specific findings for 
SNPs searched in Genecards.org, KEGG and UCSC Genome Browser.  
The most important limitation of this review is the high heterogeneity, that might be explained by 
geographical setting, molecular template and type of sample. Even though we analyzed and 
identified some important findings but we could not explain the heterogeneity, therefore there 
might be other important variables to have in mind for future studies, making data more 
homogeneous. 
Clinical and population importance 
Prostate cancer is characterized by its extensive clinical heterogeneity; early stratification of 
aggressive disease from a majority of indolent cancers at diagnosis is a critical clinical task in 
cancer management and treatment.  
Based on these findings, we state that TMPRSS2:ERG fusion gene might be the new gold standard 
biomarker for the diagnosis and stratification of PCa in the very early stages, allowing clinicians 
to identify and treat locally the cancer with the advent of new technology and to establish which 
one will become a very aggressive tumor. 
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As a conclusion, there is an association between TMPRSS2:ERG fusion gene with the diagnosis 
of Prostate Cancer, mainly based on urine samples and DNA-based molecular templates. 
TMPRSS2:ERG might be used as the gold standard biomarker for diagnosis and stratification of 
PCa.  
There is still too much work for standardizing the molecular template, the specific technique and 
the sample to be used. We recommend to increase our efforts to elucidate these issues.  
Legends 
Appendix 1. Search strategies 
Medline through ovid 
TMPRSS2.mp or (Transmembrane Protease, Serine 2).mp or (TMPRSS2 protein, human).mp or 
rs572530227.mp or rs537370123.mp or rs570454392.mp or rs545726689.mp or rs185312677.mp 
or rs540987630.mp or rs546335233.mp or rs561063944.mp or rs147233451.mp or 
rs544474510.mp or rs181414852.mp or rs565237319.mp or rs577684898.mp or rs547544037.mp 
or rs530689404.mp or rs12329760.mp or rs75603675.mp 
and/ 
exp Prostatic Neoplasms/  or exp prostatic intraepithelial neoplasia/  or (prostatic adj2 
malignanc$).mp  or (prostatic adj2 cancer).mp 
and/ 
exp randomized controlled trial/ or (randomi*ed adj2 controlled adj2 trial).mp. or exp clinical trial/  
or (clinical adj2 trial).mp or exp double-blind method/ or Exp cohort studies/  or (cohort adj2 
stud$).mp or exp case-control studies or exp Cross-sectional studies 
 
Embase: 
'tmprss2 gene'/exp or 'transmembrane protease serine 2'/exp or TMPRSS2:ti,ab or (TMPRSS2 
next/3 protein):ti,ab or (Transmembrane next/3 Protease next/3 Serine):ti,ab or (rs572530227 or 
rs537370123 or rs570454392 or rs545726689 or rs185312677 or rs540987630 or rs546335233 or 
rs561063944 or rs147233451 or rs544474510 or rs181414852 or rs565237319 or rs577684898 or 
rs547544037 or rs530689404 or rs12329760 or rs75603675):ti,ab  
and/ 
'prostate cancer'/exp or 'prostatic intraepithelial neoplasia'/exp or (prostatic next/3 
malignanc*):ti,ab or (prostatic next/3 cancer):ti,ab 
and/ 
'randomized controlled trial'/exp or (randomi*ed NEXT/2 controlled NEXT/2 trial):ti,ab or 
'clinical trial'/exp or (clinical NEXT/2 trial):ti,ab or 'double blind procedure'/exp or 'cross-sectional 
study'/exp or 'case control study'/exp or 'cohort analysis/exp 
 
Central (Ovid) 
TMPRSS2.mp or (Transmembrane Protease, Serine 2).mp or (TMPRSS2 protein, human).mp or 
rs572530227.mp or rs537370123.mp or rs570454392.mp or rs545726689.mp or rs185312677.mp 
or rs540987630.mp or rs546335233.mp or rs561063944.mp or rs147233451.mp or 
rs544474510.mp or rs181414852.mp or rs565237319.mp or rs577684898.mp or rs547544037.mp 
or rs530689404.mp or rs12329760.mp or rs75603675.mp 
and/ 
exp Prostatic Neoplasms/  or exp prostatic intraepithelial neoplasia/  or (prostatic adj2 
malignanc$).mp  or (prostatic adj2 cancer).mp 
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Table 10. Characteristics of included studies 





Sample Setting Age Study Design N 




Protein Tissue USA 40 - 84 Cohort 487 






























Turkey  43-78 Cohort  50 




























anada 56-65 Cohort 1312 
Mosquera 
2009 TMPRSS2:ERG FISH DNA Tissue  USA 54-70 Cohort  
140 
(134) 






DNA Blood Japan 48-100 Cases and controls 518 
Chan 2013 TMPRSS2:ERG RT-PCR  RNA Urine Canada Median 68 Cohort 92? 
Cornu 2013 TMPRSS2:ERG TaqManTM assays DNA Urine France 59-68 Cohort 291 
Robert 2013 TMPRSS2:ERG RT-PCR  DNA Tissue Netherlands  NA Cohort? 128(96) 
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Protein Tissue USA NA Retrospective cohort  80 
Nguyen 2011 TMPRSS2:ERG RT-PCR  RNA Urine Canada 19-88 Cases and controls 101 
Albadine 




TagMan DNA Urine Greece 45-83 Cohort 66 
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INTRODUCTION 
One of the most prevalent neoplastic pathologies associated with male gender is prostate cancer, 
which has been estimated for 1.1 million people around the world (301–303). This changes 
according to ethnicity and geographical location (240). The population mainly affected is Afro-
descendant, which had its prevalence increased by 11% in recent years(304). Latin American and 
Afro population inhabits in southwest Colombia, approximately in same proportion with different 
rates of disease incidence(6). 
Variants in certain genes have been associated with a higher frequency of prostate cancer (BRCA1-
2, ATM, NBN, TMPRSS2, among others) (305). Serine proteases like the TMPRSS2, are 
recognized by their mechanisms of action in inflammatory and immune processes. This gene is 
located on chromosome 21q22.3, and is expressed at the apex of the secretory epithelium of the 
glands. The fusion with members of the ETS family is the most frequent chromosomal 
rearrengement found in 50% of prostate cancers, produced mostly by the microdeletion of a portion 
of the TMPRSS2 gene (306). The TMPRSS2 gene, and the fusion gene (TMPRSS2:ERG), have 
been associated with the severity and prognosis of prostate cancer, although the actual 
pathophysiological process or the variant associated to this condition is not very well known (307). 
The fusion gene has been widely studied and, at the moment, it has been postulated as one of the 
most important biomarkers today for diagnostic and prognostic purposes, of prostate cancer 
population (298). There are some reported SNPs in the literature that have been most frequently 
related to these clinical scenarios. 
The importance of this study is that there are no similar descriptive studies characterizing the 
presence and its variants for this gene in the southwest Colombia population. This study focuses 
on describing the frecuency of allelic variants of TMPRSS2 gene in this population. 
 
METHODS 
We designed an observational descriptive design which took place from 2014 to 2016 and included 
people located in Southwest Colombia (Nariño, Cauca, Putumayo y Valle) from all ages.  
 
Sample size 
According to the expected frequency for hereditary Prostate Cancer (~ 15%), alfa 15% and an 




We performed a whole exome sequencing which allows to sequence all protein-coding regions 
(exome) in the genome. This technique permits to identify variants that might alter the sequence 
of a protein. We performed it as follows: 
 
DNA extraction 
Each patient underwent blood extraction to obtain DNA. All drops were collected in filter paper 
until dried. These filters were immersed in phosphate buffer along with the DNeasy package from 
QIAGEN ® company (Hilden, Germany – Operational). Each extraction was quantified and 
quality verified to continue the sequencing processing.  
 
Sequencing protocol 
DNA aliquots from each samples underwent a preparation process with the TruSeq Exome Library 
Prep®, then the obtained libraries were normalized to be sequenced using the TruSeq Rapid 
Exome®. These packages were provided by Illumina® from San Diego, California, USA. The 
normalized fragments with its corresponding adaptors for sequencing were charged in HiSeq2500 
machine. 
We sequenced the full exome and identified the variants associated, specifically the single 
nucleotide polymorphisms (SNPs) for TMPRSS2 gene, associated with Prostate Cancer (PCa).  
 
This project accomplished all ethical international standards. Descriptive statistics were performed 
in R and the results are shown in frequency tables for each gene and its variants associated. We 
finally searched the variants in the following public databases: Exome Aggregation Consortium 
(ExAC), PharmGKB(308), Clinvar(309), Ensemble, dbSNP(310) in order to look for some pattern 




We included 162 patients with 7.315.466 data sequenced and TMPRSS2 gene was found in 414 
data (4.3%). Missense variants were found in 23% of data, although the most frequent variants 
were synonymous and introns. Only one stop variant was found in this data (Table 11).   
 
Additionally, the most common variants for the TMPRSS2 gene were: rs140530035 (32.12%), 




The transmembrane protease, serine 2 also called TMPRSS2, is a protease of 492 amino acids 
expressed on the cell surface of multiple organs and it is theorized that they are strategically located 
to regulate cell-cell interactions. It has been shown to be positively regulated by androgenic 
hormones in neoplastic tissue and that could modulate the inflammatory response of prostate cells 
through the activation of PAR-2 (311,312). 
 
The TMPRSS2 gene has historically been associated with the malignant tumor of prostate cancer 
which is one of the most frequent in the male gender, has been the subject of study by multiple 
authors during the last decades, in order to link its presence with the frequency of cancer and its 
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prognosis(276). Although there are studies that have found that this gene does not represent a 
worse prognosis for prostate cancer (313), an important fusion of this gene with the ERG gene was 
described, with increasing association with diagnosis and aggressiveness of the prostate neoplasm 
(Present in 50% of high risk prostate cancer) (97,314). 
 
We found a low frequency of the allelic variant associated with TMPRSS2:ERG fusion gene in 
this cancer-free population of southwest Colombia. Although this is not the most frequent SNP 
found in this study, literature reports that the rs12329760 is a variant having a non-negligible allele 
frequency in populations of East Asia and Northern Europe (0.38 and 0.37 respectively) 
considering having a ratio of major homocygote (> 7%). Moreover, the Hispanic population has a 
frequency (0.155) finding low proportion of homozygotes (315). It should be noted that in the 
southwest Colombia, there is a large volume of Afro-descendant population, in which has been 
identified that the frequency of this allelic variant is higher (0.29). Therefore this is an important 
data to keep in mind when identifying new biomarkers for prostate cancer. 
 
Rs140530035 was the most sequenced polymorphism in the present study. It is a very common 
intron in the world population and the allele frequency of this variant achieves 0.9 (316). 
Comparing to populations, citizens of northern Europe (Finland) have an AF of 0.99 while in 
Latino population it is only 0.66, according to Lek et al. 2016 (316). 
 
The rs17854725 and rs2298659 are synonyms variants that, according to the literature is rare in 
the Latinoamerican population with an AF of 0.15 or less and pathological associations are 
unknown. Like the previous ones, rs75603675 has no known pathological associations (316). 
 
Strengths and limitations 
 
This is the first study in southwestern Colombia to perform the description of this gene and its 
allelic variants in relation to the cancer-free population. In addition, the quality of samples, analysis 
and data was one of the advantages of the project. Finally, a few variants associated with the 
TMPRSS2 gene were identified, which is a very important information that calls our attention for 
longitudinal studies in patients without cancer to determine the risk for this condition. 
 
About the limitations of the study, we did not found information regarding whether there is a 
pathological relationship with prostate cancer. 
 
CONCLUSIONS 
The TMPRSS2 gene was not frequent in the cancer-free population of southwestern Colombia. 
Nonetheless, the most common variants for the TMPRSS2 gene were: rs140530035 (32.12%), 




Table 11. Associated Variants 
Variant  Absolute Frequency Percentage (%)  
5UTR 3 0.72 
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Intron 144 34.78 
Missense 98 23.67 
Stop 1 0.24 





Table 12. Variants identified for TMPRSS2 gene 
Variants Absolute Frequency Percentage (%) 
No identifier 
available 36 8.70 
rs12329760 44 10.63 
rs140530035 133 32.13 
rs143049780 1 0.24 
rs148125094 1 0.24 
rs149527323 1 0.24 
rs17854725 82 19.81 
rs181414852 1 0.24 
rs2298659 56 13.53 
rs3787950 15 3.62 
rs61735789 2 0.48 
rs61735790 1 0.24 
rs61735792 1 0.24 
rs61735793 1 0.24 
rs61735794 3 0.72 
rs61735795 1 0.24 
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Prostate cancer (PCa) is the most frequent malignant neoplasia diagnosed in men, considering 
developing countries and the developed ones (excluding skin cancer); besides it is one of the main 
causes of death (216–218). PCa is the second most commonly diagnosed worldwide cancer among 
men (mainly >65 years). It is a public health concern in developed countries, in which elderly men 
correspond to the greatest proportion of general population(9). This relevant condition is a 
heterogeneous disease with a variable natural history and slow growth pattern. It may display 
latency periods of up to 20 years in which it remains organ-confined. Although prostate cancer 
lesions can remain localized for long periods, more aggressive forms might occur and when 
metastasis occurs, lymph nodes and bones are affected predominantly with detrimental 
results(270).  
Patients at high risk and susceptibility to develop PCa, require screening over time. Age, race and 
family history are the most important risk factors(271).  
There has been concerns about the diagnosis and early treatment of this disease due to the absence 
of specific markers(273). Until now, the gold standard for the diagnosis of PCa is an invasive 
procedure consisting in the histopathological evaluation of the prostate, a procedure with 
significant morbidity(92).  Currently, the use of prostate-specific antigen (PSA) as a screening and 
monitoring marker for prostate cancer is widespread (274), although there is still debate about the 
screening for PCa among men in the general population. This biomarker is prostate-specific but it 
has a low specificity and could also increase unnecessary biopsies, without lowering mortality(1).  
 
In the search for new biomarkers, metabolomics is one of the omics sciences that has been studied 
during the last 5 to 10 years. It mainly indicates and measures the systemic activity and conditions 
in the human body, suggesting that dysregulation of metabolism has a fundamental role in the 
development and progression of common conditions and malignancies (317).  
Specifically, prostate cells´ metabolism produces the components for prostatic fluid, such as: 
Prostate Specific Antigen (PSA), spermine, myo-inositol and citrate (Higher levels than in any 
other organ). In Prostate Cancer, cells loss the ability to accumulate citrate by lowering the zinc 
	 72	
levels (317). Additionally, there is some evidence demonstrating that chronic inflammation and 
related markers like in metabolic syndrome, increase tumor growth (318) 
 
Metabolomics employ different techniques to detect the components in every tissue with different 
statistical or bioinformatic methods (319). The major approaches are: 1. Targeted analysis, 
2.Metabolite profiling and 3.Metabolic fingerprinting, nevertheless, the three of them have 
advantages and disadvantages as any other technique. Regarding the metabolites, so far, the most 
promising biomarkers for PCa diagnosis are: Sarcosine (AUC 0.67)(187), choline, 
phosphocholines (AUC 0.982) (186) , phosphorylcholines, carnitines (AUC 0.97)(188), citrate 
(AUC 0.89) (189), amino acids (lysine, glutamine and ornithine) (190–193), arachidonoyl amine 
(AUC 0.86) (188) and lysophospholipids (Steroid hormone biosynthesis pathway and bile acids – 
Sensitivity and Specificity 92- 94%) (192). 
 
The purpose of this experiment was to identify the metabolites in patients with malignant 
disturbances of the prostate compared to non-cancer patients. 
 
Methods 
This research was carried out by the UROGIV Research Group along with the research group 
Labiomol and Development and Applications in Nuclear Magnetic Resonance (DARMN). An 




Samples were taken in the urology section of the Hospital Universitario del Valle and in the 
Prostate biopsy section of the Rafael Uribe Uribe Clinic. 
 
Population 
Two sample groups of patients older than 18 years of male gender who were at risk of Prostate 
cancer due to elevated PSA or abnormal digital rectal examination were selected and divided as 
follows: Group 1. Patients with localized prostate cancer (PCa), who were characterized 




Patients were excluded for the following conditions: Other concomitant cancer types, 
coagulation disorders, with renal or metabolic disorders such as diabetes mellitus, gout or 
hyperthyroidism. 
Additionally, symptoms of acute diseases two weeks before the sample taken as: Febrile episode, 
cough, headache, diarrhea, hematuria as well as psychic disorders or episodes of stress trauma. 
Ingestion of medications up to two weeks before taking samples such as: Antibiotics, hormones, 
non-steroidal anti-inflammatory drugs and chemotherapy or radiotherapy medication. Those who 
did not sign the informed consent 
 
Selection of samples and sample size 
Sampling was done by convenience and according to the availability of patients upon admission 
to the urology unit of the HUV and Rafael Uribe Uribe Clinic. 
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Patients were taken according to convenience sampling at the institutions and had an indication 
for prostate biopsy, they were instructed and requested informed consent for the handling of 
samples. He was also informed of the risks and benefits that had both the procedure and the 
research project. The patients underwent blood sample, as well as urine and the standard 
procedure of prostate biopsy to confirm the diagnosis. 
 
According to the result of the histology, 12 patients were admitted with confirmation of prostate 




Blood sampling procedure 
The procedure was carried out by trained and trained personnel for sampling in humans. After 
collecting, the blood was mixed by inverting the tube 8 to 10 times. It was stored in the 
vacutainer tubes (collection tubes with EDTA) in vertical position at 4ºC until centrifugation. 
The samples were transported within the next two hours for collection. 
 
Procedure for separating the serum 
Prior to the centrifugation of the sample, the centrifuge was switched on and cooled at 4º C. 
Previously, an aliquot of 500 µL of phosphate buffer pH 7.4 (0.142M Na2HPO4) was taken in 
1.5 mL Eppendorf® tubes. 
The blood samples were centrifuged in a rotor (oscillating head) for 5 minutes at 4000 rpm at 4 ° 
C. After centrifugation, 250 µL of the plasma layer was taken with an appropriate micropipette 
without disturbing the buffy coat layer. It was stored in a -80ºC bio-freezer. 
 
Preparation for resonance 
Each sample was thawed at room temperature and centrifuged at 12000g at 4oC for 5 min. 65 µL 
of Phosphate Buffer pH 7.4 (0.142M Na2HPO4) prepared with D2O and TSP (3- 
(Trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt), and 585 µL of sample were added in 
eppendorf. It was centrifuged again at 12000g at 4oC for 5 min. Finally, 600 µL of supernatant 
was transferred to a 5mm NMR tube. 
 
1 H-NMR spectra were acquired on Bruker Avance II Ultra Shield 400 MHz spectrometer 
(Bruker BioSpin, Rheinstetten, Germany) with direct BBO probe equipped with 3 gradients at a 
temperature of 300K. The spectra were obtained by means of the pulse sequence CPMG at 64 
scans and with pre-saturation of the water signal. Through the CPMG sequence, signals 
belonging to molecules of high molecular weight can be eliminated from the spectrum, 
improving the resolution of the signals corresponding to the metabolites. The resonance 
frequency and the homogeneity of the field were adjusted automatically, while the calibration of 
the solvent suppression was performed manually for each sample. The spectra were referenced 
with respect to the resonance of the α-glucose doublet at δ 5.233 ppm 
 
Data analysis 
The spectral data matrix was pre-processed with scripts in software R (R Development-Core 
Team) (231) ; firstly there was a base line correction, then the regions of the TSP, water and 
anticoagulant signals, as well as the spectral regions of the ends, were eliminated. Additionally 
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binning was performed in the spectral region comprised between δ 0.1 - 9.0 ppm. For the 
analysis of the spectral data, multivariate methods were used; PCA and OPLS-DA were applied 
in R, using pareto as a scaling method and combined with the statistical total correlation 




The study accomplishes all international ethical requirements for human research and it was 




We included 32 patients 12 with prostate cancer diagnosis and 20 with hyperplasia. The median 
age was 69.5 years (46 to 82). All patients had localized prostate cancer showing no evidence of 
metastasis in extension studies (Table 13). 
 
Table 13. Characteristics of included patients 
 
Age Ethnic group Setting Past history 
Urethral 
catheter PSA Histology Tumor Gleason Risk group 
Included patients with Cancer 
61 Multiracial Cali No No 15.3 Adenocarcinoma T1c 3+3 Intermediate 
77 Multiracial Silvia No Yes 75.85 Adenocarcinoma T2c 4+3 High 





No No 7.08 Adenocarcinoma T2c 3+3 High 
78 Multiracial Cali No No 20.2 Adenocarcinoma T2a 3+3 High 
82 Black Zarzal No No 16.61 Adenocarcinoma T2c 3+3 High 
57 Black Cali No No 8.01 Adenocarcinoma T2a 3+3 Low 
74 Multiracial Popayán No No 15.99 Adenocarcinoma T2c 3+3 High 
74 Multiracial Sabaneta No No 9.05 Adenocarcinoma T2a 3+3 Low 
82 Multiracial Cali No No 13.74 Adenocarcinoma T2a 4+4 High 
60 Black Puerto Tejada No No 14.82 Adenocarcinoma T2a 3+3 Intermediate 
67 Black Tumaco No No 11.2 Adenocarcinoma T2a 3+3 Intermediate 
Included patients without Cancer 
75 Multiracial Cali No No 4.88 Negative for malignancy       
54 Multiracial Cali No No 10.1 Negative for malignancy       
60 Multiracial Cali No No 8 Negative for malignancy       
65 Multiracial Cali No No 4.37 
Atypical Acinar 
Proliferation / Glandular 
Atrophy (IHC) 
      
51 Multiracial Cali No No 4.24 Chronic prostatitis       
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77 Multiracial Cali No Yes 10.57 
Atypical Acinar 
Proliferation / Glandular 
Atrophy (IHC) 
      









      





      





      




      




No 10.8 Glandular Atrophy (IHC)       




      










      
66 Multiracial Palmira No No 6.63 Glandular Atrophy (IHC)       





      






      






      






      
 
 
Sample metabolomic profile in plasma 
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We found the following graphical profile for metabolites in a sample of healthy patients (Figure 
18). Some of the metabolites represented by their resonances are: the acetone, the acetoacetate, 
the alanine, the glucose, the valine and some others (Table 14). 
 




Table 14. Spectrums of resonances 1H-RMN of metabolites of healthy human plasma. 
 
Signal δ 1H-RMN (ppm) Signal δ 1H-RMN (ppm) 
Valine 0.98 (d) Acetate 1.91 (s) 
1.04 (d) Glutamine 2.14 (m) 
2.28 (m) 2.44 (m) 
3.61 (d) 3.77 (t) 
3-hidroxibutirate 1.19 (d) Acetone 2.23 (s) 
2.30 (dd) Acetoacetate 2.28 (s) 
2.40 (dd) Creatinine 3.04 (s) 
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4.15 (m) 4.05 (s) 
Lactate 1.32 (d) Glucose 3.22 - 3.92 (m) 
4.11 (c) β-glucose 4.64 (d) 
Alanine 1.48 (d) α-glucose 5.23 (d) 
3.76 (c)   
 
Principal component analysis 
We pretend to obtain with the two first components to explain more than 50% of data. We had to 
eliminate two data from healthy patients and one for cancer patients due to contamination with 
ethanol. We obtained 18 non-cancer patients, however we had to exclude two atypical data, 
therefore we only included 16 non-cancer patients (Figure 19). 
 




We only had to eliminate one patient (atypical data) after the PCA for cancer patients, therefore 
the figure is shown with 10 patients (Figure 20) 
 




After including the 16 samples of non-cancer patients and the 10 samples of cancer patients, we 
still found one atypical data therefore we excluded and the final analysis included 15 non-cancer 
patients and 10 cancer patients. In Figure 21, we can show the discrimination of cancer and non-

















Subgroup analysis Risk  
 
Although this is a low sample, we can show that the most important discriminative patients with 
cancer have high risk of progression.  The patients with low and intermediate risk are apart from 
this group (Figure 22 and 23). 
 









OPLS-DA model  
We included 15 non-cancer patients and 10 patients with cancer, then we applied the 5-fold 
method. It resulted in a discriminative expression of patients with and without cancer (R2 = 0.5902; 
Q2 = 0.3302; Figure 24).  
 











Additionally, we describe the loadings plot to identify the metabolites associated with cancer 
(Figure 25 and Figure 26). 
 










The metabolites associated with prostate cancer were shown in a statistical total correlation 
spectroscopy (STOCSY) 1D graph to better discriminate metabolites. The figure 27 is for the 
loading 657 (Lipids) and the Figure 28 is for the loading 647 (The lactate), which were found 
with positive correlation with prostate cancer.   
 
Figure 27. STOCSY 1D for lipids (A barplot color-coded for positive (red), negative (blue) 





Figure 28. STOCSY 1D for Lactate (A barplot color-coded for positive (red), negative (blue) 








Summary of the main results 
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There was a consistent difference between the two groups (cancer and non-cancer patients) 
according to the PCA, mainly in the high risk of progression PCa patients. The two most important 
metabolites that discriminate cancer from non-cancer patients were lactate and lipids in plasma 
samples. 
 
Contrast with literature 
In 1920, it was described that cancer cells, even in the presence of oxygen, produce ATP through 
anaerobic pathway (anaerobic glycolysis) instead of tricarboxylic acid cycle (Krebs cycle). The 
Warburg effect consists in the ability of sustaining high rates of glycolysis for ATP generation 
(320). In the prostatic epithelial cells, we find an overexpression of zinc-regulated transporter/iron-
regulated transporter-like protein 1(ZIP1) which inhibits the m-aconitase in the tricarboxylic acid 
cycle. This leads to accumulation of citrate in the healthy prostate (321). In prostate cancer, the 
ZIP1 lowers, since the malignant tissue cannot accumulate zinc and the anaerobic glycolysis 
increases, overproducing lactate. This process might be a hallmark in the beginning of prostate 
cancer, even before of histological changes (321).  
 
According to this, lactate has been associated with tumor progression, as well as pyruvate and 
alanine. Lactate, for example, has been studied as urine biomarker for non-invasive detection of 
PCa, nonetheless there are not consistent results (322).  
 
There is an important difference in PCa regarding the glucose metabolism due to the dependence 
of Androgen receptor (AR) signaling. It has been described that glycolysis differs between cell 
sensitive to androgen (early stages) and non-sensitive (advanced), according to the dependence to 
glucose (322,323). AR also regulates the activity of several genes related to glucose consumption 
such as: Hexokinase-2(HKII), Pentose phosphate pathway (PPP) and Calcium/calmodulin-
dependent protein kinase beta (CaMKKB) among others. Overall, AR stimulates glycolysis and 
anabolic metabolism(322). 
 
Regarding the metabolomics, we performed an experiment based on plasma samples and nuclear 
magnetic resonance (NMR) which is broadly accepted in literature. These have advantages such 
as: easy to obtain, less diurnal variation and less invasive than a prostate biopsy. On the other side, 
the disadvantages are: higher concentration of proteins and more sample preparation than 
urine(321).  
 
Our results indicate a dysregulation in energetics pathway according to the differences in lactate 
and lipids between groups. There are only few studies describing the use of 1H-NMR in plasma 
samples with few patients and their findings were the following: 1.Increased levels of alanine, 
pyruvate and sarcosine and low levels of Glycine (Disturbances in energetic metabolism and 
lipogenesis, and alterations in glycine synthesis and degradation)(324). 2. Acylcarnitines, Choline 
and arginine (Alteration in fatty acids metabolism, alteration in membrane phospholipidic 
metabolism and alteration in amino acids metabolism)(182). 
 
Some other studies but with different approach (Liquid and gas chromatography/Mass 
spectrometry) have found similar results with different biomarkers: Alteration in lipid metabolism, 
disturbances in growth inhibition and induction of apoptosis, alteration in amino acid metabolism 
and alteration in energetic metabolism (Increased levels of Palmitic acid, linolenic acid, aspartic 
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acid, choline, alanine, lysine, sarcosine and phosphatidylcholine and low levels of ornithine, stearic 
acid, glutamine, valine, tryptophan, DHEAS, epiandrosterone sulfate, carnitines, 2-
hydroxybutyrate, ketone bodies among others)(191,325–327). 
 
Strengths and limitations 
This is the first pilot study in Colombia to identify a biomarker for diagnosis localized prostate 
cancer in a very early stage through metabolomics. We designed a consistent method to analyze 
the samples through nuclear magnetic resonance (NMR) and found interesting results to 
understand the pathophysiology of PCa. The finding of lactate and lipids might be tried in a 
population study with higher sample size to extrapolate results and to consider using these 
metabolites and this technique as a way for screening or diagnosing PCa, depend on the context. 
Regarding the limitations, we found the following to be considered in next trials: a low sample 
size and the lack of association with mass spectrometry (MS) to complement and identify low 
weight molecules (Lipidomics). 
 
Conclusions 
The main differences between patients with prostate cancer versus non-cancer regarding their 
metabolomics profiles confirmed that lactate and lipids are the most reliable biomarkers to trace 
cancer development in prostate.  
We suggest to continue research in this important omics technology to try to elucidate what really 





























Chapter 9. Integrative model 
 
Prostate cancer is one of the most common and studied malignancies around the world, however, 
the molecular mechanisms underlying its development are poorly understood since most of the 
research has been focused on progression and advanced stages. Similar to other cancers, PCa has 
multiple genomic disturbances including microsatellite variations, point mutations and 
chromosomal alterations such as deletions, insertions, translocations and duplications, nonetheless 
in this tumor, these alterations result in a high frequency of gene fusions. Additionally, there are 
important disturbances in physiological and metabolic processes inside the gland which might 
trigger or complement the tumorigenesis.  
 
The highly heterogeneous nature of PCa provides a real challenge for clinical disease management. 
In our case, the knowledge of each one of these different elements in conjunction, might increase 
the better understanding of the complexity of the pathophysiology of the prostate cancer and 
perhaps in the future we might find different targets to prevent or cure it in early stages. 
 
Inherited Prostate Cancer 
Race, diet, family history, environmental factors and hereditary components have been reported 
as risk factors for PCa (219–222). Regarding the latter, genes such as BRCA1, BRCA 2, MSH2, 
HOXB13, ATM, CHEK2 and NBN have been proposed as important candidates contributing to 
PCa (223,226–229). In this compendium, we found that the most frequent genes were ATM 1221 
data (13.2%), BRCA1 1178 data (12.8%), BRCA2 1484 data (16.12%) and NBN 965 (10.42%) 
with missense and stop variants for most of them. On the other side, there were non-pathological 
variants like rs169547, rs206075, rs206076 and rs9534262 and some other variants like rs799917, 
rs3736639, rs1061302 and rs1805794 associated to NBN gene, which are highly linked to PCa in 
the literature. 
 
The existence of single nucleotide polymorphisms (SNPs) for these genes, further increase the risk 
and even could be used as a prognostic biomarker for this condition (236). Additionally, observing 
a germline mutation in some DNA-repair gene provides information to patients to look for 
counseling, identify predisposition to cancer (226).  
 
BRCA2 has an important role in the repair of double-strand DNA breaks that function by 
regulating the intracellular transport and activity of RAD51, a critical protein in homologous 
recombination (241–243). The most frequent variants found for this gene, such as: rs169547, 
rs206075, rs206076 and rs9534262, are similar with other studies (244,245).  
 
The second most frequent gene was ATM, which exerts control in cell division. When detecting a 
damage in the genetic material, leading to either cell cycle arrest, DNA repair or apoptosis (251–
253). In addition, it can be considered as the main transducer in the double-strand rupture repair 
process, where it recruits and cooperates with other sensor proteins such as 53BP1 (p53 binding 
protein) and BRCA1.  
BRCA1 is the third most frequently gene found and associated with an increased risk of sporadic 
PCa (3.5 times), while for germline mutations in this gene only 0.44% of the cases have been 
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observed of PCa (220,254,255). The Breast Cancer Linkage Consortium (BCLC) described that 
men aged 65 with mutations in BRCA1 report an increase in the risk of PCa with a relative risk 
(RR) of 1.82, being linked to a series of cellular processes such as response and repair of DNA 
damage (220,253,255,256), transcriptional regulation and chromatin modeling.  
 
NBN was another important gene found, which is a component of the protein complex hMRE11 / 
hRad50 / NBN that participates in the initiation of a response to DNA damage and is linked to the 
repair of double-strand rupture (260–262). This acts in the non-homologous junction pathway as 
a DNA damage sensor and in the homologous recombination pathway, participating in DNA repair 
and in the cell cycle check point in the S phase (262).  
 
These genes are fundamental for considering the risk of familial PCA since at least 15% of patients 
might have this kind of condition and as a clinicians we need to consider and look for the 
susceptibility in our population. We need population-based studies with higher sample size and a 




The transmembrane protease, serine 2 also called TMPRSS2, is a protease of 492 amino acids 
expressed on the cell surface of multiple organs and it is theorized that they are strategically located 
to regulate cell-cell interactions. This gene was considered a promising biomarker located at 
21q22.2 and expressed in normal and malignant prostatic epithelium as an intracellular and 
membrane proteins, according to RNA (transcripts per million) or protein (antibodies) levels. 
Additionally, ERG is a member of the E-twenty six family members (ETS), which are key 
regulators of differentiation, apoptosis, embryonic development, cell proliferation and 
inflammation. It has been shown to be positively regulated by androgenic hormones in neoplastic 
tissue and that could modulate the inflammatory response of prostate cells through the activation 
of PAR-2 (311,312). 
 
The TMPRSS2 gene has historically been associated with the malignant tumor of the prostate, 
which is one of the most frequent in the male gender, has been the subject of study by multiple 
authors, in order to link its presence with the frequency of cancer and its prognosis (276). Although 
there are studies that have found that this gene does not represent a worse prognosis for prostate 
cancer (313), an important fusion of this gene with the ERG gene was described, with increasing 
association with diagnosis and aggressiveness of the prostate neoplasm (Present in 50% of high 
risk prostate cancer) (97,314). 
 
TMPRSS2:ERG has been assessed as a specific biomarker for PCa, since 2005 (275). There are 
few studies trying to look for the association between this gene, the fusion and the advanced 
prostate cancer, but less research for this gene as a diagnostic tool (276). Up to 53% of patients 
with ERG-positive HGPIN revealed progression to PCa, which needs to be addressed in other 
studies and systematic reviews. (275)(Figure 1). Additionally, Huang et al, determined that the 
fusion between the androgen regulated TMPRSS2 gene and the members of the ETS transcription 
factor family (ERG, ETV1, ETV4) has been identified as a genomic aberration in prostate cancer 
(286). The main mechanisms by which the TMPRSS2-ERG fusion genes are produced are 
interstitial deletion and balanced translocation (276,291).  
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According to the information pooled in our systematic review and meta-analysis from 15 studies, 
we found that TMPRSS2: ERG fusion was significantly associated with diagnosing PCa (OR 2.24 
95%CI 1.29 to 3.91), mainly in urine samples (OR 2.79 95%CI 1.12 to 6.98) and DNA-based 
molecular templates (OR 3.55 95%CI 1.08 to 11.65).  On the other side, we found a low frequency 
of the allelic variant associated with TMPRSS2 (4.3%) in the south-west Colombia population. 
Missense variants were found in 23% of data, although the most frequent variants were 
synonymous and introns. Only one stop variant was found in this data. These are another important 
data to consider when assessing the risk of prostate cancer in this population.  
 
Because of its specificity and according to the results presented in this research, detection of these 
fusion gene might be used as an important diagnostic tool in the early detection of PCa and part of 
the comprehensive framework for understanding the pathophysiology of this condition. These 
rearrangements might be detected either by fluorescence in situ hybridization (FISH), reverse 
transcription polymerase chain reaction (RT-PCR) (292), or branched DNA (bDNA) analysis, 





According to the present, there was a consistent difference between the two groups (cancer and 
non-cancer patients) according to the PCA, mainly in the high risk of progression PCa patients. 
The two most important metabolites that discriminate cancer from non-cancer patients were lactate 
and lipids in plasma samples. 
 
Cancer cells have the ability of produce ATP through anaerobic pathway (anaerobic glycolysis) 
instead of tricarboxylic acid cycle (Krebs cycle) even in the absence of oxygen (320). One 
subpopulation of these cells are capable of consume high levels of glucose and secrete high levels 
of lactate, whereas the others, utilizes the lactate produced by others as their main energy source 
(328). Therefore, tricarboxylic acid cycle and oxidative phospholylation (OXPHOS) play 
important roles in the metabolic study of PCa. This has been associated with mutation or loss of 
function of tumor-suppressor genes with the activation of tumoral pathways such as: Nuclear factor 
kappa-light –chain-enhancer of activated B-cells, protein kinase B (Akt), epidermal growth factor, 
insulin-like growth factor I, phosphoinositol 3-kinase, mammalian target of rapamycin, and HIF-
1alfa (329). HIF-1alfa upregulates the following on an oxygen-independent manner: Glucose 
transporter 1, monocarboxylate transporter four (MCT-4) and lactate dehydrogenase A (LDH-A) 
(329). I will discuss this issue further. 
 
As previously mentioned, in prostate cancer, the ZIP1 lowers, since the malignant tissue cannot 
accumulate zinc and the anaerobic glycolysis increases, overproducing lactate (Figure 29). This 
process might be a hallmark in the beginning of prostate cancer, even before of histological 
changes (321) and leading to two important ways that focus in a pre-cancer state such as: the 
chronic inflammation, lipogenesis and the energetic pathways those that might be associated or 
synergic to the TMPRSS2:ERG fusion gene. 
 






Lactic acid, for many years, was considered an inert end-product of glycolysis during hypoxia. 
However, during the last few years, it has been considered that under different contexts, lactate 
can have multiple regulatory functions and might be seen as a signal for different metabolic, 
physiologic and immune processes inside the prostatic cell. The acidic environment requires the 
adaptation of tumor cells for surviving, representing the tumor advantage over the normal cell. As 
a result, adjacent tissues go into a necrotic phase that allow, not competing for substrates and 
facilitating tumor growth (331,332). 
 
According to this, the following must be stated: Lactate must be seen as an important marker since 
it has been found that promotes cancer cell survival, invasion and angiogenesis; it also plays and 
important regulatory position for the immune system (329). The lactate produced by the tumor, 
attacks the immune system lowering the pH in the stroma (ranges between 6.0 to 6.5); at these 
values, the cytolytic response and the cytokine secretion of tumor infiltrating T-cells are 
diminished, therefore regulating tumor growth. Additionally, the extracellular levels of lactate 
inhibit the differentiation of monocytes and dendritic cells (329).  
 
Lactate also induces the activation of HIF-1alfa and the secretion of VEGF alpha and ARG1, 
triggering neovascularization and immunosuppressive and remodeling processes, leading to high 
proportion of M2 macrophages (Tumor-associated macrophages) in the tumor stroma (329). 
 
The fundamental role of lactate in the microenvironment of PCa led the attention to the 
monocarboxylate transporters (MCTs), which transport monocarboxylates across the membranes, 
acting as a way to communicate between tissues (328). MCTs are also important to transport 
another monocarboxylates such as pyruvate, the branched-chain oxoacids derived from leucine, 
valine and isoleucine, and the ketone bodies, acetoacetate, beta-hidroxybutyrate and acetate (333). 
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According to this, MCTs maintain the hyper-glycolytic and acid-resistant phenotypes, as part of 
the adaptation to the hypoxic microenvironment. The upregulation of MCTs is considered an 
adaptive mechanism by exporting the accumulating end-product (Lactate) (328). 
 
According to Pertega-gomez et al (334), there is only MCT1 expression in the normal epithelium; 
there is an increase in MCT2 expression in the Prostatic intraepithelial Neoplastic lesions (PIN) 
and an increase in MCT4 plus MCT2 and MCT1 expression in localized PCa (Figure 30). 
 





As a summary, normal prostate cells rely on glucose oxidation to provide precursors for synthesis 
and secretion of citrate, resulting in minimal energy production due to an incomplete krebs cycle 
and oxidative phosphorylation. On the other side, PCa cells no longer secrete citrate, they activate 
krebs cycle, however, primary and localized PCa does not increase aerobic glycolysis (328). 
 
Another important event in PCa tumorigenesis is an increase in lipogenesis. Regarding this issue, 
many mechanisms have been proposed to link obesity and PCa, including the dysregulation of the 
insulin/insulin-like growth factor (IGF-1) axis, alteration of adipokine signaling and higher 
oxidative stress (335,336). 
Obesity has been associated with higher levels of insulin which might be correlated with hyper-
activation of intra-cellular transduction pathway that increases anabolic, antiapoptotic and mitotic 
activities of cancer cells. Additionally, the IGF-1 promotes mitogenesis, proangiogenesis and 
inhibits apoptosis facilitating the cancer progression. On the other side, adiponectin has been found 
to have antitumor effects by inhibiting cancer cell growth and inflammation. In obese men, 
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hypertrophic adipose tissue releases a disturbed profile of adipokines with elevated levels of leptin 
and low levels of adiponectin (337,338). Additionally, there is an obstruction of capillaries leading 
to hypoxia and ischemia which further creates a state of oxidative stress and an increase of reactive 
oxygen radicals that are able to damage cell DNA (336). 
Adiponectin has been involved in different signaling pathways associated to cancer. By binding to 
AdipoR1 and AdipoR2, adiponectin initiates a cascade of events such as the activation of AMPK 
and other regulatory proteins to instigate a variety of actions. For example, anti-apoptotic actions 
mediated via the activation of ceramidase, Akt, and AMPK as well as via the supression of 
ERK1/2, PI3K/Akt, Wnt/β-catenin, NF-κB, JNK and the cell cycle regulators p53/p21, and by 
negatively influencing the mTOR/S6K axis and fatty acid synthase. On the other side, adiponectin 
can mediate inflammation by activation of sphingosine kinase-1 (Sphk1) and cyclooxygenase-2 
(COX-2) (339) (Figure 31).  
 
Figure 31. Adiponectin pathways. Taken from (339) 
 
To conclude, there are a variety of mechanisms proposed to the pathophysiology of Prostate 
Cancer, therefore all those might be important elements to target in order to prevent the 
development of PCa or to perform therapeutic interventions in a localized PCa. According to this 
compendium I would like to propose the following pipeline just before the development of cancer 
or exactly at the very beginning of this condition (Figure 32): 
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Resumen  El antígeno  prostático  específico  y  el tacto  rectal  son  herramientas  diagnósticas  que
en la  actualidad  se  quedan  cortas  al  momento  de  diferenciar  entre  procesos  malignos  como  el
cáncer prostático  y  procesos  benignos  como  la  hiperplasia  prostática.
Nuevos  biomarcadores  con  altas  sensibilidades  en  el  diagnóstico  de  procesos  malignos  prostá-
ticos han entrado  a  desempeñar  un  papel  significativo  en  la  determinación  temprana  de  cáncer
de próstata  (CP).
El  gen  de  cáncer  de próstata  3 está  implicado  en  la  supervivencia  de  la  célula  cancerígena;
puede identificarse  en  orina  y  permite  diferenciar  entre  cáncer  y  prostatitis  crónica/hiperplasia
prostática. Por  otro  lado,  la  b2-microglobulina  es  una  proteína  que  forma  complejos  con  el
complejo  mayor  de histocompatibilidad  tipo  I  de la  célula  cancerígena  prostática,  y  gracias  a
esta interacción  hace  parte  de  procesos  moleculares  que  terminan  generando  metástasis  ósea;
sus niveles  séricos  pueden  ser  determinados  por medio  de  exámenes  de laboratorio,  y  de  esta
forma se  puede  hacer  una  diferenciación  entre  procesos  benignos  y  cáncer.  Las  calicreínas  (test
4K score),  las  mucinas  (MUC1),  la  proteína  LRPPRC,  el  ADN  circulante  del tumor,  la  alfa  metilacil
coenzima a  racemasa  y  las  células  madre  prostáticas  son  moléculas  prometedoras,  tanto  en  el
diagnóstico  temprano  del  CP  como  en  el  pronóstico  y  respuesta  al  tratamiento.
La importancia  del  hallazgo  de nuevos  biomarcadores  con  especificidades  y  sensibilidades
altas para  el  diagnóstico  precoz  del  CP  no solo  podrá  reducir  la  mortalidad  por  esta  enfermedad,
sino también  propiciará  nuevos  campos  de investigación  en  busca  de  dianas  terapéuticas  más
efectivas en  el tratamiento  del  mismo.
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A  general  overview  of  biomarkers  for  the  screening  and  early diagnosis  of  prostate
cancer
Abstract  Prostate  specific  antigen  and digital  rectal  examination  are  diagnostic  tools  that
currently  fall  short  when  differentiating  between  malignant  processes,  such  as  prostate  can-
cer and  benign  prostatic  hyperplasia.  New  biomarkers  with  high  sensitivity  in  the  diagnosis  of
prostate  malignancies  have  come  to  play  a  significant  role  in  the  early  identification  of  pros-
tate cancer  (PC).  Prostate  cancer  gene  3 is involved  in cancer  cell  survival.  It  can  be identified
in urine  and  used  to  differentiate  between  cancer  and  chronic  prostatitis/.  Furthermore,  b2-
microglobulin  is a  protein  that  complexes  with  major  histocompatibility  complex  type 1 prostate
cancer cell,  and  through  this  interaction  is part  of  the  molecular  processes  that  end  up  genera-
ting bone  metastases.  Serum  levels  can be determined  by  laboratory  tests  and  as  such  can be
used to  differentiate  between  benign  processes  and  cancer.  Kallikreins  (4K  score  test),  mucins,
the leucine  rich  pentatricopeptide  repeat  containing  protein,  circulating  tumour  DNA,  the  alpha
methyl acyl  coenzyme  A racemase,  and  Stem  Cells  are  promising  molecules,  both  for  the early
diagnosis  of  PC,  as well  as  for  the  prognosis  and  response  to  treatment.  The  importance  of  the
discovery of  new biomarkers  with  high  sensitivity  and  specificity  for  early  diagnosis  of  PC  not
only can  reduce  mortality  from  this  disease,  but  will  also  foster  new  fields  of  research  for  more
effective treatment  in the  same  therapeutic  targets.
©  2016  Sociedad  Colombiana  de Uroloǵıa.  Published  by  Elsevier  España, S.L.U.  All  rights  reser-
ved.
Introducción
En la  actualidad,  el  antígeno  prostático  específico  en  con-
junto  con  el  tacto  rectal  constituyen  los métodos  de
tamización  principalmente  usados  en  la  clínica  para  detec-
tar  el  cáncer  de  próstata,  sin  embargo,  estos  tienen  bajo
rendimiento  diagnóstico,  tanto  individualmente  como  en
conjunto.
La  importancia  de  encontrar  nuevos  biomarcadores,  que
sean  más  sensibles  y  específicos  para  tamización  y  diag-
nóstico  temprano  del  cáncer  de  próstata,  se ha  visto
especialmente  reforzada  por la  falencia  del PSA.  El  hecho
que  este  último  se eleve  en  una  condición  benigna  como
la  hiperplasia  prostática  y  también  en condiciones  de
malignidad1,  ha generado  que  se  soliciten  biopsias  costo-
sas  e  innecesarias  a  pacientes  que  no  lo requerían  desde
un  comienzo1.  Como  consecuencia  de  esto,  se  han  explo-
rado  otras  técnicas  y  moléculas  para  hacer un diagnóstico
más  específico,  tales  como  el  PCA3,  la microglobulina  y  las
mucinas,  entre  otros.
El  objetivo  del presente  trabajo  fue  describir  algunos  de
los  nuevos  biomarcadores  involucrados  en la tamización  y  el
diagnóstico  temprano  del cáncer  de  próstata.
Epidemiología
El  cáncer  de  próstata  (CP)  es el  segundo  tipo  de  cáncer  más
común  en  la población  masculina  del mundo2. Se  estima
que  uno de  cada  7  hombres  será diagnosticado  a  lo largo
de  su  vida  con  CP,  y  uno  de  cada  38  hombres  morirá  como
consecuencia  de  este.  De  igual  manera,  en  Estados  Unidos
6  de  cada  10  hombres  diagnosticados  con  cáncer  de prós-
tata  son  mayores  de  65  años3.  Es  el  tipo  de  cáncer  que  con
mayor  frecuencia  se diagnostica  como  consecuencia  de  la
introducción  en 1980  del test  de antígeno  prostático  espe-
cífico  (PSA)  como  herramienta  diagnóstica3.  Se  estima  que
para  el  año 2030  haya  1,7  millones  de casos  nuevos  de  CP
en  el  mundo,  con  una  mortalidad  esperada  de  499.000  casos
(29,3%)4.
Durante  la última  década  se  ha observado  una  notable
disminución  en  la mortalidad  por CP  en países  desarrolla-
dos.  El estudio  GLOBOCAN  2012  notifica  que  la  incidencia
del  CP es variable  en  el  contexto  mundial:  las  tasas  son
más  altas  en países  como  Australia/Nueva  Zelanda,  Amé-
rica  del  Norte  (ASR -----por  sus  siglas  en  inglés----  111,6  y  97,2
por  100.000  respectivamente)  y  en  Europa  Occidental  y del
Norte,  debido  a que  la  tamización  con PSA y  posterior  biop-
sia  se realizan  de forma  rutinaria5.  En  países  de América  del
Norte  (Estados  Unidos  y  Canadá)  la  mortalidad  por  CP  ha
disminuido  a 4,3%  y  3,1%  respectivamente,  y  en países  como
Dinamarca,  Noruega  y Suecia  (Europa  del Norte)  las  tasas  de
mortalidad  han  venido  en descenso  desde  el  año 2000  hasta
3,1%  por  año6;  sin embargo,  en  países  en vías  de desarrollo
la  mortalidad  por este  se ha visto  en  aumento  (aunque  hay
tendencias  hacia  el  incremento  en  el  diagnóstico,  la  mor-
talidad  ha  aumentado  en  países  como  Colombia  ----3,4%  por
año----,  Costa  Rica  ----3,4%  por año----, Chile  ----2,8%  por  año----
y  Cuba  ----5,5%  por  año----)4,6. Con  respecto  al contexto  mun-
dial,  Colombia  cuenta  con una  de las  incidencias  de CP más
bajas  de Latinoamérica,  y  una  proporción  de 28%  entre  inci-
dencia  y mortalidad  por el  mismo,  muy  cercano  al  promedio
mundial  de 28,6%  e  inferior  a  países  como  Ecuador  (40,41%),
Perú  (37,74%)  y  Cuba  (46,65%)6.
Finalmente,  en  Colombia  la  tasa  de mortalidad  por  CP
ha  disminuido  en  los  últimos  4 años4 y  el  mayor  número  de
casos  reportados  se origina  en ciudades  como  Bogotá,  Valle
y Antioquia  (las  regiones  más  pobladas  y  con mayor  cantidad
de  urólogos)4.
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¿Qué  teníamos?
Antígeno  prostático  específico
Los  antecedentes  de  uso del PSA  (prostatic  specific  anti-
gen)  datan  de  la década  de  1980,  cuando  era utilizado  en
el  seguimiento  de  pacientes  diagnosticados  con CP7,  poste-
riormente,  para  el  año 1994  la Food  and Drug  Administration
de  Estados  Unidos  aprobó  el  uso  del PSA junto  con el  tacto
rectal  como  métodos de  tamización  para  CP8.
El  PSA,  también  llamado  calicreína  iii,  es una  gluco-
proteína  de  34KDA  producida  casi  exclusivamente  por  las
células  epiteliales  de  la  glándula  prostática,  la  cual  circula
unida  a  alfa-1-antiquimiotripsina  y  la alfa-2-macroglobulina,
y  su  deber  es  la de  dividir  la semenogelina  i y  ii  en polipép-
tidos  de  menor  tamaño, evitando  así formación  del  coágulo
seminal8--12.  En  condiciones  normales  una  pequeña  cantidad,
menos  de  4  ng/ml,  es  liberada  al torrente  sanguíneo,  pero
en  un  proceso  neoplásico  estos  niveles  se  elevan8.  Por  tal
motivo  se  considera  realizar  biopsia  de  próstata  a aquellos
hombres  con  un  nivel  de  PSA sérico  mayor  a  4  ng/ml8.  Sin
embargo,  el  PSA  también  se ha encontrado  elevado  en  otras
enfermedades  como  cáncer  de  mama,  carcinoma  de células
renales,  cáncer  de  ovario  y  neoplasia  suprarrenal13.  De igual
forma,  en  hiperplasia  prostática  benigna  (HPB),  prostatitis,
cistitis,  traumatismo  perineal  y cirugía  del tracto  urinario
reciente  podría  encontrarse  elevada8,14.
El  PSA  puede  transitar  en  el  suero  libremente  (fPSA) o
acompañado  de  inhibidores  de  proteasa  (cPSA)  con el  fin de
evitar  proteólisis.  Al  sumar  el  fPSA  y PSA  acompañado  de
inhibidores  de  la  proteasa  se  obtiene  como  resultado  el  PSA
sérico  total  (tPSA),  gran  parte  de  este, alrededor  del 70-90%
puede  estar  ligado  a  alfa-1-antiquimiotripsina,  en menor
proporción  a  la  alfa-2-macroglobulina,  alfa-1  antitripsina  o
a  un  inhibidor  de  la  proteína  C12.  Consecuentemente,  cerca
de  un  10-30%  del PSA  total  (tPSA)  circula  libremente  (fPSA),
esta  forma  libre  del PSA  se caracteriza  por  asumir  3 formas
moleculares  específicas15.  Una  de  ellas  se  encuentra  predo-
minantemente  en  la  zona  de  transición  de  la  próstata  en
pacientes  con  HPB  y se denomina  BPSA16,  la  segunda  repre-
sentación  se llama  PSA  intacto  (iPSA)  y por  último  se tiene
el  proPSA,  hallado  en  su mayoría  en la  zona periférica  de la
glándula  prostática,  el  cual se  asocia  a  CP17.
Según  la  American  Cancer  Society,  la sensibilidad  del PSA
para  valores  de  referencia  de  4  ng/ml  y  3 ng/ml  para  el  diag-
nóstico  de cáncer  es del  21%  y 32%  respectivamente.  Una
especificidad  de  91%  para  valores  de  corte  de  4  ng/ml  y  de
85%  para  valores  de  3 ng/ml  de  PSA18.
En  EE.  UU. se  llevó  a  cabo  el  estudio  (PLCO)  para  evaluar
la  incidencia  de  cáncer  de  ovario,  colorrectal,  pulmonar  y
de  próstata.  En  el  caso  de  CP se evaluaron  hombres  entre  los
55-74  años,  a quienes  se le  realizó  tamización  anual  con PSA
durante  13 años,  y como  resultado  se obtuvo  que  realizar
tamización  con  PSA  no  lleva  a  disminución  de  la incidencia
de  CP  (RR:  1,09,  IC 95%:  0,87-1,36)19. Otro  gran  estudio  fue
el  The  European  Randomized  Study  of  Screening  for  Pros-
tate  Cancer  (ERSPC),  donde  se realizó  tamización  con PSA
durante  11  años  a hombres de  ciertos  países  europeos,  eva-
luando  la  mortalidad  por  CP;  los resultados  indicaron  una
reducción  relativa  en  las  tasas de mortalidad  de un  21%  (RR:
0,79,  IC  95%: 0,68  a 0,91)20.
Un  metaanálisis  de Cochrane  realizado  en  2011 resumió
los  resultados  de 5  experimentos  poblacionales,  con  un  total
de  341.351  participantes,  y  mostró  que  realizar  tamización
con  PSA  es  efectivo  para  la  detección  de  cáncer  de  prós-
tata (RR: 1,35:  IC  95%: 1,06-1,72),  sin  embargo  esta prueba
no  disminuyó  la  mortalidad  (RR:  0,95;  IC  95%:  0,85-1,07)21.
Otro  metaanálisis  del año  2010  obtuvo  resultados  similares;
tenía  como  objetivo  mostrar  evidencia  de los  beneficios  de
la  tamización  con el  PSA,  para lo cual  se tomaron  resultados
de 6  experimentos  con  un total  de  387.286  participantes.  Los
resultados  mostraron  que  la tamización  con PSA  se  relaciona
con  una  probabilidad  aumentada  de diagnosticar  cáncer  de
próstata  (RR:  1,46,  IC  95%:  1,21-1,77),  pero  al  igual  que  en
el  estudio  anterior  no  se  observa  disminución  en  la  morta-
lidad  por  CP  (RR:  0,88,  IC 95%:  0,71-1,09)22, de manera  tal
que  en la actualidad  no se recomienda  realizar  tamización
poblacional  de CP.
Lo anterior  nos sugiere  la importancia  de determinar
otros  biomarcadores  más  específicos,  que  lleven  a una  dismi-
nución  de biopsias  innecesarias,  al  igual  que  a una  detección
precoz  del  CP,  y  así mejorar  la  supervivencia  de los  pacien-
tes.
¿Qué  hay  más  reciente?
Gen  de cáncer  de  próstata  3
El  Long  non-coding  RNA  prostate  cancer  associated  3  gene
test  (PCA3)  se ha visto  implicado  en un número  importante
de investigaciones  que  reflejan  el  fundamento  para  el  estu-
dio  del CP23. Este  se encuentra  implicado  en la  supervivencia
de  la  célula  cancerígena;  este  efecto  lo logra  en parte  modu-
lando  la señalización  al  receptor  de andrógenos  y  ejerce  su
función  principal  en  el  núcleo  y  en la fracción  microsómica
de la  célula24.
Tomar  este test  requiere  que  el  proceso  se  divida en  2
grandes  partes;  primero  debe realizarse  un masaje  prostá-
tico  y  luego  se obtiene  la  muestra  de orina,  esto  facilitará
la  aparición  del  biomarcador  en  la orina24.
Los  estudios  han  mostrado  resultados  promisorios,  pero
controvertidos  a la vez por distintas  causas.  Son  promi-
sorios  porque  se  ha  encontrado  que  la medición  de  este
biomarcador  puede  diferenciar  entre  cáncer  y prostatitis
crónica/HPB1. En  parte el  motivo  para  que  esto  sea  posi-
ble  se relaciona  con la  alta expresión  de  la molécula  en
tejido  cancerígeno  de 60  a  100  veces  más  que  en  tejido  infla-
mado,  pero  sin  neoplasia,  y  cabe  resaltar  también  que  esto
se observó  en  el  95%  de los  pacientes23.  Christos  et  al.1 men-
cionan  que  este biomarcador  es  útil  para  diferenciar  entre
HBP  del  cáncer  localizado,  sin embargo,  sugieren  que  el  uso
de  la molécula  para  tamización  no  debe ser única,  sino  más
bien  debería  ser un  panel  de  nuevos  biomarcadores  que  pro-
vean  mayor  precisión  diagnóstica23. Se menciona  además  el
uso  de la  beta  2  microglobulina  (B2M)  y mucina  intestinal
(MUC3)  asociados  al  PCA31.  Se  conoció  en este  estudio  que
los  valores  tenidos  en cuenta  para  decir  si  es relevante  el
aumento  de PCA3  son:  195 DU  (con  este  valor  de  referencia
se mejora  la precisión  diagnóstica  hasta  en  un 77%)1.
Si bien las  ventajas  del uso  de PCA3  para  el  diagnós-
tico  de CP  han  sido  dilucidadas  y se  ha apoyado  la  idea  de
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usarlo  en  programas  terapéuticos  como  un  apoyo23, hay  una
contraparte  que  discute  la validez  clínica  de  los  hallazgos
encontrados  en los  diferentes  estudios.  Esta  controversia  se
basa  en  el  hecho  de  que  existan  pocos  estudios  que  pro-
vean  un  mayor  conocimiento  del biomarcador,  y  a  los que
existen  actualmente  se  les critica  que  hayan  usado  mues-
tras  poblacionales  pequeñas que  hacen  menos  fidedigno  el
resultado  final.  Se  necesitan  más  estudios  que  incluyan  una
proporción  mayor  de  pacientes  y  a los  cuales  se  les  haga
un  seguimiento  en  el  tiempo  más  prolongado23. Producto  de
lo  mencionado  anteriormente  se  ha encontrado  que  hay  un
fallo  para  demostrar  que  las  asociaciones  entre  PCA3  y cán-
cer  de  próstata  tienen  alguna  relevancia  en  el  pronóstico
del  paciente24.  De acuerdo  a este  estudio,  usando  de esta
manera  los  biomarcadores,  se  incrementa  el  valor  predictivo
de  la  prueba  y  es  posible  diferenciar  entre  condiciones  infla-
matorias  benignas  de  aquellas  que  requieren  un  seguimiento
especial,  como  lo sería  la  neoplasia24.
2-microglobulina
La  2-microglobulina  (B2M)  es un polipéptido  de  bajo  peso
molecular  (11.815  D),  sintetizado  por  células  nucleadas  y
que  forma  complejos  con el  complejo  mayor  de  histocom-
patibilidad  I25 (por  lo cual se asume  que  desempeña  un  rol
en  la  respuesta  inmune).  Fue  identificado  inicialmente  en
la  orina  de  pacientes  con enfermedad  tubular  renal26 y pos-
teriormente  en pacientes  con  cáncer  de  mama27 y cáncer
gástrico28.
Se  ha  reportado  que  la B2M  estimula  el  crecimiento  e
incrementa  la  expresión  de  genes  que  codifican  para  la
osteocalcina  y la  sialoproteína  ósea  en  las  células  canceríge-
nas  del  CP  mediante  la  activación  de  la cascada  enzimática
de  la  proteín  quinasa  A dependiente  de AMP  cíclico.  De
este  modo,  cuando  hay  una  sobreexpresión  de  B2M  en  célu-
las  cancerígenas  prostáticas,  se genera  un aumento  en  la
codificación  de  genes  que  en última  instancia  serán los
responsables  de  generar  metástasis,  tales  como  la osteo-
calcina,  sialoproteína  ósea, ciclina  A,  ciclina  D1  y  factor  de
crecimiento  endotelial  vascular.  Estas  vías  génicas  sugieren
que  la  señalización  mediada  por  B2M  podría ser un  target
terapéutico  para  el  tratamiento  de  CP con  metástasis  ósea
(fig.  1)29--31.  Igualmente,  otra  vía  molecular  en la que  se ha
visto  involucrada  la  B2M  es en  la  interacción  con la  homeos-
tasis  del  hierro.  Cuando  la  B2M  interactúa  con la  proteína
hemocromatosis  (HFE)  (que  actúa  como  su receptor),  se pro-
duce  una  modulación  en la homeostasis  del hierro  y  una
posterior  transdiferenciación  epitelio-mesenquimal  (EMT),
que  termina  promoviendo  el  crecimiento,  la invasión  y  la
metástasis  hacia  huesos  y  tejidos  blandos  (fig.  2)32.
En  estudios  realizados  por Zhang  et al.  se demostró  que
el  marcador  B2M sérico  podría  ser usado  como  un  marcador
diagnóstico  de  CP y útil  en la diferenciación  entre  procesos
malignos  e HPB  al encontrar  que  los  niveles  en  suero  de B2M
se  notaban  significativamente  elevados  en  pacientes  con  CA
de  próstata,  a  diferencia  de  los  niveles  del  mismo  marcador
en  pacientes  con HPB o  de  los  pacientes  del  grupo  control.
Sin  embargo,  no  se encontró  una  diferencia  marcada  entre
los  niveles  del B2M  entre  los  pacientes  con HPB  y  los  del
grupo  control.
Así  mismo,  pacientes  con niveles  de  PSA mayores
(≥  20  mg/ml)  tienen  niveles  de  B2M mayores  y viceversa33.
Por  lo tanto,  los niveles  de B2  M  se asocian  con  mayor  agre-
sividad  clínica33.
La B2M  puede,  por lo tanto,  ser  un  biomarcador  eficiente
para  el  diagnóstico  clínico,  seguimiento  y  pronóstico  del
CP y  a  su vez  un  blanco  terapéutico  posiblemente  eficaz
para  revertir  la EMT  y, de  esta manera,  evitar  la  progresión
metastásica34.
Examen  4K  (panel 4-calicreínas  séricas)
El  4K score  test  (por  su descripción  en inglés),  como  su nom-
bre  indica,  combina  los  valores  plasmáticos  de  4  calicreínas
usadas  como  marcadores  prostáticos:  PSA  total  (tPSA),  PSA
libre  (fPSA),  PSA intacto  (iPSA)  y  la calicreína-2  (hK2)35.  En  su
mayoría  el  PSA  en plasma  se encuentra  unido  a inhibidores
de  proteasas  y  una  pequeña  cantidad  se encuentra  libre-
mente  (fPSA),  este  PSA  libre  asume  3 formas  moleculares:
iPSA,  pro-PSA  y BPSA.  Un  menor  valor  de fPSA  en proporción
con  tPSA  se relaciona  más  con  CP,  mientras  que  un  mayor
valor  se asocia  con enfermedad  benigna.  La calicreína-2
se  ha encontrado  aumentada  en  pacientes  con  CP de  alto
grado.  Adicionalmente,  en el  4K test  se toman  datos  como
la  edad  de  la  persona,  hallazgos  al tacto  rectal  (nódulos)  y
antecedente  de  biopsia previa35.
En  diferentes  estudios: Gothenburg  ERSPC36,  ProtecT37,
Rotterdam  ERSPC38,  Braun  et al.39 y Parekh  et  al.40,  entre
otros,  se  ha concluido  que  el  uso del 4K  test  reduce  prác-
ticamente  a la  mitad  la práctica  de biopsias  en aquellos
pacientes  con  PSA  en zona gris  (4-10  ng/ml),  ya  que  permite
identificar  a  aquellos  individuos  susceptibles  a desarrollar
cáncer  clínicamente  relevante  de aquellos  con  enfermedad
no  maligna.
En  conclusión,  el  panel  4K  permite  individualizar  la  pre-
dicción  de CP aun  si  previamente  no  se le  ha realizado
al  paciente  la  prueba  de  tamización  o  una  biopsia.  Este
panel  disminuye  alrededor  de 41-71%  de biopsias  practica-
das  innecesariamente35. Sin  embargo,  existen  limitaciones
en  cuanto  a la disponibilidad  del panel en el  escenario  clínico
cotidiano.  Actualmente  solo  se encuentra  disponible  en los
Estados  Unidos  y  el  costo  para  los  pacientes  oscila  alrededor
de  1.185  dólares  americanos35.
Mucinas
Las  mucinas  son proteínas  glucosiladas  de elevado  peso
molecular,  presentes  en  la mayoría  de tejidos  epiteliales,
incluidos  el  tracto urinario  y  el  aparato reproductor41.
En  la actualidad  se conocen  un total  de 21 genes
codificantes  de mucinas,  estos  han  sido divididos  en  2  gru-
pos: MUC1,  MUC3  y  MUC4  codificantes  para  mucinas  de
membrana,  siendo  estas  necesarias  en  la  interacción  célula-
célula,  mientras  que  los  genes  MUC2,  MUC5AC,  MUC5B  y
MUC6  codifican  para  mucinas  secretoras  de moco42.
La  función  de las  mucinas en  general  es la  de  proteger
e  hidratar  el  epitelio.  Sin  embargo,  en  procesos  neoplásicos
se  ha visto afectada  su función43.
MUC1  ha  sido la más  estudiada  en el  desarrollo  de  dife-
rentes  cánceres,  entre  ellos  CP, donde  se ha visto  implicada
en  la  angiogénesis,  proliferación  y  transducción  de señales
tumorales,  así  como  también  en  la  invasión  y  metástasis  del
tumor43,  ya  que  aminora  la  respuesta  inmune  y promueve  la
propagación  tumoral  a  otros  tejidos,  al  perderse  las  inter-
acciones  célula-célula  y  célula-matriz  extracelular41.
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Figura  1  Señalización  mediada  por  B2M.  ADN:  ácido  desoxirribonucléico;  AMPc:  adenosín  monofosfato  c;  ATP:  adenosín  trifosfato;
B2M: beta  2  microglobulina;  C-A:  ciclina  A; C-D1:  ciclina  D1;  GTP:  guanosín  trifosfato;  MHC  I:  complejo  mayor  de histocompatibilidad
















































Figura  2  La  beta  2 microglobulina  (B2M)  regula  directamente  los niveles  de  hierro  (Fe)  celular  al  formar  complejos  con  la
proteína hemocromatosis  (HFE),  que  bloquean  el  receptor  de  transferrina  1 (RT1)  y  previenen  la  entrada  de hierro  a  la  célula,  y
como consecuencia  una  disminución  de  su concentración  intracelular.  Este  fenómeno  promueve  la  expresión  del  factor  inductor
de hipoxia  1 (HIF-1),  que actuará  sobre  el  núcleo  celular  para  generar  la  síntesis  del  factor  de  crecimiento  vascular  endotelial
A (VEGF-A),  que  inducirá  el proceso  de  angiogénesis  en  las  células  vasculares  endoteliales,  y  como  consecuencia  un  crecimiento,
invasión y  metástasis  tumoral.
ADN:  ácido  desoxirribonucléico;  T:  transferrina.
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En  tejido  prostático  maligno,  mediante  microarreglos
tisulares,  se  ha reportado  una  sobreproducción  de  MUC1,
junto  con  una  distribución  aberrante  y  alteraciones  en  la glu-
cosilación  de esta  mucina41,43.  Adicionalmente,  en  estudios
realizados  por  Cozzi  et al.,  se demostró  la  sobreexpresión
de  MUC1  en  el  58%  de  las  muestras  de  tejido  prostático
neoplásico  y en el  90%  de  los  nodos  linfáticos  metastásicos,
mientras  que  en  tejido  libre  de  cáncer  no  se evidenció  lo
anteriormente  mencionado42.
Otros  biomarcadores
Recientemente  ha  habido  un  interés  sobre  proteínas  invo-
lucradas  con  la autofagia  mitocondrial,  pues  estas  pueden
estar  asociadas  a carcinogénesis44.  Dichas  proteínas  pueden
ser  vistas  como  nuevos  biomarcadores  diagnósticos  y  pro-
nósticos  en  el  cáncer  de  próstata.  Sin  embargo,  no  son  los
únicos  biomarcadores  nuevos  sobre  los  cuales  se ha centrado
la  atención,  pues  se  ha  visto  que  al  realizar  un  perfilamiento
genético  del  cáncer,  y también  al observar  la  presencia  de
células  madre  en  el  tejido  neoplásico,  se pueden  obtener
nuevos  marcadores  de  la  enfermedad.  A continuación  se
mencionan  4  de  ellos:
Leucine-rich  pentatricopeptide  repeat  motif-containing
protein
La  proteína  leucine-rich  pentatricopeptide  repeat  motif-
containing  (LRPPRC)  estabiliza  el  oncogén  BCL-2  y  bloquea
la  autofagia,  alterando  así los  mecanismos  reguladores  de
muerte  celular44.  En  la comparación  de  la  inmunohistoquí-
mica  de  la  expresión  de  LRPPRC  que  realizan  Mancini  et al.
entre  tejido  neoplásico  y  HBP se encuentra  que  esta proteína
efectivamente  se expresó  más  en el  tejido  con cáncer44.
Este  hallazgo  confirma  que  la  LRPPRC  puede  ser vista como
un  nuevo  biomarcador  diagnóstico  y la  mitocondria  como  un
objetivo  terapéutico44.
Perfilamiento  genético  del  cáncer  de  próstata:  ADN
circulante  del  tumor
El  análisis  de  fragmentos  de  ADN  circulante  del tumor  supone
la  posibilidad  de  poder  encontrar  dichos pedazos  de ADN
libres  en  fluidos  corporales  y  en el  plasma  de  los  pacien-
tes  con  tumores  sólidos44. La  ventaja  de  estas  secuencias  es
que  contienen  la información  genética  completa  del tumo,;
lo  que  permitiría  analizarlo  para  determinar  el  pronóstico
y  la respuesta  al  tratamiento44. Además  de  los  beneficios
mencionados  anteriormente,  el  ctDNA  permite  realizar  aná-
lisis  no  invasivo,  pues no  sería  necesario  obtener  una  biopsia
como  tal44. Finalmente,  el  ctDNA  permite  identificar  muta-
ciones  de  novo, lo que  en  último  término  impacta  el  curso
del  tratamiento.
Células  madre
Estudios  recientes  han  demostrado  la  presencia  de  células
madre  en  la  próstata  y  su posible  rol  en  la progresión  de
la  enfermedad  y la  respuesta  al  tratamiento44.  Lo  que  se
ha  observado  es que  a  partir  de  estas  células  de  originan
algunas  neoplasias,  y  su presencia  podría  constituir  un factor
predictor  pronóstico44. Algunos  biomarcadores  asociados  a
células  madre  podrían  en  un  futuro  ser  usados  como  ayuda
en  el  enfoque  a la terapia  personalizada  del CP44.
Alfa  metilacil  coenzima  A  racemasa
La  alfa  metilacil  CoA  racemasa,  o  también  llamada  P504S,
es  una enzima  peroxisomal  y mitocondrial  necesaria  para  la
producción  de ácidos  biliares  y la beta-oxidación  de  los  áci-
dos  grasos  de  cadena  ramificada45. En  cáncer  de  próstata
es  usada  como  marcador  molecular,  puesto  que  mediante
microarreglos  de ADN  se ha detectado  una  expresión  ele-
vada  de  alfa  metilacil  CoA racemasa  en  el  tejido  prostático
afectado,  comparado  con tejido  prostático  benigno46,47.
Como  se puede  notar,  existen  diferentes  biomarcadores
que  en  la actualidad  se encuentran  en  investigación  para
determinar  su rendimiento  diagnóstico  en  pacientes  con  CP.
Cabe  anotar  que  los  descritos  no  son todos  los  biomarcadores
en desarrollo  en la  actualidad,  y aún  es  muy  temprano  para
tomar  estas  herramientas,  pues faltan  estudios  con  mayor
tamaño  de muestra,  validez  y  confiabilidad,  que  nos permi-
tan  trabajar  con certeza  sobre nuestra  población  masculina,
sin  embargo  es  claro  que  el  presente  y  futuro  debe estar
enfocado  en la investigación  de éste  tipo  de  biomarcadores
en  cáncer  de próstata,  así como  en otros  tipos  de tumores.
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OBJECTIVE: To describe the frequency of the TMPRSS2 gene and its variants in a prostate 
cancer-free Southwestern Colombian population.
MATERIALS AND METHODS: An observational study was conducted that included cancer-
free persons, regardless of age, from Southwestern Colombia. Blood samples were drawn 
from the patients for DNA extraction. Blood drops were collected and dried on filters 
and immersed in phosphate buffer, utilizing the DNeasy kit. The preparation process 
was carried out using the TruSeq Exome Library Prep® kit and the resulting libraries were 
normalized with the TruSeq Rapid Exome® kit. The commercial kits were provided by 
Illumina®. We sequenced the full exome and identified the variants associated with the 
TMPRSS2 gene. Descriptive statistics were employed for the data analysis.  
RESULTS: The study population was made up of 162 persons from whom 7,315,466 
sequence data were obtained. The TMPRSS2 gene was found in 414 data (4.3%). The 
most common SNP was rs140530035 (32.1%) and the most relevant SNP sequenced 
was rs12329760 (10.6%).
CONCLUSION: TMPRSS2 was not frequent in the population studied. The most important 
polymorphism associated with the TMPRSS2 gene was rs12329760. 
KEYWORDS: Gene; Prostate cancer; TMPRSS2; Polymorphism.
Resumen
OBJETIVO: Estimar la prevalencia del gen TMPRSS2, y sus variantes, en pacientes libres 
de cáncer de próstata de una población del suroeste de Colombia. 
MATERIALES Y MÉTODOS: Estudio observacional, al que se incluyeron pacientes libres 
de cáncer de próstata, sin importar su edad, residentes de una población del sudoeste 
de Colombia. Se recolectaron muestras de sangre para extraer el ADN mediante filtros, 
inmersos en una solución tampón de fosfato, para evaluarse en el equipo comercial 
DNeasy. Para la lectura de resultados se utilizó el manual TruSeq Exome Library Prep® 
y se normalizaron con TruSeq Rapid Exome®, proporcionados por Illumina®. Se obtuvo 
la secuenciación del exoma completo y se identificaron las variantes asociadas con 
el gen TMPRSS2. Para el análisis de los datos se implementó estadística descriptiva. 
RESULTADOS: Se registraron 162 pacientes, de quienes se obtuvieron 7,315,466 datos 
de secuenciación. El gen TMPRSS2 se encontró en 414 datos (4.3%). El SNP más co-
mún fue rs140530035 (32.1%) y el secuenciador más relevante rs12329760 (10.6%). 
CONCLUSIÓN: la identificación del gen TMPRSS2 no es frecuente en pacientes libre de 
cáncer de próstata del suroeste de Colombia. El polimorfismo rs12329760 tuvo mayor 
relación con el gen TMPRSS2. 
PALABRAS CLAVE: Gen TMPRSS2; cáncer de próstata; polimorfismo.
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INTRODUCTION
One of the most prevalent neoplastic patholo-
gies associated with male sex is prostate cancer. 
The estimated prevalence is 1.1 million people 
worldwide (1–3) and it is  impacted by ethnicity 
and geographic location (4). Populations of Afri-
can descent are the most affected, showing an 
11% increase in prevalence  in recent years(5). 
The Southwest region of Colombia is inhabited 
by populations of Latin American and African 
descent in approximately the same proportion 
but with different rates of disease incidence(6).
Variants of certain genes have been associated 
with a higher frequency of prostate cancer 
(BRCA1-2, ATM, NBN, TMPRSS2, among others) 
(7). Serine proteases, such as the TMPRSS2 gene, 
are recognized through their mechanisms of 
action in inflammatory and immune processes. 
That gene is located on chromosome 21q22.3 
and is expressed at the apex of the secretory 
epithelium of the glands. Fusion with members of 
the ETS family is the most frequent chromosomal 
re-arrangement found in 50% of prostate can-
cers, mainly produced by the microdeletion of a 
portion of the TMPRSS2 gene (8). The TMPRSS2 
gene and the fusion gene (TMPRSS2:ERG) have 
been associated with the severity and prognosis 
of prostate cancer, although the actual patho-
physiologic process or the variant associated 
with that condition are not very well known (9). 
The fusion gene has been widely studied and at 
present has been postulated as one of the most 
important biomarkers for diagnostic and prog-
nostic purposes in the prostate cancer population 
(10). There are reports in the literature on the 
single nucleotide polymorphisms (SNPs) most 
frequently related to those clinical scenarios.
The present study is important because there are 
no similar descriptive studies characterizing the 
presence of the TMPRSS2 gene and its variants 
in a population from Southwestern Colombia. 
Our study focuses on describing the frequency 
of the allelic variants of the TMPRSS2 gene in 
that population.
MATERIALS AND METHODS
A descriptive, observational study was conducted 
on persons, regardless of age, from Southwestern 
Colombia (Nariño, Cauca, Putumayo, and Valle), 
within the time frame of 2014 to 2016.  
Sample size
According to the expected frequency for here-
ditary prostate cancer (≈ 15%), alpha 5%, and 
an expected error of 5%, the calculated sample 
size was 162 people and convenience sampling 
was carried out.
Complete exome sequencing was performed, 
which enabled the sequencing of all protein-
coding regions (exome) in the genome, thus 
identifying the variants that could alter the se-
quence of a protein. It was carried out as follows:
DNA extraction
Blood was drawn from each patient for DNA 
extraction.  All drops of blood were collected 
and dried on filter paper. The filter paper was 
then immersed in a phosphate buffer utilizing 
the DNeasy kit from the QIAGEN® company 
(Hilden, Germany-Operational). Each extraction 
was quantified, and its quality was verified, to 
continue the sequencing processing. 
Sequencing protocol
DNA aliquots from each sample underwent 
a preparation process with the TruSeq Exome 
Library Prep®. The resulting libraries were then 
normalized for sequencing using the TruSeq Ra-
pid Exome®. The kits were provided by Illumina® 
from San Diego, California, USA. The normalized 




fragments with their corresponding adaptors 
for sequencing were charged in a HiSeq2500 
machine.
We sequenced the full exome and identified the 
related variants, specifically the SNPs for the 
TMPRSS2 gene that is associated with prostate 
cancer (PCa). 
The present project was conducted following 
all ethical international standards. Descriptive 
statistics were performed in R and the results are 
shown in frequency tables for each gene and its 
associated variants. Finally, we looked for the 
variants in the following public databases: Exome 
Aggregation Consortium (ExAC), PharmGKB(11), 
Clinvar(12), Ensemble, and dbSNP(13), searching 
for a pattern through which we could use the 
variants we found as markers.
RESULTS
One hundred sixty-two patients were included 
in the study, providing 7,315,466 sequence data, 
and the TMPRSS2 gene was found in 414 data 
(4.3%). Missense variants were identified in 23% 
of the data, although the most frequent variants 
were synonymous variants and introns. Only one 
stop variant was found in those data (Table 1).  
In addition, the most common variants for the 
TMPRSS2 gene were: rs140530035 (32.12%), 
rs17854725 (19.8%), and rs2298659 (13.5%) 
(Table 2).
DISCUSSION
Transmembrane protease serine 2, also called 
TMPRSS2, is a protease composed of 492 amino 
acids expressed on the cell surface of multiple 
organs and they are theorized to be strategically 
located to regulate cell-cell interactions. The 
TMPRSS2 gene has been shown to be positively 
regulated by androgenic hormones in neoplastic 
tissue, possibly modulating the inflammatory 
response of prostate cells through the activation 
of PAR-2 (14,15).
Prostate cancer is one of the most frequent 
cancers in males and the TMPRSS2 gene has 
historically been associated with that malig-
nant tumor. Numerous authors have conducted 
studies over the past decades in an attempt to 
link the presence of the TMPRSS2 gene with 
the frequency of cancer and its prognosis (16). 
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Although there are studies that have found that 
the TMPRSS2 gene does not represent a worse 
prognosis for prostate cancer (17), an important 
fusion of that gene with the ERG gene was descri-
bed, with an increasing relation to the diagnosis 
and aggressiveness of prostate cancer (present in 
50% of high-risk prostate cancers) (18,19).
We found a low frequency of the allelic variant 
associated with the TMPRSS2:ERG fusion gene 
in our cancer-free population from Southwestern 
Colombia. The rs12329760 variant, albeit not the 
most frequent SNP found in the present study, is 
reported in the literature to have a non-negligible 
allele frequency (AF) in populations from East 
Asia and Northern Europe (0.38 and 0.37, res-
pectively), with a major homozygote ratio (> 
7%). Frequency in the Hispanic population is 
0.155, with a low number of homozygotes (20). It 
should be noted that Southwestern Colombia has 
a large population of African descent, in which 
a higher frequency of said allelic variant (0.29) 
has been identified. That is an important fact to 
keep in mind when identifying new biomarkers 
for prostate cancer.
The most sequenced polymorphism in the 
present study was rs140530035. It is a very 
common intron in the world population and the 
allele frequency of that variant reaches 0.9 (21). 
Comparing populations, inhabitants of northern 
Europe (Finland) have an AF of 0.99, whereas it 
is only 0.66 in the so-called Latino population, 
according to Lek et al. 2016 (21).
The rs17854725 and rs2298659 polymorphisms 
are synonymous variants that are rare in the Latin 
American population, according to the literatu-
re, with an AF of 0.15 or less, and they have no 
known pathologic associations. Likewise, the 
rs75603675 polymorphism is not known to be 
associated with any pathology (21).
Strengths and limitations
The present study is the first to describe the 
relation of the TMPRSS2 gene and its allelic va-
riants to a Southwestern Colombian cancer-free 
population. An advantage of the project was the 
quality of the study’s samples, analyses, and data. 
Several variants associated with the TMPRSS2 
gene were identified. That is very important infor-
mation for the performance of future longitudinal 
studies in cancer-free patients to determine the 
risk for that disease.
A limitation of the present study was the fact 
that we did not find any information associated 
with the presence of a pathologic relationship 
to prostate cancer.
CONCLUSIONS
The TMPRSS2 gene was not frequent in the 
cancer-free Southwestern Colombian population 
studied. Nonetheless, the most common variants 
for the TMPRSS2 gene were: rs140530035 
(32.12%), rs17854725 (19.8%), and rs2298659 
(13.5%).
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Introduction The amount of information and knowledge about pathways and genetic alterations regard-
ing prostate cancer, including the tools available for its study has been recently increasing. Additionally,  
a variety of molecular signaling pathways control cell proliferation, however, this incompletely understood 
process is disturbed in cancer cells.
Materials and methods A literature review was made using the MEDLINE, Embase and LILACS databases 
searching for the following keywords: prostate neoplasms, prostate cancer, molecular medicine, genomics, 
pathways, and cell cycle.
Results Different biological mechanisms have been associated with the development of prostate 
cancer, such as alterations in tumor suppressor genes, oncogenes (TP53, RB1, among others) and  
CDKIs; DNA methylation; chromosomal alterations and rearrangements; changes in PTEN and  
PI3K / mTOR; global defects in apoptosis; alterations in the androgen receptor (AR); and epigenetic 
mechanisms.
Conclusions Good clinical practice and a practical approach have to be based on basic knowledge, 
thus, in this article, the main genetic alterations, mutations and pathways involved in prostate cancer 
development were reviewed.
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INTRODUCTION
Recently, the quantity and quality of tools avail-
able for the genetic study of cancer and the whole 
genome have increased, with even greater detail 
available for the exome alone. Many molecular sig-
naling pathways provide negative or positive regu-
latory signals that control cell proliferation in a way 
that attempts to preserve cell number and homeo-
stasis, but this process is completely altered in can-
cer cells [1, 2].
Normal cells must acquire at least eight attributes 
to transition from a normal cell to a cancer cell. 
These attributes include the following: 1) genetic 
instability and mutation; 2) autonomous growth; 
3) insensitivity to internal and external anti-prolif-
erative signals; 4) resistance to apoptosis and other 
Citation: Garcia Perdomo HA, Zapata-Copete JA, Sanchez A. Molecular alterations associated with prostate cancer. Cent European J Urol. 2018; 71: 168-176.
forms of induced cell death; 5) unlimited cell divi-
sion potential; 6) ability to form new blood vessels 
(angiogenesis); 7) local invasive behavior that en-
ables the distinction of benign and malignant neo-
plasms; 8) evasion of the immune system.
Additionally, cancer cells require energy for auton-
omous growth and unlimited replication. Tumor-
associated inflammatory mediators also cause pre-
neoplastic cells to progress to invasive cancer cells; 
finally, cancer cells gain the ability to metastasize, 
that is, to migrate and colonize organs or tissues 
[1, 3, 4]. The purpose of this article was to review 
and describe the main biomolecular mechanisms 
associated with prostate cancer. Therefore, the so-
matic genetic alterations that are involved in the 
pathogenesis of prostate carcinoma progression are 
shown in Figure 1 [5, 6]. 
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MATERIAL AND METHODS
We performed a systematic literature search in Med- 
line via Ovid, Scopus (including Embase) and LI-
LACS from their inception to nowadays with the 
following keywords: prostate neoplasms, prostate 
cancer, molecular medicine, genomics, pathways, and 
cell cycle. We included reviews, systematic reviews, 
basic science studies and analytical studies, which 
tried to explain the molecular disturbances associ-
ated with prostate cancer. According to the hetero-
geneity expected, we synthesized information based 
on the molecular mechanism. Information about the 
most promising biomarkers associated with prostate 
cancer can be found elsewhere [7].
Tumor suppressor genes and oncogenes
Suppressor genes negatively regulate cell growth, 
and therefore, play an important role in the normal 
cell cycle, DNA repair and cell signaling. The loss 
of the function of both alleles of a suppressor gene 
leads to carcinogenesis; thus, different pathways can 
result in cancer, such as 1. Homozygous gene dele-
tion, 2. Loss of one allele and mutational inactivation 
of the second, 3. Mutations in both alleles, or 4. Loss 
of one allele and epigenetic inactivation of the sec-
ond allele (e.g., DNA methylation) [1]. The two best 
characterized suppressor genes thus far are the reti-
noblastoma gene (RB1) and the TP53 gene, which 
are described later.
Oncogenes are positively associated with cell prolif-
eration and are the mutated form of normal genes 
(proto-oncogenes). Two such oncogenes are MYC and 
MET. MYC is responsible for the regulation of cell pro-
liferation. This amplified gene is frequently present in 
prostate cancer (PCa), and its expression in prostatic 
cells has been associated with immortalization [8]. 
In contrast, MET has been reported in renal cell car-
cinoma (RCC), primarily in the hereditary type [9].
The mechanisms by which a proto-oncogene can 
become an activated oncogene are as follows: 
1) proto-oncogene mutation, 2) gene amplification 
and 3) chromosomal rearrangement. An example 
of the third mechanism is the translocation that 
leads to the fusion of the TMPRSS2 gene with the 
ERG oncogene in a large proportion of PCa cases 
[10]. Figure 2 schematically represents the cell cycle 
and describes how a cell in G0 is allowed to prolifer-
ate based on a signal, is duplicated in S phase, the 
phase in which DNA is synthesized, and subsequent-
ly segregates its genomic complement, which results 
in two daughter cells in a process called M phase 
(mitosis). These two processes are separated by two 
critical gaps termed Gap 1 and Gap 2. The entire cy-
cle lasts approximately 24 hours, and each phase de-
pends on the previous one. In addition, some mecha-
nisms function to verify the integrity of the DNA. 
If any alterations are found, the cell attempts to re-
pair the damage, but if repair is not possible, the cell 
enters an active process termed apoptosis, which will 
be described later. The loss of the ability to respond 
to DNA damage leads to genetic instability, increases 
the mutation rate and mutates genes associated with 
cancer, thereby contributing to carcinogenesis and 
progression of the disease [11, 12].
Retinoblastoma protein (RB1)
RB1 is important for controlling the R-point, which 
is a decisive point in late G1 phase during which the 
cell is committed to undergo division. Thus, if this 
Figure 1. Natural history of prostate cancer and the molecular 
alterations involved.
Figure 2. Cell cycle scheme.
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in the etiology of cancer. This pathway is associat-
ed with the activation of transcriptional genes and 
the inhibition of other genes that block the cascade. 
On the one hand, TP-53 is dependent on the acti-
vation of the Apaf-1/caspase-9 pathway, but on the 
other hand, Bax (Bcl-2 family) is not essential for 
TP53-dependent apoptosis.
In addition, different tumor suppressive pathways 
are associated with TP53, and some examples are the 
response to DNA damage, cell senescence and apop-
tosis, and thus, it is logical to consider that TP53 
is frequently mutated in cancer [1, 21].
Methylation of DNA
The covalent modification of the C5 position 
of the cytosine by a methyl group is mediated 
by DNA methyltransferase and results in the for-
control is lost, the cell continues to proliferate. All 
of the above events are due to inactivation of the 
RB1 pathway, which is mutated in at least 30% 
of bladder and prostate tumors, although RB1 muta-
tions have not been strongly associated with these 
cancer types. It has also rarely been associated with 
renal carcinoma [13, 14].
Cyclin-dependent kinase inhibitors
The temporal sequence of events during the cell 
cycle is dependent on cyclins and cyclin-dependent 
kinases (CDKs). CDKs phosphorylate protein sub-
strates that are involved in the execution of spe-
cific activities in each phase. In contrast, cyclin-
dependent kinase inhibitors (CDKIs) bind directly 
to CDKs and suspend their activity and their ability 
to phosphorylate other proteins [15]. CDKIs belong 
to one of two classes: the Cip / Kip Family, which 
includes the CDKN1A (p21), CDKN1B (p27) and 
CDKN1C (p57) proteins, and the INK4 (inhibits 
CDK4) family, which includes the INK4B (p15), 
INK4A (p16), INK4C (p18) and INK4D (p19) pro-
teins. The p16 protein binds to CDKs 4 and 6 and 
inhibits their interaction with cyclin D1; nor-
mally, active CDK4 and 6 mediate the passage 
of the cell through G1 phase via the phosphorylation 
of RB1 [1, 16]. The latter has also been associated 
with bladder cancer (by deletion of INK4A) and with 
renal cancer, and p16 inactivation has been shown to 
occur by hypermethylation of the DNA (epigenetic 
mechanism) [17]. In prostate cancer, hypermethyl-
ation of INK4A is typically seen in 60% of cases, al-
though INK4B is rarely inactivated [18].
Decreased CDKN1B has been correlated with de-
creased overall survival and disease-free survival 
after radical prostatectomy. In addition to positive 
CDKN1B in prostate biopsies, it has been associ-
ated with increased biochemical recurrence, and 
in mice, absence is associated with prostatic hyper-
plasia [19, 20].
Tumor suppressor TP53
TP53 is a suppressor gene that plays an important 
role in response to cellular damage. It signals a halt 
to the cycle or leads to damage repair pathways 
(Figure 3), but if repair is not possible, the cell will 
undergo apoptosis. This suppressor is often mutat-
ed in genitourinary cancers. Additionally, Figure 4 
shows the possible causes of alterations in TP53 and 
its responses in the cell cycle.
TP53-induced apoptosis is mediated by Bcl-2 
through an intrinsic pathway, and alterations in 
the regulation of this pathway have direct relevance 
Figure 3. TP53-dependent repair mechanisms.
Figure 4. Causes of alterations in TP53 and its response in the 
cell cycle.
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ent pathways associated with cancer, leading to chang-
es in tumor suppressor genes and oncogenes through 
epigenetic, mutational and copy number distortions.
To counteract these elements, the cell employs dif-
ferent defense mechanisms including the use of free 
radicals such as alpha tocopherol, vitamin C, carot-
enoids, bilirubin and urate and protective enzymes 
such as superoxide dismutase, glutathione peroxi-
dase and glutathione transferase. In addition to the 
previously described methylation of GSTP1, associa-
tions have been found between the polymorphisms 
of this gene and the risk of biochemical recurrence 
in patients with PCa [28].
The cell additionally employs a series of mechanisms 
termed the DNA damage response (DDR), which in-
volves a number of genes. DDR relies on the repli-
cation machinery, as well as on specific mechanisms 
such as repairs of base cleavage, nucleotide cleavage, 
double helix rupture and imbalance [1].
Chromosomal abnormalities
Deletions of chromosomal segments are frequently 
found, although gains and amplifications are seen 
more frequently in cases of advanced disease [12]. 
These changes have been demonstrated through 
cytogenetic techniques such as genomic hybridiza-
tion, fluorescence in situ hybridization or detection 
of microsatellites. Cytogenetic methods detect nu-
merical changes, while molecular analytic methods 
identify recombinations that do not lead to changes 
in copy number [12].
The most frequently altered autosomes are 8, 13, 7, 
10, 16, 6 and 17, likely in this order. In addition, gains 
or amplification of parts of the X chromosome and 
losses of the Y are also observed. A decreased copy 
number and loss of heterozygosity of chromosome 
8p are also consistent in previous studies (observed 
in approximately 50% of cases). Specific alterations 
are observed in each of the chromosomes, but special 
attention must be paid to the functional impact each 
alteration may have on the tumor phenotype and 
the indication or expression of the tumor suppressor 
genes or oncogenes in the affected regions [12].
Recurrent genetic rearrangements in PCa
Recurrent gene fusions have been identified, primar-
ily between the androgen-regulated gene TMPRSS2 
and ERG, which is a member of the ETS (E26 trans-
forming sequence) family. This fusion occurs in 90% 
of all fusions that involve ETS genes in prostate can-
cer [29]. The other fusions occur as a result of more 
complex types of translocations [10, 30]. In 60% 
of cases, the fusion occurs due to a deletion of the 
mation of 5-methylcytosine, which is an epigen-
etic modification that occurs in vertebrates and 
is part of normal and essential embryological de-
velopment. As vertebrates have evolved, CpG di-
nucleotides have become depleted within the ge-
nome, but in some areas, this depletion is not seen; 
these areas are termed CpG islands and represent 
approximately 1% of the genome. The epigenetic 
properties of methylation can affect the genetic 
activity without alterations in the DNA sequence 
and represent an alternative means to inactivate 
the gene apart from a mutation or deletion. The 
three major pathways that DNA methylation uses 
to result in genetic alterations include the follow-
ing: 1) inherent mutational effects of 5-methylcyto-
sine, 2) epigenetic effects of the promoter on tran-
scription and 3) activation and potential induction 
of a gene due to instability of the chromosome 
by DNA hypomethylation [1].
DNA methylation and prostate cancer
Glutathione S transferases are a family of en-
zymes that are responsible for the detoxifica-
tion of a large group of xenobiotics that catalyze 
the nucleophilic attack of reduced glutathione 
in potentially harmful electrophilic compounds. 
The aberrant methylation of the CpG island 
at the glutathione S transferase pi (GSTP1) locus 
is the most frequent somatic alteration reported 
in PCa [22]. This methylation has been detected 
in up to 90% of PCa and in 70% of prostatic in-
traepithelial neoplasia (PIN), however it might 
be present in normal or hyperplastic tissue [22]. 
Due to oxidative stress, this aberrant methylation 
leads to the overexpression of GSTP1 in prostatic 
epithelial columnar cells. These findings are also 
associated with worse clinical outcomes [23].
The gene for the ras association domain of the fa-
milial protein 1 isoform A (RASSF1A) is located 
on chromosome 3p21. This is a suppressor gene 
that is methylated in 60–70% of prostate carcino-
mas, and it has been observed that this alteration 
is more frequent in high-grade tumors than in 
less aggressive tumors [24, 25]. The methylation 
patterns are not consistent since they can consist 
of either hypo- or hypermethylation, and in addi-
tion, the methylation is conserved in all metasta-
ses, suggesting an alteration that follows clonal 
selection [26, 27].
DNA damage and repair
Cancer is fundamentally a genetic disease. Alterations 
in different genes will lead to the activation of differ-
Central European Journal of Urology
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sequence that separates the two genes (3 Mb).
These rearrangements can be readily identified 
through reverse transcription polymerase chain re-
action (RT-PCR) or by multicolor fluorescence in situ 
hybridization (FISH).
At present, several clinical studies have evaluated 
these markers in urine and blood, while other studies 
have evaluated the expression of the ERG protein us-
ing a simpler method (immunostaining) [31, 32, 33]. 
The TMPRSS2-ERG fusion status is considered 
a possible diagnostic marker, although its prognostic 
significance is still unclear, which is a fundamental 
part of patient follow-up [34, 35].
The TMPRSS2 gene can be merged with other mem-
bers of the ETS family including ETV1, ETV4 and 
ETV5 [36, 37].
Studies have been performed with different tech-
nologies including next generation RNA sequencing; 
in these studies, it was found that some fusions are 
single events or events that occur in only one pa-
tient, which might imply that we actually know very 
little about PCa [38].
PTEN and PI3K/mTOR
The PI3K/mTOR (mammalian target of rapamy-
cin) pathway plays an important role in cell growth, 
proliferation and oncogenesis in PCa [39, 40, 41]. 
PTEN is a negative regulator of this pathway. In ret-
rospective studies, it has been shown how the loss 
of PTEN and consequently, the activation of the 
mTOR pathway lead to a poor prognosis in PCa 
[5]. PTEN deletions have been found in up to 20% 
of patients with PCa and have been associated with 
earlier biochemical relapse, metastasis, resistance 
to castration, presence of ERG gene fusions and the 
accumulation of nuclear TP53 [5].
Association with telomeres
A potential association between telomere length and 
prostate cancer has been found. Initially, this asso-
ciation was found only in studies with small sample 
sizes, but subsequently, some studies with larger 
sample sizes were performed in which associations 
were observed between a short telomere length 
and decreased overall survival and increased bio-
chemical recurrence. These findings have been con-
sistent even when adjusted for age, Gleason score 
and lymph node involvement. It has been proposed 
that cancer that develops from these areas can lead 
to greater genotype and phenotype heterogene-
ity, as well as to an increase in aggressiveness [42]. 
Some studies have even suggested that the risk 
of death is increased up to 14 times in patients with 
short telomeres compared with patients with long 
telomeres [43].
Apoptosis
Apoptosis is an orderly, energy-requiring process 
in which the cellular content is degraded and con-
densed into an apoptotic body that is finally digested 
by neighboring cells or macrophages [44]. The posi-
tive or negative signals of the apoptotic process final-
ly converge in a family of proteases termed cysteine 
proteases with aspartic acid specificity. Caspases total 
at least 13, and some of them are initiators (caspase 
– 8, caspase – 9, caspase – 10), whereas others are ex-
ecutioners (caspase – 3, caspase – 6 and caspase – 7). 
Caspases are derived from procaspases, which are 
larger inactive forms that require proteolytic cleav-
age in order to become active. They are frequently 
activated by other caspases (initiator) to generate 
an activating cascade of executioner caspases. The 
latter type attacks different anti-apoptotic intracel-
lular proteins such as Bcl-2 and Bcl-XL. They not 
only destroy their anti-apoptotic functions but also 
release carboxyl-terminal fragments to remove the 
cell [45]. They also degrade DNA repair and replica-
tion proteins such as DNA-PKcs and replication fac-
tor C, leading to nuclear dysregulation.
Nuclear proteins such as laminin, NuMa and SAF-
A are fragmented and undergo nuclear dissolu-
tion and nuclear condensation (milestones in the 
cell that lead to apoptosis). Proteolysis of cytoskel-
etal proteins such as keratin and actin also occurs, 
which leads to the destruction of the integrity of the 
internal structure. A final step is the breakdown 
of cell-to-cell interaction proteins such as beta-
catenin and focal adhesion kinase, which precipi-
tates the phenotypic and irreversible changes associ-
ated with apoptosis [45].
Global defects in apoptosis
In both PCa and PIN, a high level of apoptosis 
is seen, although compared with other malignancies, 
PCa has low apoptotic activity along with increased 
replication. As PCa progresses, it is unclear whether 
androgen-resistant cells have an increased or de-
creased apoptosis rate because both have been found 
in patients with castration-resistant prostate can-
cer [46]. In contrast, an advanced infiltrative tumor 
whose DNA is mutated and that is fast-growing may 
have a high rate of apoptosis despite the protective 
mechanisms that the cell has acquired.
Apoptosis can be initiated by two pathways: the 
intrinsic and the extrinsic pathways (Figure 5). 
The intrinsic pathway monitors conditions within 
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the cell and responds to various forms of stress. 
Pro-apoptotic signals can originate from damaged 
and unrepaired DNA or from the lack of signals from 
the cell surface (cell-cell or cell-matrix contacts, in-
cluding hormones or diminished growth factors).
Mitochondria and the Bcl-2 family are major com-
ponents of the intrinsic pathway. The Bcl-2 family 
contains 12 pro-apoptotic proteins including Bax, 
Bak, Bok, Bik, Bas, Bid and Bim. It also contains six 
pro-survival proteins including Bcl-2, Bcl-XL, Bcl-W 
and Mcl1 [47].
Each protein in the family responds to different 
stimuli; however, their primary function is to in-
crease the permeability of the mitochondrial mem-
brane [48]. Subsequently, cytochrome c is released 
from the intermembrane space into the cytoplasm, 
where it binds to Apaf-1 proteins and forms the 
apoptosome complex. Caspase-9 is activated, which 
then activates the entire cascade described above.
In addition, other activations occur such as ones that 
involve Bid, which is regulated by initiating caspas-
es in the cytosol. Caspase-8 allows the dimerization 
of Bid with Bax or Bcl-2. This active form of Bax in-
hibits Bcl-2, which leads to apoptosis. This process 
can be blocked by anti-apoptotic proteins and by the 
IAP proteins that inhibit specific caspases [1].
The extrinsic pathway mediates apoptosis after re-
ceiving external signals from surface receptors called 
‘death receptors’, such as tumor necrosis factor re-
ceptor 1 (TNFR1) and Fas receptor. The death recep-
tor domain is located in its intracellular region and 
allows binding to adapter proteins that also contain 
a death domain (RIP, TRADD, FADD). Additionally, 
these proteins have an effector domain that binds 
to the caspase recruitment domain (CARD) of the 
initiating caspase [49]. Subsequently, the initiator 
caspase is cleaved and is able to activate the cascade.
The most well-known death receptor is CD95 or Fas, 
but this receptor does not appear to have a direct 
effect on the etiology of cancer. In contrast, IGF-1 
can activate the PI3K / AKT anti-apoptotic pathway 
and stimulate the expression of Bcl-like proteins 
along with Bax suppression. In addition, the expres-
sion of IGF binding proteins may also be altered 
in PCa [12, 50, 51].
Androgens and prostate cancer
Most treatments for PCa are based on androgenic 
suppression, but they are rarely curative. To cure 
the disease, different mechanisms should be consid-
ered and are described as follows (Figure 6): 1) some 
carcinomas do not express androgen receptor (AR) 
in some cases because the gene is silenced by a hy-
permethylated promoter; 2) several peptide growth 
factors and cytokines such as fibroblast growth fac-
tor 7 (FGF7), epidermal growth factor (EGF) and 
interleukin-6 (IL-6) can activate the AR synergis-
tically with or independently of a steroid ligand; 
3) in some carcinomas, somatic mutations in the AR 
alter its receptor specificity and cause it to respond 
to estrogen, progesterone, dehydroepiandrosterone 
or synthetic anti-androgens; 4) amplification of the 
AR gene can occur in up to 30% of cases, even in the 
presence of depletion, which leads to increased sen-
sitivity to a minimal androgen level; 5) different co-
activating proteins have been identified as mediators 
of the effects of AR on chromatin structure, as well as 
transcriptional initiators and their interactions with 
other signaling pathways. All of the circumstances 
Figure 5. Intrinsic and extrinsic pathways of apoptosis.
Figure 6. Mechanisms of altered androgen signaling in prostate 
carcinoma: 1. The androgen receptor (AR) is absent in some 
carcinomas. 2. Growth factors activate the AR or a coactivator 
in a ligand-independent fashion. 3. AR mutations alter ligand 
specificity and affinity. 4. AR expression is increased by gene 
amplification. 5. Coactivators are differentially expressed  
or mutated.
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gene, GSTP1, which is found throughout all stages 
of prostate cancer progression [5].
CONCLUSIONS
The natural history of prostate cancer involves nu-
merous genetic and molecular alterations that cause 
the normal prostatic epithelial cell to become cancer-
ous and resistant to castration. Different biological 
mechanisms have been associated with the develop-
ment of prostate cancer, such as alterations in tumor 
suppressor genes, oncogenes (TP53, RB1, among oth-
ers) and CDKIs; DNA methylation; chromosomal al-
terations and rearrangements; changes in PTEN and 
PI3K / mTOR; global defects in apoptosis; alterations 
in the AR; and epigenetic mechanisms. These are not 
the only mechanisms, but they have been found to be 
associated with prostate cancer at a higher frequency 
than others. Similarly, the development of prostate 
cancer does not have a unique etiology, but rather, 
it is predominantly multifactorial and can be ex-
plained by the different mechanisms described here.
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described above could lead to androgen-independent 
tumor growth [12].
Expression profiles
With the advent of the analysis of gene expression 
patterns by cDNA or oligonucleotide microarrays, 
research related to the diagnosis, prognosis and 
new therapeutic markers has become increasingly 
important. For example, it has been found that hep-
sin is not a good marker since its down-regulation 
increases tumor heterogeneity in prostate carci-
nomas [52]. Another marker is the P504S protein, 
which is identical to Alpha-Methyl-Acyl-CoA Race-
mase (AMACR); the latter is a peroxisomal enzyme 
that is involved in the metabolism of branched-
chain amino acids, which might be useful for the 
differentiation of hyperplasia and atrophy from 
cancer [53, 54].
Epigenetics / Environmental factors
Lifestyle and dietary habits have been found to be 
triggers of the oncogenic cascade in PCa. For exam-
ple, dietary carcinogens, estrogens and oxidants act 
as a trigger for chronic inflammatory changes with-
in the prostatic tissue and thus act as a promoter 
of PCa [5, 55, 56]. It has been suggested that the in-
take of red meat (formation of heterocyclic aromatic 
amines and polycyclic aromatic hydrocarbon, which 
have carcinogenic properties) or animal fat is a risk 
factor for PCa. However, when prevention studies 
on both of these micronutrients and other elements 
of the diet were performed, the suppression of those 
elements was not found to prevent prostate cancer 
[57]. Additionally, sexually transmitted diseases 
as part of a system that triggers chronic inflamma-
tion in epithelial cells have been associated with the 
development of PCa (Figure 7) [58, 59, 60].
Given the change from persistent oxidative stress, 
a survival response is generated by glutathione S 
transferase, cyclooxygenase-2 and other mediators. 
In general, the epigenetic silencing of multiple genes 
occurs, including the silencing of a fundamental 
Figure 7. Epigenetic factors associated with prostate cancer.
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Introducción. El cáncer de próstata es una patología importante en la 
salud pública y tiene alto impacto mundial. El conocimiento y manejo 
de esta enfermedad debe ser del dominio de todo médico general y 
especialista que tenga a cargo pacientes que la padezcan. 
Objetivo. Obtener una visión actualizada de la epidemiología, los 
factores de riesgo, la clasificación, el diagnóstico y el tratamiento 
del cáncer de próstata. 
Materiales y métodos. Se realizó una búsqueda en las bases de datos 
Embase y MEDLINE desde enero del 2000 hasta marzo del 2017 
mediante la cual se hizo un recorrido a través de las condiciones de 
riesgo, tamizaje, diagnóstico, nuevos biomarcadores y tratamiento 
del cáncer de próstata.
Resultados. Factores genéticos y medioambientales son foco de 
estudio en la actualidad. La sospecha diagnóstica del cáncer de 
próstata sigue siendo con el antígeno específico prostático y el tacto 
rectal y su diagnóstico se debe hacer con la biopsia de próstata. Se han 
hecho cambios importantes en cuanto a la clasificación y tratamiento 
de los pacientes con esta enfermedad. 
Conclusión. Existe mucha investigación en curso y por venir sobre 
la prevención, el diagnóstico y el tratamiento de esta condición tan 
importante, relevante y pertinente para los hombres alrededor del mundo. 
Palabras clave: Próstata; Neoplasias de la Próstata; Biomarcadores; 
Revisión (DeCS).
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| Abstract |
Introduction: Prostate cancer is a major public health concern with a 
high impact worldwide. Knowledge and management of this disease 
should be mastered by general practitioners and specialists who treat 
patients with this pathology. 
Objective: To obtain an updated and detailed review of the 
epidemiology, risk factors, classification, diagnosis and treatment 
of prostate cancer. 
Materials and methods: A search was carried out in the Embase 
and MEDLINE databases from January 2000 to March 2017, 
comprising risk factors, screening, diagnosis, new biomarkers and 
treatment of prostate cancer.
Results: Genetic and environmental factors are currently the focus 
of studies. Prostate-specific antigen and digital rectal examination 
are still used to suspect prostate cancer, while diagnosis is 
achieved with a prostate biopsy. Important changes have been 
made regarding the classification and treatment of patients with 
this disease. 
Conclusion: Significant changes have been made in the area. Several 
ongoing and upcoming researches on prevention, diagnosis and 
treatment of this condition are available, which are relevant for men 
around the world.
Keywords: Prostate; Prostatic Neoplasms; Biomarkers; Review 
(MeSH).
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Introducción
Dada su frecuencia en las poblaciones, el cáncer de próstata (CAP) 
es una patología de importancia en la salud pública a nivel nacional 
e internacional (1). Debido a las dificultades del sistema de salud, 
la poca disponibilidad de especialistas y la alta prevalencia, el 
conocimiento de esta condición debe ser del dominio de todo médico 
general y no se debe quedar en esferas de la medicina especializada 
como la urología y la oncología. No obstante, el tratamiento, de 
manera integral, debe ser dado por centros de excelencia en cáncer (2).
El objetivo de esta investigación fue obtener una visión actualizada 
a través de una revisión detallada y al día de la epidemiología, los 
factores de riesgo, la clasificación, el diagnóstico y el tratamiento 
del CAP. 
Materiales y métodos
Se realizó una búsqueda en las bases de datos Embase y MEDLINE 
(a través de OVID) desde enero de 2000 hasta marzo de 2017. Las 
palabras clave utilizadas fueron: “prostate” OR “prostate, neoplasm” 
AND “diagnosis” OR “treatment”. Además, se realizó una exhaustiva 




El CAP es la neoplasia con mayor frecuencia en hombres alrededor 
del mundo y representa la segunda causa de muerte por cáncer en 
esta población en EE. UU. (3). Esta patología presenta una incidencia 
de 131.5 por cada 100 000 habitantes (3) con una distribución según 
raza de 123 por cada 100 000 habitantes en la raza blanca y 208 por 
cada 100 000 habitantes en la raza negra (4). Se estima que 1 de 
cada 7 hombres serán diagnosticados a lo largo de su vida con CAP 
y que 1 de cada 38 hombres morirán como consecuencia de este (5). 
El estudio GLOBCAN notificó que en países del norte de Europa 
(Dinamarca, Noruega y Suecia) se ha incrementado el diagnóstico 
de CAP 8.2% por año; sin embargo, se presenta una mortalidad en 
descenso desde el 2000 de 3.1% por año (6). En EE. UU. y Canadá 
se han encontrado datos similares, con una incidencia estable de 
4.3% y una disminución en la mortalidad de 3.1%; no obstante, en 
países en vía de desarrollo la mortalidad ha ido en aumento (6,7). 
En cuanto a la epidemiología nacional, Colombia tiene una de las 
incidencias más bajas de CAP en Latinoamérica y una proporción de 
28% entre incidencia y mortalidad, un valor muy cercano al promedio 
mundial de 28.6% e inferior al de países como Ecuador (40.41%), 
Cuba (46.65%) y Perú (37.74%) (6); del igual forma, la mortalidad 
ha disminuido en los últimos 4 años (7) y las regiones con el mayor 
número de pacientes con CAP reportados son Bogotá D.C., Valle 




Los pacientes de raza negra presentan mayor prevalencia de CAP 
(8); además, en esta población se presenta a edades más tempranas 
y con mayor volumen tumoral, mayor antígeno prostático y peor 
pronóstico (9,10). Algunos autores relacionan estos resultados con 
las inequidades sociales y dificultades de acceso a servicios de salud 
a las que se expone esta población (11); sin embargo, existe mucha 
más evidencia que sustenta la raza como factor riesgo para CAP. Por 
otro lado, se han encontrado tasas mucho menores en asiáticos, lo 
cual se ha relacionado con la dieta, los estilos de vida y los factores 
ambientales (12).
Historia familiar
Cerca del 10-15% de los hombres con CAP tienen, por lo menos, 
un familiar con antecedente de esta patología (8,13). Se estima que 
contar con un familiar de primer grado de consanguinidad con CAP 
incrementa el RR 2 a 4 veces y es 5 veces mayor si son dos los 
familiares con dicho diagnóstico. 
Inflamación
La inflamación crónica se considera un factor de riesgo dado que conlleva 
a hiperproliferación celular; esto, a su vez, genera una alteración en los 
niveles de antioxidantes, en la reparación del DNA y en la apoptosis. 
Además, se ha encontrado que el antecedente de una infección de 
transmisión sexual tiene un OR=1.5 (14) y haber tenido o tener prostatitis 
tiene un OR=1.57 (15). A pesar de ser una de las hipótesis más fuertes, 
aún no es claro el mecanismo que llevaría a la inflamación a producir 
el CAP o si es una causa suficiente para su desarrollo.
Estrés oxidativo
Algunos estudios han sugerido que las especies reactivas de oxígeno 
(ROS), como el superóxido o el peróxido, crean un ambiente de 
mutagénesis propicio para el inicio del CAP (16,17). Este elemento 
podría estar asociado con la hipótesis de la inflamación crónica.
Andrógenos
Existe evidencia de que un aumento en la concentración de los niveles 
de testosterona incrementa la incidencia de CAP, aunque no se ha 
establecido una relación dosis-respuesta ni una concentración a partir 
de la cual se incremente el riesgo; además, no se ha encontrado mayor 
riesgo de CAP en pacientes con hipogonadismo tratados con terapia 
de reemplazo de testosterona (18).
Estrógenos
Se ha evidenciado que los estrógenos pueden predisponer e incluso 
causar CAP. En este aspecto es necesario recalcar que el 17β-estradiol 
ya se ha clasificado como carcinógeno, sobre todo en cáncer de mama 
y endometrial. Se cree que el efecto de los estrógenos en el CAP es 
causado por mutaciones directas a través de la regulación por efectos 
epigenéticos o por alteración endocrina propiamente dicha (19).
Dieta
Diversos estudios han sugerido que una dieta baja en grasas y calcio 
y con aumento en el consumo de vitamina E y licopenos, así como 
el ejercicio regular, podrían comportarse como factores protectores 
para el desarrollo de CAP. Por otro lado, la ingesta elevada de grasas 
saturadas de origen animal y las carnes rojas han sido descritas como 
factores de riesgo; sin embargo, los hallazgos no son consistentes 
entre los diferentes estudios, por ejemplo, en el estudio SELECT no se 
demostró el factor protector del uso de la vitamina E ni el selenio (20). 
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Aumento de niveles del factor de crecimiento similar  
a la insulina (IGF-1)
El factor de crecimiento similar a la insulina es un factor mitogénico 
y antiapoptótico. Altos niveles implican más riesgo de CAP (21); 
sin embargo, otros estudios no lo encuentran como factor de riesgo.
Genética
Se han encontrado alteraciones en genes supresores como el p53 
y el PTEN, los cuales se relacionan con aumento de la incidencia 
y progresión y agresividad del CAP. Entre otros genes alterados 
se ha encontrado: oncogén RAS, EIF3S3, BCL2 (anti-apoptosis), 
EGFR, FGFR2c, ERBB2, BRCA 2, MET, además de algunas 
mutaciones en el cromosoma 1 (riesgo CAP familiar) y 8 (cáncer 
esporádico). Asimismo, se han evidenciado polimorfismos genéticos 
en algunas enzimas como: 5 alfa reductasa, mayor en raza negra; 
receptor de vitamina D (VDR), el cual ha sido reconocido como un 
factor protector, aunque en pacientes de raza negra se disminuye e 
incrementa el riesgo de CAP; receptor androgénico (AR), el cual 
aumenta el riesgo de CAP familiar, y telomerasa, un factor para 
cáncer esporádico. 
Muchas de las investigaciones han centrado su atención en el 
gen BRCA2 (Breast Cancer susceptibility protein type 2), el cual 
presenta un patrón de herencia autosómica dominante con una 
dominancia incompleta. Este gen codifica para una proteína del 
mismo nombre, cuya función es actuar como centro reclutando 
proteínas reguladoras para reparar las rupturas de doble cadena por 
recombinación homóloga; además, facilita la reparación de cadenas 
simples al promover la formación del complejo RAD51-ssDNA 
(cadena simple de DNA) (22).
A lo largo de la historia, el gen BRCA2 se ha relacionado con el 
cáncer de mama; sin embargo, hallazgos recientes indican que este 
puede jugar un papel importante en el CAP. No se ha logrado identificar 
con certeza el mecanismo por el cual sus mutaciones predisponen al 
desarrollo del CAP, aunque por su función se deduce que alteraciones 
y mutaciones de este predisponen a una menor reparación de los daños 
del genoma, lo cual podría resultar en alteraciones del ciclo celular 
y, por consiguiente, en una mayor proliferación celular.
Por lo general, los pacientes con mutaciones del gen BRCA2 
presentan mayor incidencia de CAP (23), estadios más avanzados 
(T3-T4), fenotipos más agresivos y menor sobrevida a pesar de recibir 
un tratamiento local con intento curativo similar (24). 
Obesidad
Algunos autores sugieren que la obesidad juega un papel en el 
desarrollo del CAP, pues se cree que la resistencia a la insulina 
producida por la obesidad lleva a una elevación de esta hormona, 
la cual, por su capacidad anabólica, podría generar desarrollo de 
cáncer o su progresión (25). Se cree que los obesos tienen menos 
probabilidad de tener el antígeno específico prostático (PSA) elevado 
y por consiguiente menos probabilidad de realización de biopsia y 
de diagnosticar CAP; esto, junto a las asociaciones con los niveles 
circulantes de hormonas metabólicas y sexuales, lleva a que se sugiera 
a la obesidad como un factor de riesgo para CAP agresivo (26).
Alcohol
La relación de la ingesta de alcohol con el CAP es controvertida. 
Rota et al. (27), en un metaanálisis con 52 899 casos de cáncer 
(50 estudios de casos y controles y 22 cohortes), no encontraron 
evidencia material entre la ingesta de alcohol y CAP, incluso no 
se hallaron diferencias estadísticas en el grupo de alta ingesta (≥4 
bebidas alcohólicas al día) (27).
Cigarrillo
Es conocida la capacidad cancerígena del tabaco, así como el 
mecanismo por el cual se genera el daño genético. En el CAP no 
se ha descrito un aumento en la incidencia, sin embargo sí se ha 
encontrado que puede generar mayores tasas de muerte que, aunque 
son modestas, podrían tener impacto a nivel de salud pública por 
tratarse de un factor de riesgo modificable (28).
Historia natural
En autopsias se ha encontrado una prevalencia a nivel histológico de 
30-40% de CAP en hombres >50 años, de 5% o menos en <30 años y 
de 60-70% en >79 años (29). Se calcula que el 1.5% de estos se hacen 
detectables por clínica cada año. El CAP es de carácter progresivo y 
su agresividad biológica está directamente relacionada con el grado 
de diferenciación celular (escala de Gleason), el TNM, el valor de 
PSA, entre otros factores.
Clasificación histopatológica
Para la clasificación de histopatología es utilizado el sistema Gleason, 
el cual expone el grado de diferenciación celular encontrado en el 
estroma prostático. Esta clasificación está compuesta por dos valores: 
el grado encontrado más frecuentemente y el siguiente, así se obtiene 
un valor final (por ejemplo: 4+5=9), el puntaje va de 2 a 10. En el caso 
en que los dos valores se encuentren en las mismas proporciones, se 
coloca el más indiferenciado primero.
La nueva clasificación de Gleason realizada por el Colegio 
Americano de Patología relaciona la puntuación con el pronóstico 
que tiene cada grupo (Tabla 1) (30).
Tabla 1. Clasificación de Gleason del Colegio Americano de Patología.
Grado Puntuación Características
1 ≤6 Sólo glándulas bien diferenciadas
2 3+4=7
Glándulas predominantemente bien diferenciadas con 
menor componente de glándulas mal diferenciadas, 
fusionadas o cribiformes
3 4+3=7
Glándulas predominantemente mal diferenciadas, 
fusionadas o cribiformes con menor componente de las 
glándulas diferenciadas
4
8 puede 4+4; 
3+5; 5+3
Solo glándulas mal diferenciadas, fusionadas o 
cribiformes; predominantemente glándulas bien 
diferenciadas y menor componente que carece de 
glándulas; predominante carencia de glándulas y menor 
componente de las glándulas bien diferenciadas
5 9 o 10
Carece de formación de glándulas (o con necrosis) con 
o sin glándulas mal diferencias, fusionada o glándulas 
cribiformes
Fuente: Elaboración con base en Epstein et al. (30).
Clasificación clínica y patológica
La clasificación clínica y patológica se realiza con base en la 
clasificación TNM 2016 (Tabla 2) (31). Esta consta de tres elementos: 
la T, relacionada con el compromiso tumoral en la glándula y fuera 
de ella; la N, asociada con el compromiso nodular local, y la M, 
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relacionada con la extensión o difusión a distancia por metástasis 
del tumor.




TX El tumor primario no puede ser evaluado
T0 No hay evidencia de tumor primario
T1 
El tumor primario no es clínicamente aparente (no visible, 
no palpable)
T1a 
Tumor incidental en 5% o menos del tejido prostático 
resecado
T1b 
Tumor incidental en más del 5% del tejido prostático 
resecado
T1c 
Tumor identificado por biopsia con aguja (por elevación del 
APE)
T2 Tumor primario confinado a la próstata
T2a Tumor compromete <50% de un lóbulo 
T2b Tumor compromete >50% de un lóbulo 
T2c Tumor compromete ambos lóbulos
T3 
El tumor se extiende más allá de la cápsula prostática 
(invasión al ápex prostático o a la capsula prostática es 
clasificado como T2).
T3a Extensión extracapsular unilateral o bilateral
T3b El tumor compromete vesículas seminales
T4 
Tumor fijo o que invade estructuras adyacentes diferentes de 
las vesículas seminales: cuello vesical, esfínter externo, recto, 
elevadores del ano o pared pélvica
El tumor detectado por biopsia en uno o ambos lóbulos prostáticos, 
que no es palpable o visible por imagenología, se clasifica como T1c.






Nx Metástasis regionales no evaluables
N0 No hay metástasis regionales




Mx Metástasis a distancia no evaluables
M0 No hay metástasis a distancia
M1 Metástasis a distancia
M1a A ganglios linfáticos no regionales
M1b A hueso
M1c A otro sitio
Cuando hay más de un sitio de metástasis se clasifica como M1c
Fuente: Elaboración con base en (31).
Estadíficación
La estadificación del CAP se muestra en la Tabla 3. Para determinar 
este estadio hay que tener en cuenta que si el PSA o el valor de 
Gleason no están disponibles, la clasificación debe tener en cuenta 
el T o el valor de PSA o el Gleason que esté disponible. 
Tabla 3. Estadificación del cáncer de próstata.
Estadio T N M PSA Gleason
I
T1a-c N0 M0 <10 ≤6
T2a N0 M0 <10 ≤6
T1-T2a N0 M0 X X
IIa
T1a-c N0 M0 <20 7
T1a-c N0 M0 ≥10 - <20 ≤6
T2a N0 M0 <20 ≤7
T2b N0 M0 <20 ≤7
T2b N0 M0 X X
IIb
T2c N0 M0 Cualquier Cualquier
T1-2 N0 M0 ≥20 Cualquier
T1-2 N0 M0 Cualquier ≥8
III T3a-b N0 M0 Cualquier Cualquier
IV
T4 N0 M0 Cualquier Cualquier
Cualquier N1 M0 Cualquier Cualquier
Cualquier Cualquier M1 Cualquier Cualquier
T: tumor; N: nódulo; M: metástasis; PSA: antígeno específico prostático. 
Fuente: Elaboración con base en (31).
Clasificación de riesgo para carcinoma localizado
La clasificación de riesgo para carcinoma localizado utilizada por 
tradición para el CAP es la de D’amico (Tabla 4) (32). Sin embargo, 
durante los últimos años se han generado diferentes cambios de 
acuerdo al pronóstico tan heterogéneo que puede presentarse con 
diferentes factores, por lo cual se han realizado modificaciones y una 
nueva clasificación sugerida por la National Comprehensive Cancer 
Network (NCCN) (Tabla 5) (33).
Tabla 4. Clasificación de D’Amico para carcinoma localizado.
Riesgo PSA Gleason TNM
Bajo <= 10 <= 6 <= T2a
Intermedio 10 a 20 7 T2b
Alto >20 >= 8 >= T2c
PSA: antígeno específico prostático; TNM: tumor, nódulo, metástasis. 
Fuente: Elaboración con base en D’Amico et al. (32).
Tabla 5. Nueva clasificación para carcinoma localizado sugerida por la 
National Comprehensive Cancer Network.
Riesgo PSA Gleason TNM Otros
Muy bajo <10 ≤6 T1c
<3 cores de la biopsia positivos, todos 
con <50% del core comprometido; 
Densidad de PSA <15 ng/mL/gr





Alto >20 8 a 10 T3a
PSA: antígeno específico prostático; TNM: tumor, nódulo, metástasis. 
Fuente: Elaboración con base en (33).
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Diagnóstico
En la actualidad, el PSA y el tacto rectal constituyen los métodos 
diagnósticos más usados en la clínica para detectar el CAP; sin 
embargo, estos tienen bajo rendimiento diagnóstico, tanto a nivel 
individual como en conjunto (5).
Antígeno específico prostático
El PSA, también llamado calicreína III, es una glicoproteína de 
34kDA, la cual es casi exclusiva de las células epiteliales prostáticas y 
circula unida a la alfa-1-antiquimiotripsina y la alfa-2-macroglobulina; 
su función es dividir la semenogelina I y II en polipéptidos de menor 
tamaño, evitando así formación del coágulo seminal (34-38). 
El PSA es encontrado en el fluido prostático en concentraciones 
de 1 000 000 ng/mL; en condiciones normales una pequeña 
cantidad —<4 ng/mL— es liberada al torrente sanguíneo, pero en 
un proceso neoplásico estos niveles se elevan (34). Por tal motivo 
se considera realizar biopsia de próstata a aquellos hombres con 
un nivel de PSA sérico >4ng/mL (34). Sin embargo, este valor 
también se ha encontrado elevado en otras patologías como cáncer 
de mama, carcinoma de células renales, cáncer de ovario, neoplasia 
suprarrenal (39) y patologías urológicas como hiperplasia prostática 
benigna (HPB), prostatitis, cistitis, instrumentación y cirugía del 
tracto urinario reciente (34,40). Cabe aclarar que el tacto rectal no 
incrementa los valores de PSA.
Según la American Cancer Society, la sensibilidad del PSA para 
valores de referencia de 4 ng/mL y 3 ng/mL para el diagnóstico de 
cáncer es de 21% y 32%, respectivamente. La especificidad es de 
91% para valores de corte de 4 ng/mL y de 85% para valores de 
3 ng/mL (41). 
En el estudio PLCO, en lo concerniente a CAP, se evaluaron 
hombres entre los 55 y los 74 años, a quienes se les realizó tamizaje 
anual con PSA durante 13 años. Como resultado se obtuvo que realizar 
tamizaje con PSA no lleva a disminución de la incidencia de CAP 
(RR: 1.09, IC95%: 0.87-1.36) (42). 
Otro gran estudio fue el ERSPC, donde se realizó tamizaje con PSA 
durante 11 años a hombres de ciertos países europeos, evaluando la 
mortalidad por CAP. Los resultados indicaron una reducción relativa 
del 21% en las tasas de mortalidad (RR: 0.79, IC95%: 0.68-0.91) (43). 
Un metaanálisis de Cochrane realizado en el 2011 resumió los 
resultados de cinco experimentos poblacionales con un total de 
341 351 participantes y mostró que realizar tamizaje con PSA es 
efectivo para la detección de CAP (RR: 1.35, IC95%: 1.06-1.72); sin 
embargo, esta prueba no disminuyó la mortalidad (RR: 0.95, IC95%: 
0.85-1.07) (44), de manera tal que en la actualidad no se recomienda 
realizar tamizaje poblacional de CAP. 
No existe evidencia suficiente para determinar la mejor medida 
de tamización en salud pública, por ahora se sugiere tamizaje de 
oportunidad en hombres entre 50-70 años (de acuerdo a la expectativa 
de vida de la población) que ingresen a la consulta del urólogo y 
pacientes con factores de riesgo (raza negra y familiares con CAP).
Es de vital importancia hacer claridad en que al decidir el inicio 
de la búsqueda del diagnóstico del CAP debe realizarse el tacto rectal 
en conjunto con PSA.
Otros biomarcadores en el diagnóstico del cáncer de próstata
La falencia del PSA ha llevado a la necesidad de identificar nuevos 
biomarcadores con mayor sensibilidad y especificidad que permitan 
alcanzar un diagnóstico temprano del CAP (5). El PSA, al encontrarse 
elevado tanto en condiciones benignas (hiperplasia prostática benigna) 
como malignas (45), ha generado que se soliciten biopsias costosas e 
innecesarias a pacientes que no lo requerían desde un comienzo (45). 
Como consecuencia, se han explorado otras técnicas y moléculas 
para hacer un diagnóstico más específico, tales como el PCA3, la 
microglobulina, las mucinas, entre otras (5). Algunos de estas técnicas 
fueron incluidas en una revisión detallada publicada con anterioridad 
por Esquivel-Parra et al. (5), pero se sugiere revisar para profundizar 
en el tema.
Otras herramientas que intentan disminuir el número de biopsias 
innecesarias, pero que aún no han tenido éxito y se utilizan para 
pacientes con valores de PSA entre 4 y 10 ng/mL, son:
Relación PSA libre/PSA total: con relación a éste ítem, la relación 
eleva la especificidad para el diagnóstico del CAP en aquellos casos 
con los niveles mencionados ante presencia de duda en cuanto a la 
indicación para la toma de biopsia.
El PSA puede transitar en el suero libremente (fPSA) o acompañado 
de inhibidores de proteasa (cPSA) con el fin de evitar proteólisis. Al 
sumar el fPSA y cPSA se obtiene el PSA sérico total (tPSA), gran 
parte de este (70-90%) puede estar ligado a alfa-1-antiquimiotripsina 
y en menor proporción a la alfa-2-macroglobulina, alfa-1 antitripsina 
o a un inhibidor de la proteína C (38). En consecuencia, cerca del 
10-30% del tPSA circula libremente (fPSA) (5).
Con índices <0.07, la probabilidad de CAP es casi del 90%. Aún 
no se encuentra definido un valor límite, sin embargo se recomienda 
el uso de 0.20 para decidir entre biopsia o seguimiento; los valores por 
encima de este sugieren un diagnóstico y tratamiento adecuado para 
hiperplasia prostática benigna. Por otro lado, se sugiere la realización de 
biopsia en valores menores a este por la probabilidad elevada de CAP. 
Densidad de PSA: este ítem se calcula con base en el valor de PSA 
total dividido por el volumen de la próstata en cm3 (determinado por 
ecografía). Se sugiere realizar biopsia ante valores >0.15 ng/mL/cm3, 
ya que estos sugieren adenocarcinoma. 
Velocidad de PSA: con relación a este ítem, se encuentra que un 
valor >0.75 ng/mL/año, sugiere la presencia de cáncer. Además, 
para aquellos pacientes que han sido sometidos a prostatectomía por 
patología benigna, sugieren un incremento >0.4 ng/mL/año. 
Aunque se cuenta con todas estas herramientas para intentar 
elevar la especificidad del PSA, hasta el momento no han demostrado 
disminuir el número de biopsias innecesarias y en la actualidad 
se considera la toma de biopsia prostática en todo paciente con 
PSA >4 ng/mL; sin embargo, algunos autores sugieren tomar un valor 
único de PSA como <2.5 ng/mL (puede ser aplicado para pacientes 
<50 años dado que faltan estudios para confirmar su valor) para definir 
la necesidad de biopsia prostática.
Biopsia transrectal de próstata guiada por ecografía
Es el estándar de oro para el diagnóstico del CAP en la actualidad. 
Las muestras son tomadas en la periferia prostática, que es el sitio 
en el que más se presenta carcinoma. Por lo general, en la primera 
biopsia se deben tomar mínimo seis cilindros por cada lóbulo; en 
caso de contar con biopsia negativa con persistencia de PSA elevado, 
es necesario proceder a la realización de una biopsia por saturación 
(>10-12 muestras/lóbulo). Existen estudios que demuestran que la 
biopsia de próstata requiere adecuada analgesia/anestesia y el uso 
de profilaxis antibiótica.
La ecografía transrectal de próstata solo se encuentra indicada si 
va acompañada de biopsia, no debe realizarse en otra condición. Las 
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indicaciones para biopsia de próstata son PSA >4ng/mL y presencia 
de alteraciones en la superficie prostática (nódulo o próstata pétrea) 
predominantemente, aunque hay variantes que no son el objeto de 
esta revisión. 
Medicina nuclear
La gammagrafía ósea se debe realizar obligatoriamente de manera 
inicial en pacientes con PSA >10 ng/mL o en aquellos clasificados 
como de riesgo intermedio y alto. La probabilidad de que los pacientes 
con niveles de PSA <10 ng/mL tengan una gammagrafía positiva se 
encuentra por debajo del 1%; sin embargo, un PSA >49 tiene un LR+ 
(likelihood ratio positivo) >6, es decir, hay 6 veces más probabilidades 
de encontrar una gammagrafía positiva en pacientes con CAP que 
en pacientes sin CAP (46). 
Tomografía computarizada (TC)
La TC abdominal, al igual que la resonancia magnética (RM), 
evalúa de forma indirecta la invasión nodal al medir el diámetro 
de los ganglios linfáticos. Sin embargo, su sensibilidad es baja y la 
invasión microscópica no puede ser detectada. La sensibilidad es 
<40%. Si se utiliza un umbral de 10mm, la mediana de la sensibilidad, 
la especificidad, el valor predictivo negativo y el valor predictivo 
positivo estimado son de 7%, 100%, 85% y 100%, respectivamente. 
Aunque la biopsia por aspiración con aguja fina puede ser un 
buen complemento en casos con imágenes positivas, la dificultad 
de alcanzar los ganglios por su posición hace que esta no sea muy 
sensible para la estadificación y tenga una tasa de falsos negativos 
de 40%. Para la TC, al igual que la RM, la detección de invasión 
ganglionar microscópica es <1% en pacientes con puntaje Gleason <8, 
PSA <20 ng/mL o enfermedad localizada. Su uso debe ser reservado 
para pacientes de alto riesgo.
Aunque la TC de hueso tiene baja especificidad, se prefiere su uso 
sobre otras técnicas que evalúan metástasis óseas. Se recomienda su 
realización en pacientes sintomáticos, sin importar los niveles de 
PSA, la clasificación de Gleason o el estadio clínico (47).
Resonancia magnética de próstata/pelvis
La imagen ponderada en T2 es la más útil para la estadificación 
local en la RM. A 1.5T (Tesla), la RM tiene baja sensibilidad para 
detectar extensión extraprostática de carcinoma (22-82%) o invasión 
de vesículas seminales (0-71%), pero mayor especificidad (61-100% 
y 62-100%, respectivamente). La exactitud global de la RM para 
distinguir las etapas T1/T2 de la T3 es 50-85%; estos resultados se 
deben a que la RM no puede detectar la extensión extraprostática 
microscópica, de tal manera que su sensibilidad aumenta con el radio 
de extensión dentro de la grasa periprostática (47). 
El uso de la sonda endorrectal mejora la precisión del estadio a 1.5T, 
además se ha demostrado una mejor precisión en el uso combinado 
de sondas endorrectales y externas frente al uso solo de las externas. 
La alta intensidad de campo permite una alta resolución T2-WI y los 
resultados a 3T parecen mejores que a 1.5T. Aunque la experiencia del 
lector sigue siendo de suma importancia, la precisión de la RM a 3T 
varía entre 67% y 93%, dependiendo de la experiencia del personal. 
La predicción de la etapa patológica por parte de la RM puede mejorar 
cuando se combina con datos clínicos. Dada la baja sensibilidad para 
la extensión extraprostática focal (microscópica), la RM de próstata 
multiparamétrica no se recomienda para estadificación local en 
pacientes de bajo riesgo. Sin embargo, puede ser útil en la planificación 
del tratamiento en seleccionados pacientes de bajo riesgo (48).
Tomografía por emisión de positrones/tomografía computarizada
La tomografía por emisión de positrones de 11C- o 18F-colina 
(PET/TC) tiene una buena especificidad para las metástasis 
ganglionares, pero la sensibilidad es de 10-73%. En un metaanálisis 
de 609 pacientes, la sensibilidad y la especificidad de la PET/TC para 
las metástasis a ganglios pélvicos fue de 62% (IC95%: 51-66) y 92% 
(IC95%: 89-94), respectivamente (49); dada su baja sensibilidad, esta 
no se recomienda para la estadificación inicial en metástasis ganglionar, 
por lo que en la actualidad se están desarrollando estudios con 
psmaPET-TC (antígeno de membrana específico de próstata-PET/TC).
La PET/TC de 18F-colina muestra una sensibilidad superior a 
la TC ósea convencional a la hora de evaluar metástasis en hueso. 
No está claro si la PET/TC de 11C-colina es más sensible que la 
exploración ósea convencional, pero tiene mayor especificidad con 
menos lesiones indeterminadas; sin embargo, la relación costo-
efectividad de estas intervenciones todavía no se ha evaluado. Por 
lo tanto, se prefiere la TC ósea sobre la base de la disponibilidad y 
el costo.
Tratamiento
El tratamiento de elección depende del estadio del tumor en el 







Carcinoma de próstata localizado <cT2c, Nx, M0
El abordaje del carcinoma de próstata localizado depende del nivel 
del riesgo, determinado con anterioridad por D´amico y las guías del 
NCCN, realizándose de la siguiente forma:
Riesgo muy bajo: puede realizarse cualquier modalidad del 
tratamiento. Se han encontrado buenos resultados con la 
observación y la vigilancia activa para evitar el sobretratamiento; 
sin embargo, en pacientes con expectativa de vida >10 años se 
podría considerar el tratamiento quirúrgico.
Riesgo bajo: al igual que en el grupo anterior, puede realizarse 
cualquier modalidad de tratamiento. La expectativa de 
vida también cobra un papel importante, ya que en aquellos 
pacientes con pronóstico <10 años es probable que no se 
justifique el tratamiento quirúrgico. En aquellos que presenten 
una expectativa de vida >10 años, y se consideren candidatos a 
tratamiento quirúrgico, la prostatectomía radical es el tratamiento 
de elección, sin necesidad de realizar linfadenectomía, la cual 
ha demostrado mayor efectividad en comparación con la 
radioterapia (50).
Riesgo intermedio: la prostatectomía radical retropúbica con 
linfadenectomía pélvica bilateral es el manejo de elección en 
estos pacientes con expectativa de vida >10 años; este, como 
todo procedimiento quirúrgico, puede tener complicaciones como 
sangrado, infección, incontinencia urinaria y disfunción eréctil, 
sin embargo las de mayor importancia para el paciente son las dos 
últimas. Cabe aclarar que la frecuencia de estas dos ha disminuido 
dada la mejoría de la técnica quirúrgica y la preservación de las 
bandeletas neurovasculares junto con el esfínter externo. Otra 
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modalidad de tratamiento pata estos pacientes es la radioterapia 
externa, que puede ser 3D conformacional, con intensidad modulada 
(74- 80 Gy) o braquiterapia de baja tasa (preferible para pacientes de 
bajo riesgo). Todas tienen complicaciones relacionadas, similares a la 
cirugía, como incontinencia, disfunción eréctil, proctitis o cistitis.
Riesgo alto: en este grupo de pacientes el tratamiento se realiza 
de la misma forma que en el paciente de riesgo intermedio.
Carcinoma de próstata localmente avanzado cT3-4, Nx, M0
Una de las opciones terapéuticas para carcinoma de próstata localmente 
avanzado es la prostatectomía radical retropúbica con linfadenectomía 
pélvica bilateral en pacientes jóvenes muy seleccionados, con estadio 
clínico T3, gleason <8 y PSA <20 ng/mL, esto dado que hasta 25% 
pueden estar sobreestadificados. Otra opción es la radioterapia externa 
combinada con terapia hormonal (análogos LHRH neoadyuvante, 
concurrente y adyuvante (por 1-3 años)).
Carcinoma de próstata avanzado cualquier T, N1, M1
El tratamiento de elección en los pacientes con CAP avanzado es la 
hormonoterapia (quirúrgica o médica). Los medicamentos que se 
utilizan en la actualidad para la orquiectomía médica son los análogos 
LHRH (acetato de leuprolide, acetato de goserelina y acetato de 
triptorelina) y los antagonistas del receptor de la hormona liberadora 
de gonadotropina (GnRH)(Degarelix), cuyo uso lo debe llevar a cabo 
personal especializado. A estos medicamentos se les puede adicionar 
otros emergentes como la abiraterona (inhibidor de la síntesis de 
testosterona), la enzalutamida (inhibidor del receptor de andrógenos) 
y el radio-223 cuando el paciente es denominado resistente a la 
castración (51). Los criterios para ser definido como resistente a la 
castración son (51) nivel de testosterona <50 ng/dl o 1.7 nmol/l más
Progresión bioquímica: tres elevaciones consecutivas del PSA 
al menos con una semana de diferencia y con resultado en dos 
incrementos del 50% por encima del nadir y un PSA >2, o
Progresión radiológica: aparición de dos o más lesiones nuevas en 
una gammagrafía ósea o una lesión de tejidos blandos usando los 
criterios RECIST (Response Evaluation Criteria in Solid Tumors).
Los antiandrógenos se utilizan como coadyuvantes en el tratamiento 
y existen de dos tipos: esteroideos y no esteroideos. Dentro de estos 
últimos se encuentran la flutamida, la bicalutamida, entre otros, sin 
embargo sus indicaciones, dosis y seguimiento deben ser realizados 
por el especialista (51). 
En aquellos pacientes con CAP metastásico y resistente a la castración 
se pueden hacer clasificaciones de acuerdo con el estado funcional y 
con la presencia de síntomas o metástasis viscerales. Para aquellos con 
deterioro del estado funcional, el tratamiento aún está en investigación 
dado el pobre pronóstico de los pacientes. Por el contrario, para aquellos 
con buen estado funcional, se cuenta con diferentes tratamientos 
como los antiandrógenos de nueva generación y la quimioterapia. 
Los pacientes asintomáticos o levemente sintomáticos podrían recibir 
abiraterona, enzalutamida y radio 223, mientras que los sintomáticos 
y que tienen metástasis viscerales son candidatos a quimioterapia 
(docetaxel o cabazitaxel, como segunda línea), cuyo manejo es dado 
por el especialista en oncología o en juntas interdisciplinarias (51). 
Conclusiones
La presente investigación presenta una visión actualizada en diferentes 
aspectos del CAP. Se trata de una patología muy frecuente, con una 
incidencia que varía entre mantenerse estable o aumentar y una 
prevalencia que, con claridad, está en aumento, quizá debido a la 
mejoría para diagnóstico y tratamiento. Con respecto a los factores 
de riesgo, se tienen los clásicamente reconocidos, como raza, edad 
y factores genéticos; los que todavía no se ha podido encontrar el rol 
que juegan, como la alimentación, y algunos que antes se creía eran 
factores protectores y ahora apuntan a jugar un papel carcinógeno, 
como los estrógenos. 
Es importante realizar una adecuada clasificación y estadificación 
clínica, anatómica y patológica del CAP, ya que de dicho proceso 
depende la aproximación y utilización de técnicas de imágenes y 
radiología, además del tratamiento oportuno, individualizado e 
indicado según la medicina basada en la evidencia.
La caracterización genética y microbiológica del CAP es hacía 
donde apuntan y apuntarán la mayoría de esfuerzos e investigaciones, 
ya que se requieren pruebas con mayor sensibilidad y especificidad 
que lleven a un diagnóstico más temprano y certero y, de ser posible, 
faciliten terapias más específicas y menos mórbidas.
Se realizó un recorrido a través de las condiciones de riesgo, 
tamizaje, diagnóstico, nuevos biomarcadores y tratamiento del CAP. 
Varios elementos han cambiado en los últimos años, principalmente 
acerca de la comprensión de la fisiología del cáncer, los factores 
asociados, la búsqueda de nuevos biomarcadores en cada una 
de las etapas del cáncer y varios elementos relacionados con el 
tratamiento; sin embargo, hay mucha investigación en curso acerca 
de la prevención, el diagnóstico y el tratamiento de esta condición 
tan importante, relevante y pertinente para los hombres alrededor 
del mundo. 
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